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Zusammenfassung 
Das Zytoskelett, mitsamt seinen Motorproteinen spielt bei der Bewältigung so 
essentieller biologischer Prozesse wie der Zellbewegung, der Muskelkontraktion, 
der Chromosomen-Segregation und dem intrazellulären Transport eine 
Hauptrolle. So ist z. B. während der Tarnung bei Fischen und Amphibien der 
rasche Farbwechsel in der Haut überhaupt erst durch den Transport von 
pigmenthaltigen Organellen (Melanosomen) von der Zellmitte zur Peripherie und 
zurück möglich. Dieser Vorgang, bei dem abertausende Organellen im 
Zytoplasma verteilt werden, bedarf einer streng regulierten Zusammenarbeit der 
verschieden Transportsysteme einer Zelle. Hierbei wird der 
Langstreckentransport zur Zellperipherie entlang der Mikrotubuli vom 
Motorprotein Kinesin-2 bestimmt, während im Aktin-reichen Zellkortex Myosin V 
den Kurzstreckentransport steuert. Es wird daher angenommen, dass eine Art 
Frachtübergabe vom einen zum anderen Transportsystem vonnöten ist.  
Bis zum heutigen Tage ist sowohl der Mechanismus als auch die Regulation der 
Interaktion zwischen den beiden Transportsystemen noch weitestgehend unklar. 
Durch neuere in vitro-Studien wurde gezeigt, dass an Aktin-Mikrotubuli-
Kreuzungen Myosin V die “Schiene” wechseln kann und entlang des Mikrotubulus 
auf Diffusion basierende Bewegungen ausführt (Ali et al., 2007). 
Ein Hauptziel dieser Arbeit war es, die molekularen Faktoren dieser unerwarteten 
Interaktion zwischen Myosin V und dem Mikrotubuli-basierten Transportsystem zu 
untersuchen. Mit Hilfe von Total Internal Reflection Fluorescence-Microscopy 
sowie Mikrotubuli-Affinitäts- und Cosedimentations-Experimenten, konnte in 
diesem Teil der Arbeit gezeigt werden, dass für die elektrostatische Interaktion 
zwischen Myosin V und Mikrotubuli, anders als ursprünglich vermutet, die positiv 
geladene Myosin-Oberflächenstruktur Loop 2 und die negativ geladenen 
Carboxy-terminalen Mikrotubuli-Enden (E-hooks) wider Erwarten entbehrlich sind. 
Des Weiteren  zeigten Ali et al., dass in vitro der Myosin V-Motor dem Kinesin-
gesteuerten Transport unter die Arme greifen kann. Dazu passend zeigen die hier 
präsentierten Ergebnisse für das Binden von Myosin V an den Mikrotubulus eine 
neue und unkonventionelle Art auf, welche den E-hook-abhängigen 
Langstreckentransport durch Kinesin nicht behindert. 
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Ob Zellen tatsächlich den hier vorgeschlagenen biophysikalischen Trick 
anwenden, um die Transporteffizienz in vivo zu steigern, bleibt nach wie vor zu 
klären. Um dies zu beantworten bedarf es eines biologisch relevanten Systems, 
mit dem das Transportverhalten einer natürlichen Cargos (z.B. Organellen), 
welches entweder beide Motoren (d.h. Myosin V und Kinesin-2) oder Kinesin-2 
allein besitzt, in vitro untersucht werden kann. Hierfür sind Melanosomen von 
Pigmentzellen (Melanophoren) ideal geeignet, da sie als funktionell intakte 
Organellen isoliert werden können. Aber wie kann nun der Cargo so manipuliert 
werden, dass das am Cargo gebundene Kinesin-2 haften bleibt, während Myosin 
V abgelöst wird? Um mich dieser Frage anzunehmen, nutze ich das Ergebnis 
einer früheren Studie, in der gezeigt wurde, dass die Phosphorylierung von 
Myosin V, die durch Calcium-/Calmodulin-abhängige Kinase II-α (CaMKII-α) 
vermittelt wird, den Motor selektiv von Melanosomen löst. Die hier präsentierten 
Daten zeigen, dass schon allein die in den Pigmentzellen vorkommende 
endogene CaMKII-α das Ablösen von Myosin V vom Melanosom auslöst, und 
dass die Aktivierung der Kinase ausschließlich von ihrer Rekrutierung an das 
Melanosom abhängt. Hingegen war für die hier generierte und in vitro-aktivierte 
exogene Kinase kein signifikanter Effekt auf Melanosom-gebundenes Myosin V  
erkennbar. Daraus lässt sich schließen, dass womöglich weitere Cofaktoren am 
Ablösen des Myosin V-Motors vom Melanosom beteiligt sind. Der hier vorgestellte 
„CaMKII-α Release Assay“ wirft wichtige Fragen nach den regulatorischen 
Mechanismen während des Bindens von Motorproteinen an Organellen auf. Des 
Weiteren bildet der „CaMKII-α Release Assay“ nun eine Grundlage für das 
Etablieren eines Protokolls, mit dem es möglich sein sollte, die Rolle von Myosin 
V bei der Unterstützung des Kinesin-gesteuerten Transports zu ergründen. 
Wie ist die Regulation des intrazellulären Organellentransports zeitlich und 
räumlich organisiert? Und wie reagiert das Melanosomen-assoziierte Proteom auf 
extrazelluläre Einflüsse? Um diesen Fragen sowohl qualitativ als auch quantitativ 
auf den Grund zu gehen, bieten hochentwickelte Technologien wie die 
Massenspektrometrie vielversprechende Möglichkeiten. Bis jetzt wurden eventuell 
auftretende Proteommodifikationen am Melanosom noch nicht experimentell 
hinterfragt. Beim Anwenden so sensibler Techniken wie der Massenspektrometrie 
stellt die Probenreinheit die größte Herausforderung dar. Obgleich zum 
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Aufreinigen von Mitochondrien oder Lipoproteinen die Sucrosegradienten-
Ultrazentrifugation standardmäßig verwendet wird, birgt die harsche Behandlung 
der Probe die Gefahr, Teile des auf dem Organell sich befindenden Proteoms zu 
verlieren. Daher war es mein Ziel eine Technik zu etablieren, mit der es möglich 
ist, Melanosomen von kontaminierenden zytoplasmatischen Bestandteilen zu 
reinigen. Dabei sollten keine harschen Zentrifugationsschritte oder später 
eventuell störende Zusätze (z. B. Sucrose) verwendet werden. Mit der hier 
präsentierten Methode werden mittels eines Magneten sowie paramagnetischer 
Nanokügelchen, welche gegen Melanosomen-spezifische Oberflächenmarker 
gerichtet sind, intakte Organellen aufgereinigt. Zusätzlich zur der Tatsache, dass 
diese Technik eine alternative Aufreinigungsmethode von Melanosomen darstellt, 
bietet sie auch die Möglichkeit, anhand von spezifischen Oberflächenmarkern 
Melanosomenpopulationen aus unterschiedlichen Zellstadien (Aggregation oder 
Dispersion) zu gewinnen. 
Obwohl bereits vor über drei Jahrzehnten gezeigt werden konnte, dass Myosin V 
für die vollständige Pigmentverteilung in Melanophoren von Xenopus l. 
unentbehrlich ist, ist die vollständige Sequenz dieses Motors erstaunlicherweise 
noch immer nicht bekannt. Im letzten Teil dieser Arbeit wird nun die vollständige 
Sequenz des Myosin V aus Xenopus l. präsentiert. Mit Hilfe von Einzelmolekül-
Motilitätsversuchen wurde rekombinantes Xenopus l. Myosin V erstmals 
biophysikalisch untersucht. Die Bewegungsgeschwindigkeit des überexprimierten 
Myosin V-Motorproteins stimmt mit in vivo-bestimmten Melanosomen-
Transportgeschwindigkeiten überein. 
Zusammenfassend kann gesagt werden, dass diese Arbeit sowohl neue Einblicke 
in das komplexe Zusammenspiel zwischen dem Aktin- und Mikrotubuli-basierten 
Transportsystem eröffnet, als auch alternative Wege aufzeigt, um bislang 
ungelöste Probleme des Organelltransports besser erforschen zu können. 
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Summary 
The cytoskeleton along with its motor proteins plays a central role in the 
accomplishment of essential biological processes such as cell motility, muscle 
contraction, chromosome segregation and intracellular transport of entire 
organelles. For instance, the rapid color change of the skin during camouflage in 
fish and amphibians is achieved by the transport of pigment-filled organelles 
(melanosomes) from the cell center to the periphery and vice versa. This highly 
concerted distribution of thousands of organelles throughout the cytoplasmic 
microcosm of a cell requires a strictly regulated networking between the different 
transport systems.  
The long-range transport of melanosomes along microtubules towards the cell 
periphery is powered by the Kinesin-2 motor, while Myosin V accomplishes the 
short-range transport in the actin-rich cell cortex. Therefore, some form of hand-
off mechanism is believed to be required. However, to date the mechanistic 
nature and regulation of the crosstalk between the two transport systems remains 
elusive. 
Recently, in vitro Myosin V was shown to switch tracks at actin-microtubule 
intersections, followed by diffuse movements on the microtubule (Ali et al., 2007).  
To dissect the molecular determinants of this unexpected interaction between 
Myosin V and the microtubule transport system was a major goal of this thesis. By 
means of single-molecule Total Internal Reflection Fluorescence microscopy as 
well as microtubule-affinity co-sedimentation assays, in this study the originally 
suggested electrostatic tethering between the positively charged myosin loop 2 
and the negatively charged C-terminal E-hooks of microtubules was proven to be 
dispensable. Consistent with the observation by Ali et al., who showed that 
Myosin V is able to assist kinesin-driven transport in vitro, the findings presented 
in this work provide evidence for a novel and unconventional way of Myosin V 
tethering to microtubules that does not interfere with other E-hook-dependent 
processes such as kinesin-driven long-range transport.  
However, a still open question is whether cells indeed employ this proposed 
biophysical trick to enhance the transport efficiency in vivo. Answering this 
question requires a biologically relevant system, in which the transport behavior of 
Summary 
________________________________________________________ 
 
a native cargo (e.g., organelles) containing either both sets of motors (i.e., Myosin 
V and Kinesin-2) or Kinesin-2 alone, can be assessed in vitro. For this, 
melanosomes from pigment cells are ideally suited, as they can be isolated as 
functionally intact organelles. But how can the cargo be manipulated in such a 
way that bound Kinesin-2 remains attached, while the Myosin V motor is depleted 
from the cargo? To address this question I made use of a previous finding, where 
Myosin V was shown to being released upon phosphorylation by the Calcium-
/Calmodulin-dependent Kinase II-α (CaMKII-α). The data presented in this work 
demonstrate that endogenous kinase alone is capable of triggering Myosin V 
release and the activation of the kinase is dependent on the recruitment onto the 
melanosome. In contrast, activated exogenous kinase had no significant effect on 
the melanosome-bound Myosin V, indicating that additional co-factors might be 
involved. The CaMKII-α release assay presented here raises important questions 
about the regulatory mechanisms involved in binding of motor proteins to 
organelles. It further provides important clues for the establishment of an 
experimental setup by which it will be possible to test Myosin V’s potential role in 
assisting kinesin-driven cargo transport. 
Inside cells, how is spatio-temporal regulation of organelle transport 
orchestrated? And how does the proteome of an organelle respond to 
extracellular clues? Advanced technologies such as mass-spectrometry hold the 
promise of qualitatively and quantitatively addressing those questions. So far, 
potential cell state-dependent proteomic modifications on the melanosome have 
not been experimentally scrutinized. When applying sensitive techniques like 
mass-spectrometry, the greatest challenge is to obtain highly pure samples. While 
sucrose density gradient ultra-centrifugation has been successfully used to obtain 
pure mitochondria, lipoproteins etc., the harsh sample treatment often leads to 
loss of parts of the associated proteome. Therefore, I established a novel 
technique to obtain pure melanosomes free of cytoplasmic contaminants. This 
technique does neither involve harsh ultra-centrifugation steps, nor does it include 
any potential contaminating additives (e.g., sucrose). Instead, by applying 
paramagnetic beads directed against unique melanosome-specific markers, pure 
fractions of intact organelles are retrieved. The technique presented here not only 
represents an alternative way to purify melanosomes, but by exploiting unique 
cell-state-dependent surface markers, it will also allow for the sorting of different 
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melanosome populations from distinct cellular states. 
Even though over three decades ago on specialized pigment cells 
(melanophores) from Xenopus l. it has been elegantly demonstrated that for the 
successful distribution of pigments into the distal tips of a cell, Myosin V-powered 
organelle transport is indispensable, the full-length Xenopus l. Myosin V 
sequence remained unresolved. Therefore, in the final part of this thesis, the full-
length Myosin V sequence from Xenopus l. melanophores is presented. 
Furthermore, by means of gliding filament as well as single-molecule motility 
approaches, recombinant full-length Myosin V from Xenopus l. was subjected to 
initial biophysical characterization. The reconstituted velocity of the 
overexpressed Myosin V motor protein from Xenopus l. is in remarkable 
agreement with in vivo melanosome transport velocities inside pigment cells. 
To conclude, this work not only provides novel insights into the intricate interplay 
between the actin- and microtubule-based transport system, it also presents new 
and alternative ways to approach the yet unsolved problems in the field of 
cytoskeletal organelle transport. 
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1 Introduction 
1.1 The cytoskeleton and its motor proteins 
Cellular motility becomes essential with the progression past the single-cell state 
and is required for nearly all the cellular processes that accomplish life itself. 
Motile immune cells are able to accumulate at sites of infection, active 
movements within a cell realize the nourishment of distal parts in nerve or plant 
cells and for animals to respond physically to dangerous situations, muscle 
contraction is indispensable. Those and many more examples in biology have 
been driving scientists to unravel the secrets of cellular motility, a process 
accomplished through the intricate work of the cytoskeleton along with its 
molecular motors. 
The cytoskeleton itself consists of a complex network of protein polymers that 
resist deformation and transmit mechanical forces. The three polymer classes are 
referred to as actin filaments, microtubules and intermediate filaments and are 
composed of specific protein subunits. In this thesis, actin filaments and 
microtubules took the center stage and are thus described in more detail. 
Microtubules are hollow, cylindrical polymers (approx. 25 nm in diameter) that 
sustain both compression and tension. This feature makes them useful for 
supporting asymmetrical cellular processes as well as for bidirectional traffic that 
is generated by the respective motor proteins 2,3. Filamentous actin (F-actin; 
approx. 8 nm in diameter) is much more flexible and builds up a cytoskeletal 
transport as well as motility system, which is present in all eukaryotes. The actin 
cytoskeleton complements and interacts physically with cytoskeletal structures 
composed of microtubules and intermediate filaments 4. 
Inside cells, most biological movements are accomplished by motor proteins − 
small nano-scale machines, which move along two different types of polarized 
cytoskeletal tracks (i.e., actin filaments and microtubules). These motor proteins 
take nanometer steps along their track to transport cargo from one location inside 
the cell to another. To do so, motor proteins convert chemical energy (adenosine 
triphosphate, ATP) into mechanical energy. The thereby generated force is then 
used to propel cargoes along their specific tracks. 
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Altogether three different classes of motor proteins transport cargo molecules 
along two different types of cytoskeletal tracks. Kinesins and dyneins move along 
microtubules, whereas myosins move on actin filaments. 
In addition, these molecular motors are specialized regarding their directional 
movement along their appropriate track. While the majority of kinesin motors 
moves toward the plus-end of microtubules, all dyneins exhibit minus end-
directed movements on the microtubule. With the exception of Myosin VI, which 
moves towards the minus-end, all myosins perform barbed end (also referred to 
as plus end) -directed movements on actin filaments 2. 
Microtubule-based motors are used not only for the transport of particles through 
the cytoplasm or chromosomal movement during cell division, but they also carry 
out more specialized roles. One of these roles is for instance flagellar motility, for 
which microtubules and dynein are crucial components 5,6. Many types of cellular 
movements, including muscle contraction, cytokinesis, cytoplasmic streaming and 
amoeboid motion are accomplished by the actin-myosin system 4. 
As large parts of this work focus on characterizing the behavior of the class V 
myosin, an overview on the superfamily of myosins is presented in the following 
section. 
 
1.2 The myosin superfamily 
Myosins as a large family of actin-based mechano-enzymes bind and hydrolyze 
ATP to generate force and movement along actin filaments, which is necessary to 
assist in a variety of cellular tasks. Besides the classic example of skeletal muscle 
contraction, many other cellular events such as cell motility, cell adhesion, 
cytokinesis, endocytosis, exocytosis, membrane trafficking, movement of mRNA 
and organelle transport are controlled by the joint action of myosin and actin 
filaments 7. Mutations within myosin genes often result in severe phenotypes such 
as cardiomyopathy, deafness, blindness, sterility and neurological seizures 8,9. To 
date 35 different classes have been officially designated as classes Myosin I to 
XXXV, of which at least 12 are present in vertebrates 10. Myosins are further 
divided into conventional and unconventional myosins. Due to historical reasons, 
all class II myosins are denoted conventional myosins, whereas all the other 
members of the myosin superfamily are referred to as unconventional myosins. 
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1.3 Myosin V-Overview 
Initially described as an unusual calmodulin-binding protein from brain with a 
number of myosin-like biochemical properties, today Myosin V is known to 
provide continuous transport of membranous cargo, lipids, mRNA, secretory as 
well as protein vesicles and organelles on actin 11. 
Myosin V is found in a wide variety of eukaryotic cells (excluding plant cells) 
including organisms as primitive as yeast, which contain two class V myosins. 
Interestingly, plants contain the class XI Myosins, which almost certainly derived 
from an ancient class V myosin 10,12. 
Three class V myosins (Va, Vb, Vc) are found in mammalian cells, each one 
associated with different tissue specificity and with a specific set of membrane 
trafficking events 13. For example, mutations in the human ortholog of the dilute 
Myosin V (class Va) gene cause Griscelli syndrome, a rare recessive disease 
characterized by pigmentary dilution of the skin, neurological disorders and in 
some cases even immunodeficiency 14,15. Myosin Va is known to associate with 
diverse organelles, for example pigment granules (melanosomes) in pigment cells 
of the skin and secretory vesicles in neurons of the brain 16,17. Very recently, 
Myosin Va was shown to move endoplasmatic reticulum into the spines of 
Purkinje cells 18. Myosins Vb and Vc are mainly expressed in epithelial cells 
where they have been implicated as motors involved in recycling endosomes 
13,19,20. 
1.3.1 Myosin V structure and function 
As all other myosins, class V myosins are composed of three functional domains: 
a) the motor or head domain; b) the neck domain or lever arm; and c) the tail 
domain (Figure 1). In vivo two Myosin V heavy chains dimerize along their tail 
domains to form a double-headed homodimer 21. The N-terminal motor domain 
(catalytic domain) shares conserved sequence homology with other members of 
the myosin superfamily and contains both the nucleotide and actin binding sites 
22. The ATP binding site is located near the so-called loop 1 region, which was 
shown to be involved in the catalytic ATPase cycle 23.  
The actin-binding interface is part of a surface loop, referred to as loop 2 region 
and is involved in the initial weak electrostatic interaction of myosin with actin 24.  
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The long (24 nm) neck domain contains six light chain-binding consensus repeats 
(IQ motifs) and fulfills two major functions: i) regulating the activity of Myosin V via 
calcium-dependent binding of calmodulin-like light chains to its IQ motifs and 
thereby affecting the ATPase cycle and processivity; and ii) enabling the Myosin 
V dimer to bind to actin with a 36 nm pitch, which in turn allows for taking 36 nm 
steps along the actin filament 25,26,27. Myosin V’s step size on actin is the longest 
among all yet identified myosin family members 28.  
In contrast to the catalytic domains, the tail domains are the most diverse in their 
primary sequence and structure among the different myosin classes. The tail 
domain of Myosin V is divided into two functional regions, i.e. the rod region and 
the globular tail domain (GTD). 
Figure 1. Atomic resolution and schematic domain structure of the full-length Myosin Va. 
(A) Surface features were rendered based upon atomic resolution structures and appear as 
smooth images for domains of unknown structure (adapted from Vale, R., Cell, Vol. 112, 2003). 
(B) Schematic domain structure of the full-length Myosin Va. At the N’-terminus, the motor 
catalytic domains (light purple) contain the actin-binding site and nucleotide-binding site, 
followed by an approx. 24-nm-long lever arm (grey) that binds six calmodulin-like light chains. 
The rod region (black) of the tail domain contains three stretches of α-helical coiled-coil, which 
are interrupted by two major regions of non-coiled-coil. At the very C’-terminus, the globular tail 
domain (magenta, GTD) binds to adaptor proteins that link the GTD to cargo molecules. 
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The N-terminal rod region with its three major stretches of α-helical coiled-coil is 
responsible for dimerization of the two heavy chains, whereas the C-terminal GTD 
has two distinct major functions: i) linking the motor protein to cargo molecules; 
and ii) stabilizing the auto-inhibited folded conformation of Myosin V via 
interactions with portions of the motor domain. In addition, the GTD was shown to 
be important for the motor’s cellular localization 29,30,31. 
1.3.2 Myosin V processivity and ATPase activity 
To generate motility, Myosin V converts chemical energy into mechanical work by 
coupling the hydrolysis of ATP to conformational changes. All myosins 
characterized to date show a characteristic cyclic interaction with actin 
(actomyosin ATPase cycle).  
The kinetic cycle of class V myosins is characterized by the following four major 
steps: i) the rapid binding of ATP to actin-bound myosin; ii) the hydrolysis of ATP; 
iii) the rapid release of phosphate (Pi) but slow release of ADP; and iv) the 
rebinding of ATP to myosin 32,33 (reviewed in 34). By progressing through these 
four states, myosin alternates between the actin-detached and actin-attached 
(strong-binding) state. Importantly, only the strong-binding state allows myosin to 
generate mechanical force (power stroke), and thus directed movement on actin 
32,35 (Figure 2). 
Belonging to the class of cytoplasmic transport motors, in vivo Myosin V typically 
works in isolation under conditions where it must move its cargo long distances 
without dissociating from its track 36,37. The ability to take multiple steps along the 
actin filament without detaching is thus a mechanical prerequisite to Myosin V 
function. Vertebrate Myosin V was the first myosin shown in vitro to be capable of 
exhibiting this so-called processive walking behavior 38,39. It should be mentioned 
that some of the details regarding processivity of Myosin V are still under debate. 
Therefore, in Figure 2 only a consensus mechanism is shown 34. 
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The kinetic cycle starts with the two-heads-bound intermediate state (also 
referred to as “waiting state”), which the motor adopts in between steps 40. Being 
tethered by the actin-bound trailing head, the leading head cannot swing its lever 
arm forward. ADP-release from the trailing head is required for a step to occur 
(state 2). The release of ADP is the rate-limiting step and triggers the following 
sequence of events 32. ATP binds to the vacant site on the trailing head and 
makes it dissociate from the actin track leading to a transient one-head bound 
intermediate. This allows the lead head to release stored elastic energy and to 
throw the trailing head in front (state 3). The detached “new” leading head 
hydrolyzes ATP and undergoes a diffusional search to interact weakly with the 
next binding-site on actin. The weak-binding state is in rapid equilibrium with the 
dissociated state, so that phosphate release must be fast for the motor to 
eventually interact strongly with actin 38,41.  
Unique structural and kinetic adaptations allow Myosin V to be an efficient 
processive motor. The slow release (12 s-1) of ADP leaves the ADP-bound head 
strongly attached and thus the predominant steady-state intermediate of the 
cycle. This way a Myosin V molecule spends most (70%) of its ATPase cycle 
attached to the filament, making it a high duty ratio motor (i.e., time that one head 
Figure 2. Consensus model for the processive movement of Myosin Va on F-actin. 
(State 1) Both heads are strongly bound to actin with ADP bound at the active site of the motor 
domain (“waiting state”). The trailing head is in a post-powerstroke conformation, and the leading 
head is in a strained, pre-powerstroke state. The trailing head releases ADP at approx. 12 s-1, 
thereby representing the rate-limiting state of the ATPase cycle (state 2). ATP binding to the 
trailing head causes it to dissociate from actin, thereby allowing the actin-bound leading head to 
complete its powerstroke. Simultaneously, the detached head is thrust forward, hydrolyzes ATP, 
and becomes the new leading head in a pre-powerstroke conformation (state 3). While detached 
from the filament, the head undergoes a diffusive search for the next actin binding site, Pi release 
follows and the detached head undergoes a transition to the strong binding state. The lead-head 
may pass through an isomerized ADP* state before returning to state 1 (state 1’). The half-helical 
actin repeats (approx. 36 nm apart from each other) to which Myosin Va binds, is illustrated by 
darker grey actin filament-subunits. Figure was adapted from Trybus, K., Cell. Mol. Life Sci., Vol. 
65, 2008. 
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spends attached to the filament during one kinetic cycle). Not only does the high 
duty ratio ensure that one head always remains strongly bound to the filament, 
but it also provides enough time for the detached head to hydrolyze ATP and to 
search for the next binding site. 
The characteristic 36-nm step-size of Myosin V matches exactly the length of one 
half-helical repeat on the actin filament, suggesting that Myosin V can walk 
straight along the intrinsically twisted actin filament and must not spiral around it 
25. Strain-dependent changes in the kinetics of the two heads accomplished 
through the long lever arm, account for further enhancement of the processive run 
length 42. In addition, Myosin V with its highly positively charged loop 2 possesses 
a relatively high affinity for actin in the weak-binding states. Hence there is an 
increased likelihood for the new leading head to find its next binding site 43,44. 
All of the above allow Myosin V to walk processively on actin in a hand-over-hand 
fashion 45,46, which has been demonstrated not only in vitro but also in vivo 47,48. 
1.3.3 Regulation of Myosin V 
With the exemption of the mammalian skeletal muscle myosin whose ATPase 
activity is inherently unregulated 49, in essentially all myosins characterized so far, 
regulation almost always targets the myosin’s enzymatic activity. However, the 
form of regulation varies from case to case.  
The study of myosin regulation in vitro has been greatly aided by the development 
of ATPase activity as well as gliding filament or single-motor molecule motility 
assays (see Section 1.4). With those assays at hand, enzymatic and/or 
mechanical properties of a given myosin can be elegantly defined. 
For the full-length Myosin Va to be active in vitro, micromolar levels of Calcium 
(Ca2+) must be present 21,50,51,52. In the absence of Ca2+ Myosin Va was shown to 
interact only weakly with actin, resulting in low or no actin-stimulated ATPase 
activity 53. However, Myosin Va versions that lack the GTD along with parts of the 
distal coiled-coil, have been shown to be constitutively active in vitro 54. This 
finding indicated that most likely the tail domain mediates the inhibition of the full-
length Myosin Va. Via studies using ultracentrifugation and electron-microscopy, 
the final proof that at zero Ca2+ the full-length Myosin Va adopts a closed 
conformation, was provided.  For this folded inhibited conformation, the two motor 
domains fold back to the GTD, while low concentrations of Ca2+ induce the 
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unfolding of the molecule (Figure 3) 31,52,55,56. Importantly, additional studies could 
show that upon GTD-binding to the motor’s head domain solely the ATP-binding 
pocket but not the nearby actin-binding site is blocked, making the auto-inhibited 
Myosin Va likely to stay strongly attached to the filament 55. 
It should be mentioned, however, that activation of the auto-inhibited full-length 
Myosin Va by low Ca2+ concentrations entails a dramatic decrease in the motor’s 
affinity for actin 21,50. Therefore, in vivo Ca2+ seems unlikely to be the physiological 
regulator of Myosin Va. 
At present the only known cytoplasmic regulator that has been shown to directly 
unfold auto-inhibited Myosin Va (even at zero Ca2+), is the cargo receptor 
molecule melanophilin, which in pigment cells is responsible for linking Myosin Va 
to pigment-containing organelles. Further support came from studies, which 
showed that melanophilin is essential for the Myosin Va-dependent transport of 
melanosomes on actin 57,58,59. 
At this point it seems that auto-inhibition via head-to-tail folding is a common way 
to regulate the activity of various motor proteins. 
 
 
Figure 3. Structure of switched-off Myosin Va.  
Upper panels: averaged images of negative-stained, folded whole Myosin V 
molecules; scale bar is 20 nm. Lower panel: superimposition of the left-most image in 
the upper panel; colored and labeled to show domains within folded Myosin Va. Data 
taken from Thirumurugan, K. et al., Nature, Vol. 442, 2006. 
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1.4 In vitro motility assays and TIRF-Microscopy 
For a long time the interaction between myosins and actin was studied mainly by 
ultracentrifugation, chemical cross-linking and ATPase activity-measuring 
methods. However, with the development of the so-called in vitro sliding filament 
assay by Kron and Spudich (1986)60 the study of motor proteins was 
revolutionized. This assay elegantly takes advantage of the ability to image 
fluorescently labeled actin filaments via fluorescence microscopy as they interact 
with, and are transported by, myosins attached to a coverslip (Figure 4). 
Thereby it has become possible to reconstitute the motility of purified motor 
proteins along purified cytoskeletal filaments under cell-free conditions. With the 
advent of higher resolution fluorescence microscopy, the so-called single-
molecule motility assay, resembling an advanced version of the sliding filament 
assay, was developed. Via total internal reflection fluorescence (TIRF) 
microscopy, by this assay the movement of fluorescently labeled single motor 
Figure 4. Gliding filament assay setup. 
Step one: purified myosin is attached to the surface of a coverslip, either unspecifically or by 
using a myosin tail-specific surface-adhered antibody. Step two: perfusion of fluorescently 
labeled actin filaments into the flow-cell with surface-attached myosin molecules. In vitro 
filament gliding motility is followed by fluorescence microscopy (optimally by TIRFM) and 
movements are imaged onto a CCD camera. The arrow indicates the direction of filament 
movement. 
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molecules along surface-bound filaments can be measured, allowing for highly 
accurate determination of parameters such as motor velocity, runlength and 
runtime (Figure 5). 
This movement can be imaged onto an intensified charge-coupled device (CCD) 
camera and the motion can be acquired on a computer. With standard epi-
fluorescence microscopes it has always been a challenge to distinguish between 
filaments that are bound by surface-attached motor proteins and unbound 
filaments that are still in solution. However with the development of TIRF 
microscopy, it is nowadays possible to study objects that are very close (100 to 
200 nm) to the surface because TIRF microscopy makes use of the evanescent 
field that via total internal reflection of the incoming laser-beam is formed at the 
glass-water interface 61. Therefore fluorophores that are close to the surface are 
excited, whereas molecules in the bulk of the sample are not excited, yielding 
Figure 5. Single-molecule motility assay setup. 
Step one: attachment of in vitro polymerized actin filaments to the surface of a coverslip is 
typically achieved by using a catalytically inactive and immobilized heavy-meromyosin. Step 
two: fluorescently labeled (on head or tail) Myosin V is perfused into the flow-cell with surface-
attached F-actin. In vitro motility of single Myosin V molecules on F-actin is followed by TIRF 
microscopy and movements are imaged onto a CCD camera. The arrow indicates into which 
the direction the individual motors are walking. 
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much higher signal-to-noise ratios than with conventional epi-fluorescence 
microscopy (Figure 6). 
1.5 Melanophores: A model system to study intracellular 
organelle transport 
In mammalian pigment cells (melanocytes) skin darkening is induced by UV-
radiation, which is caused by either rapid oxidation of melanin, or dispersion-
mediated transfer of melanosomes into the keratinocyte-containing layer of the 
epidermis 62.  
Figure 7. Pigment dispersion and aggregation in melanophores from Xenopus l. 
Pigment dispersion (left image) and aggregation (right image) was induced by stimulation of 
cultured Xenopus melanophores with 100 nM α-melanocyte stimulating hormone (MSH) and 
50 nM melatonin, respectively. Images were acquired by brightfield-light microscopy (objective, 
20 ×). The left and right image sections show the same cell after complete pigment dispersion 
and aggregation, respectively. 
Figure 6. Total internal reflection fluorescence microscopy (TIRFM). 
The laser beam is focused to propagate along the objective edge, so that 
total internal reflection of the beam into the slide occurs. As the electrical 
filed cannot vanish abruptly, an oscillating electromagnetic field, termed 
evanescent wave, is produced. This evanescent wave penetrates 100 to 
200 nm into the aqueous solution where it excites fluorescently labeled 
filaments that are close to the surface. 
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In fish and amphibians, the main physiological role of pigment cells 
(melanophores) is to rapidly change color in response to variations in the 
environment. This is accomplished by a synchronous and bidirectional transport 
of pigment organelles (melanosomes). In response to extracellular stimuli 
(hormones or light) melanosomes from lower vertebrates are reversibly 
transported throughout the cytoplasm 63. Upon anterograde melanosome 
transport (dispersion) animals appear darker, whereas retrograde transport 
(aggregation) makes the skin appear lighter (Figure 7) 64,65. 
To study pigment dispersion and aggregation on physiological as well as 
molecular level, in 1990 Lerner et al. established an immortalized melanophore 
cell line from Xenopus laevis (African clawed frog), which has been used also for 
the purpose of this work 66. These cells are easily maintained and large quantities 
of cells can be obtained and used for subsequent studies 64. Most importantly, 
intact melanosomes can be isolated from these cells and subjected to in vitro 
studies. Therefore, melanophores have become a central model system to 
address the issues of intracellular organelle transport and motor regulation 67,68,69. 
1.5.1 Cytoskeletal components of melanosome transport 
Melanosomes are large (approx. 500 nm in diameter) tissue-specific organelles 
that are specialized in the biosynthesis and storage of the black pigment, melanin 
70. Because of their dark appearance, melanosomes can be easily imaged and 
discriminated from other cellular components using bright field transmission 
microscopy 71,72. 
By means of in vitro motility assays, transport of purified melanosomes can be 
reconstituted, demonstrating that all factors needed to drive melanosome 
transport are present on these organelles 65,73,74. This way, purified melanosomes 
readily display bidirectional movement on microtubules, where Kinesin-2 drives 
organelles towards the plus- and dynein toward the minus-ends of surface-
attached microtubules, while frequently switching the direction of movement 65. In 
vivo this bidirectional melanosome transport is tightly regulated, favoring Kinesin-
2-dependent transport towards the cell periphery during dispersion and dynein-
dependent transport towards the cell center during aggregation, respectively.   
In vivo, the dispersion of melanosomes additionally requires the actin-based 
motor protein Myosin Va 75,76, which has been shown to be responsible for the 
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local transport and efficient tethering of melanosomes within the dense cortical 
actin meshwork to support efficient dispersion 77. The presence of an actin-based 
motor together with two oppositely directed microtubule-based motors on the 
same cargo requires a tight spatio-temporal regulation of the three motor protein 
families 78,79,80. 
It has been shown that during dispersion, with Myosin Va helping Kinesin-2 to 
dominate over cytoplasmic dynein and thereby leading to a net plus-end directed 
transport of the melanosomes, there is continuous competition between both 
transport systems. During aggregation, on the other hand, Myosin Va appears to 
be unable to compete with dynein-driven movement, resulting in an inward-biased 
transport on microtubules 63. 
1.5.2 Regulation of intracellular melanosome transport 
To date several mechanisms have been proposed for governing melanosome 
aggregation and dispersion: i) modifications of the filamentous network itself 
might be involved, therefore favoring one state over the other; ii) extracellular 
hormone-mediated regulation; iii) alterations in the number of melanosome-bound 
motors; iv) adaptor molecule complex-mediated regulation; and v) signaling-
mediated off- and on-switching of specific motors to tip the balance of the 
movement. Most likely all of these mechanisms intertwine to achieve proper 
melanosome transport 67. 
In order to efficiently regulate the transport of melanosomes, extracellular binding 
of specific hormones to cell-surface receptors must occur, which then initiates 
intracellular signaling cascades 81. Aggregation is induced by the receptor-specific 
binding of melatonin or noradrenalin 82,83, while dispersion is induced by the 
binding of α-melanocyte stimulating hormone (MSH) to its specific receptor (Figure 
7) 84,85,86.  
It is still not clear whether variations of the total amount of melanosome-
associated motors or rather the motor’s state of activity change during 
melanosome transport. While the motor number on melanosomes for both the 
microtubule-based motors, dynein and Kinesin-2, remains unaltered, during 
aggregation more dynein molecules are tuned active than during dispersion 63,87. 
The fact that Kinesin-2 activity remains unaffected, supports the notion that only 
the minus-end component of microtubule-dependent transport is regulated, 
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whereas the plus-end component is continuously active 63,88. Interestingly, for the 
Myosin Va-driven melanosome transport during dispersion an increase in the total 
number of melanosome-bound Myosin Va molecules has been reported 63. 
All three motor protein families that are involved in melanosome transport require 
motor-specific adaptor-molecules by which they are linked to their cargo. The 
dynactin protein complex on melanosomes from fish and frog has been shown to 
mediate the anchoring of both dynein and Kinesin-2 to the melanosome (Figure 8) 
87,89,90. For Myosin V to bind to melanosomes it first has to bind melanophilin, 
which then physically links the motor to its cargo. The recruitment of Myosin Va 
onto the organelle is G-protein (Rab27a-GTP)-dependent and thus a tripartite 
Rab27a-Melanophilin-Myosin Va complex is formed on the melanosome (Figure 
8), allowing the melanosome to move along actin filaments and to become 
retained in the actin-rich cell periphery 58,59,91,92. Taken together, adaptor 
molecules represent important potential regulators during actin- and microtubule-
based transport 90. 
Figure 8. The transport machinery of melanosomes.  
In pigment cells, the tripartite complex consisting of Rab27a, melanophilin and Myosin 
Va on melanosomes, enables cargo transport on F-actin. Cytoplasmic dynein and 
Kinesin-2 are recruited to the malanosome via the Dynactin-p150Glued complex, 
thereby enabling the long-range cargo transport to the plus- and/or minus- ends of the 
microtubules. 
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Recently, protein kinase A (PKA) has been shown to bind to a dynein-containing 
aggregation as well as to a Kinesin-2-/Myosin V-containing dispersion complex. 
The interaction of those signaling pathway components with the melanosome 
surface was proposed to take place via scaffolding molecules 93. However, it 
seems likely that additional signaling cascades act downstream of PKA 94. For 
instance, only recently Rab32 was shown to mediate the positioning of PKA on 
melanosomes 95. Therefore, it is very likely that Rab-GTPases constitute an 
additional switch in the regulation of melanosome transport 96,97. 
Even though each of the established hypotheses might explain certain aspects of 
melanosome transport regulation, there are still important questions that have 
remained unanswered: How do molecular motors interact with each other on 
melanosomes? What are the exact functions of scaffolding molecules? How are 
molecular motors activated and regulated via G-protein coupled receptors as well 
as downstream signaling cascades? Does the proteomic composition on 
melanosomes change during aggregation and dispersion? 
 
1.6 Networking of the cytoskeleton 
Even though at first, the actin-myosin and kinesin-/dynein-microtubule systems 
seem to constitute two fundamentally different and separate transport systems, in 
most recent years the picture has significantly changed. For example, in neurons 
Myosin Va colocalizes with both the microtubule and actin cytoskeleton 98, and 
was observed to even localize to the centrosome of interphase and dividing cells 
of various types 30,99. Furthermore, it has been observed that in vivo, individual 
cargo molecules often carry both actin- and microtubule-based motors so that a 
cargo might be able to move along either filament when encountering an 
intersection of both filament types 79,80. 
While in cultured Xenopus melanophores, the removal of microtubules results in 
shuttling movements of pigment granules and a slow movement of melanosomes 
towards the cell periphery, the disruption of the actin cytoskeleton induces 
aggregation of melanosomes. Therefore, it has been suggested that the integrity 
of the actin cytoskeleton is a crucial requirement for the maintenance of the 
dispersed state 73,100. The microtubule- and actin-transport systems seem to 
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highly depend on each other as removing either component dramatically changes 
the organization of the other 101,102.  
Furthermore, for melanophores to aggregate and disperse pigment properly, 
switching of the melanosomes between cytoskeletal tracks in both directions is 
required 63. In fish and amphibian melanophores, long-range melanosome 
transport from the cell center to the cell periphery and back takes place on 
microtubules and is driven by Kinesin-2 and cytoplasmic dynein, respectively. In 
the actin-rich cell cortex, Myosin Va drives the short-range transport along actin 
filaments (Figure 9) 103,104,105,106. 
All of this implies that for efficient transport of cellular components a coordinated 
interplay between actin- and microtubule-based motor systems is required. 
Though in various studies a number of different hypotheses to explain this 
coordinated hand-off mechanism at intersections between actin and microtubules 
have been presented, to date the regulation of this crosstalk remains elusive. 
Figure 9. Co-active working of two different transport systems during 
pigment dispersion and aggregation. 
Left: dispersing pigment granules move out on microtubules (1), then switch to 
actin filaments (2); Right: aggregating granules are transported on actin 
filaments (1 and 2) and switch eventually to microtubules, which transport them 
towards the cell center (3). + and - denote the plus- and minus- ends of 
microtubules. Figure adapted from Gross, S., Curr. Biol., Vol. 17, 2007. 
Introduction 
________________________________________________________ 
 33 
1.7 One-dimensional diffusive search of Myosin V on 
microtubules 
A further facet to the yet unclear interaction between actin- and microtubule motor 
systems was added by a recent study, where Myosin V was found to switch from 
an actin filament onto an intersecting microtubule. Furthermore, following 
microtubule binding, Myosin Va even exhibited one-dimensional diffusive motion 
over large distances in vitro 107. The authors further hypothesized that the 
observed diffusion events of Myosin Va might result from an electrostatic 
interaction with the negatively charged tubulin E-hook. So far, E-hooks have been 
shown to be important for the binding to microtubules by some members of the 
kinesin superfamily 25,31,108,109. In a follow-up publication Ali et al. provide evidence 
that in vitro the interaction of Myosin Va with microtubules enhances the 
processivity of kinesin-based cargo transport on microtubules 110. One possible 
explanation for this would be that on microtubules Myosin Va might act as a tether 
and thereby prevent diffusion of the cargo away from the track. 
To study the events that occur at intersecting filaments is crucial for the 
understanding of how intracellular organelle transport is coordinated. With this in 
mind, part of this work focused on the investigation and characterization of the 
nature of this intriguing interaction between Myosin V and microtubules and its 
biological relevance emerging from it. 
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2 Project Aims of this Thesis 
2.1 One-dimensional diffusive motility of Myosin Va on 
microtubules 
In pigment cells from fish and amphibians, the long-range transport of pigment 
granules towards the cell periphery takes place on microtubules and is driven by 
Kinesin-2. However, within the actin-rich cell cortex short-range movement is 
carried out by the actin-based motor Myosin V 103,104,105,106. 
Therefore, some kind of handoff mechanism between Kinesin-2 and Myosin V 
has been proposed, but to date the regulation and molecular basis of this 
crosstalk has remained elusive. 
Studies by Ali et al. 107 demonstrated that in vitro Myosin V is capable of switching 
from an actin filament to an intersecting microtubule, followed by long-distance 
one-dimensional diffusive movements. Furthermore, Ali et al. 110 suggested that 
Myosin V’s ability to interact with microtubules might even enhance the 
processivity of Kinesin-2-powered cargo transport on microtubules. This 
biophysical trick could enable cells to exploit both tracks for the same transport 
process without switching motors. Based on previous studies dealing with the 
binding of myosins to F-actin and kinesins to microtubules, the authors proposed 
that this novel and unconventional interaction between the heads of Myosin V and 
microtubules results from an electrostatic interaction between the positively 
charged myosin loop 2 and the negatively charged microtubule E-
hooks35,44,111,112,113,114,115,116,117,118,119,120. 
The aim of this project was to understand the underlying basis of this intriguing 
interaction between Myosin V and microtubules. Therefore, three major questions 
were addressed in this study: Does indeed the charge of loop 2 contribute to 
microtubule binding? If E-hooks are at all required for the interaction between 
Myosin V and microtubules, do they aid during the initial binding or rather during 
the diffusive movement? If E-hooks are dispensable, then what biophysical 
feature enables Myosin V to start diffusing along the filament? 
For this, via single-molecule TIRF microscopy as well as different biochemical 
assays, I set out to characterize the behavior of three Myosin V mutants 
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containing differently charged (positive and negative) loop 2 motifs, on 
microtubules and also on F-actin. 
 
2.2 Calcium-/Calmodulin-dependent Kinase II-α  and its role in 
Myosin V release from pigment organelles 
As detailed in Section 2.1, Myosin V was proposed to assist Kinesin-2-driven 
cargo transport on microtubules by enhancing kinesin’s runlength in vivo (i.e., 
processivity) 110. However, this hypothesis derives from in vitro experiments and 
awaits further clarification in a biologically relevant setup. 
An ideal set up would involve the transport of a native cargo that employs both 
Kinesin-2 and Myosin V motor proteins. As intact melanosomes can be isolated 
from melanophores and involve both Kinesin-2 as well as Myosin V to achieve 
pigment dispersion, once again the pigment cells from lower vertebrates offer the 
most suitable system to study the interplay between these distinct transport 
systems. To dissect the effects of Myosin V on the Kinesin-2-powered cargo 
transport, the composition of the melanosome transport machinery would need to 
be manipulated. How would one obtain melanosomes that lack Myosin V and 
have Kinesin-2 still attached? To solve this problem as well as to pave the way for 
testing whether Myosin V is indeed capable of assisting the Kinesin-2-powered 
cargo transport on microtubules, was the main motivation of this project.   
Rogers et al. (1999)103 reported that Myosin V undergoes motor-specific release 
from melanosomes when incubated with mitotic Xenopus egg-cell extract. In very 
elegant assays using biochemical as well as mass-spectrometry analysis, 
Karcher et al. provided evidence that Calcium-/Calmodulin-dependent kinase II-α 
(CaMKII-α) induces the release of Myosin V from melanosomes by 
phosphorylating a specific Serine in the tail of Myosin V 121. 
These findings formed the two major goals of this project: i) to establish the 
baculoviral expression and subsequent purification of recombinant CaMKII-α, and 
ii) to build-up an assay, by which Myosin V release from melanosomes can be 
induced and monitored biochemically in vitro. With this assay, the following 
questions were addressed: Without egg-cell extract, is there endogenous CaMKII-
α from melanophores that might also interact with melanosome-associated 
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Myosin V? If that is the case, then to which extent can it induce the release of 
Myosin V? And thirdly, can the recombinant exogenous kinase trigger the 
complete release of Myosin V from melanosomes? 
In collaboration with Z. Kochovski and V. Lucic from the Baumeister-laboratory 
(MPI for Biochemistry, Martinsried, Germany) one additional goal of this work was 
to analyze the structure of the stimulated as well as unstimulated form of CaMKII-
α via cryo-electron tomography. This is particularly interesting as CaMKII-α in vivo 
and in solution forms a dodecameric holoenzyme structure 122,123,124, which to 
date constitutes the most complex and unique structure among all kinases 
identified so far. 
 
2.3 MACS® bead-assisted purification of pigment organelles −  A 
novel approach 
Although melanosomes were central to study organelle transport in vivo and in 
vitro, the methodology used so far has been limited to inhibitor studies, 
microinjection and electron as well as fluorescence or differential interference 
contrast microscopy. However, with the rapid progress of proteomic analysis 
techniques, as a next step it would be important to perform a “bottom-up” 
approach, which bears the great potential to reveal novel interaction partners 
involved in spatial and temporal regulation of melanosome transport. To date just 
a couple of studies approached the melanosome via proteomics, targeting 
melanosomes from human melanoma skin cells 125,126, not those from 
melanophores with rapid intracellular transport. Undoubtedly, the greatest 
challenge of mass-spectrometry, representing a very sensitive analytical method, 
pose the crude purification techniques that are used to isolate organelles for in 
vitro functional analyses. Even though mass-spectrometry on fractions of other 
types of organelles (e.g., mitochondria) that had been obtained by sucrose 
density ultra-centrifugation has been successfully carried out 127,128,129,130, 
melanosomes tend to lose their transport machinery upon such harsh treatments.  
Therefore, the ultimate goal would be to establish a method, by which functionally 
intact but at the same time, pure melanosome fractions are obtained. For this, the 
established, conventional crude melanosome isolation protocol was combined 
Project Aims of this Thesis 
________________________________________________________ 
 37 
with a technique that uses paramagnetic beads functionalized with antibodies 
against organelle-specific surface markers. This way, neither harsh centrifugation 
nor contaminating additives (e.g., sucrose) were applied. This feat allows for the 
analysis of functional organelles without having any contaminating cytosolic 
components present, which might overwhelm the signals from any melanosome-
specific candidate. 
 
2.4 Determining the sequence of the full-length Myosin Va from 
Xenopus laevis 
Over the past three to four decades, great efforts have been undertaken to 
understand the mechanisms that drive intracellular organelle transport. In addition 
to studies on murine melanocytes, a large portion of today’s knowledge on 
cytoplasmic organelle transport derives from studies on melanosomes from 
pigment cells of the African clawed frog Xenopus laevis. By using immunohisto- 
as well as immuno-biochemistry along with drug-dependent disruption of the actin 
cytoskeleton, the motor responsible for melanosome transport on actin in the 
outer margins of the cell was identified as Myosin Va 63,121,131,132. However, the 
full-length sequence of the Xenopus l. Myosin Va has remained unknown. 
Instead, mutated or truncated versions of the mouse Myosin Va version were 
used to manipulate melanosome transport (even in frog cells) in vivo. The aim of 
this project was to obtain the full-length sequence of Myosin Va from Xenopus l. 
melanophores, and to express it in insect cells. 
I approached this problem by retrieving the full-length coding sequence of the 
Myosin Va gene using conventional step-by-step PCR and RACE (Rapid 
Amplification of cDNA Ends) PCR from melanophore cDNA. An additional aim 
was the initial biophysical characterization of the recombinantly expressed full-
length Myosin Va protein via fluorescence microscopy on F-actin as a first step 
towards a more complete characterization of this motor. 
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3 Materials 
3.1 Laboratory utensils and consumption items 
Name of Item Company, Location 
Amersham Hyperfilm ECL GE Healthcare, Munich 
Amicon Ultra-4 Centrifugal Filter Unit with Ultracel-50 
membrane 
Millipore, Munich 
Analytical Scale Analytic AC210P Sartorius, Göttingen 
Balch cell homogenizer with 0.6 µ tungsten-carbide 
ball 
Isobiotec, Heidelberg 
Centrifuge 5415 D Eppendorf, Hamburg 
Centrifuge GS-15R Beckman-Coulter, Fullerton (U.S.A.) 
Centrifuge J2-21M/E Beckman-Coulter, Fullerton (U.S.A.) 
Centrifuge Rotanta 460R Hettich, Tuttlingen 
Centrifuge Rotina 420 Hettich, Tutlingen 
Centrifuge Rotor JA-14 Beckman-Coulter, Fullerton (U.S.A.) 
Centrifuge Tube with Sealing Cap, 250 ml Nalgene Labware, Rochester 
(U.S.A.) 
Developing machine Curix 60 (formerly) Agfa, Germany 
DVS1000 Video Processor Hamamatsu Photonics, Herrsching 
ELISA 96-Well Plate for Biotek Reader Greiner, Frickenhausen 
FluoArc 01.26 Hg Lamp Jena GmbH 
FPLC Device Pharmacia GMI, Ramsey (U.S.A.) 
Front-illuminated Coupled Charge Device (CCD) 
C9100 Camera 
Hamamatsu Photonics, Herrsching  
Glass Homogenizer Fisher Scientific, Schwerte 
Hemocytometer Neubauer-improved Blaubrand, Wertheim  
Ice Machine AF20 Scotsman, Herborn 
Incubator B5060 Heraeus, Hanau 
Incubator-Shaker Device Certomat BS-T Sartorius, Göttingen 
Incubator-Shaker Device HT Infors, Bottmingen (Switzerland) 
Laboratory Film “M” American National Can, Chicago 
(U.S.A.) 
MACS LS separation column Miltenyi Biotec, B. Gladbach 
Microcentrifuge (max. Speed 6,000 rpm) Roth, Karlsruhe 
Microwave Intellowave LG, Willich 
Milli-Q®, Water Purifier Millipore, Schwalbach 
Minifuge RF Heraeus, Hanau 
MonoQ®  Pharmacia Column GMI, Ramsey (U.S.A.) 
Newicon C2400 Camera Hamamatsu Photonics, Herrsching 
Nitrocellulose Membrane Protran-Whatman, Dassel 
PCR-Thermocycler Primus 96 PeqLab, Erlangen 
pH-Meter  Knick, Berlin 
Pipetman Gilson (10, 20, 100 and 1000 µl) Gilson, Middleton (U.S.A.)  
Pipettips (with/without sterile filter) Sarstedt, Nürmbrecht 
PolyPrep®  Chromatography Column Bio-Rad, Hercules (U.S.A.) 
Power Supplier Powerpack P21 Biometra, Göttingen 
PowerWave™ Microplate Spectrophotometer Biotek, Winooski, (U.S.A.) 
Purple Nitrile Powder-free Exam Gloves Kimberly Clark, Roswell (U.S.A.) 
QuadroMACS™ Separator magnet Miltenyi Biotec, B. Gladbach 
Reaction tubes, 1.5 ml Sarstedt, Nürmbrecht 
Reaction Tubes, 13 ml Sarstedt, Nürmbrecht 
Reaction Tubes, 15 ml Sarstedt, Nürmbrecht 
Reaction tubes, 50 ml Sarstedt, Nürmbrecht 
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Rotator Labquake Barnstead, Dubuque (U.S.A.) 
SDS-PAGE Electrophoresis Module Biorad, Hercules (U.S.A.) 
Semi-dry Elektroblotter SEDEC M PeqLab, Erlangen 
Sephadex® G300 Pharmacia Column Material GMI, Ramsey (U.S.A.) 
Serological Pipettes (5, 10, 25 and 50 ml) Sarstedt, Nürmbrecht 
Silica Cuvette QS (10.00 mm) Hellma Optika, Jena 
Slide-A-Lyzer®  10K MWCO 0.1-0.5 ml capacity 
Dialysis Cassette 
Pierce, Rockford (U.S.A.) 
Slide-A-Lyzer® 10K MWCO 0.5-3 ml capacity Dialysis 
Cassette 
Pierce, Rockford (U.S.A.) 
Solid-pahse Laser Device λ 532 nm Hamamatsu Photonics, Herrsching 
Solid-phase Laser device λ 488 nm Hamamatsu Photonics, Herrsching 
Sonifier 250 Branson, Danbury (U.S.A.) 
Sorvall GSA Rotor Thermo Fisher Scientific, Waltham 
(U.S.A.) 
Spectrometer Uvikon 930 Kontron Instruments, Groß-Zimmern 
Sterile Work Bench Infinity Envair, Emmendingen 
Surgical Disposable Scalpels Braun, Tuttlingen 
Table-top Centrifuge 5415D Eppendorf, Hamburg 
Thermomixer Comfort Eppendorf, Hamburg 
Total Internal Reflection Fluorescence (TIRF) 
Microscope X71 
(Plan objective lens 100×, N.A. 1.65 Oil) 
Olympus Biosystems, Planegg 
Ultra-Centrifuge L8-70M Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Optima-TL Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Rotor 35 Ti Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Rotor 42.1 Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Rotor 45Ti Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Rotor TLA 100 Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Rotor TLA 120 Beckman-Coulter, Fullerton (U.S.A.) 
Ultra-Centrifuge Tubes for 42.1-Rotor Beckman-Coulter, Fullerton (U.S.A.) 
Vinyl Powder-free Exam Gloves Med Comfort, Stelle 
Vortex Mixer 72020 Neo-Lab, Heidelberg 
Zeiss Axiophot Microscope (Plan-Apochromatic 
Objective lens 63×, N.A. 1.4 Oil, DIC prsims and Oil-
immersion Condenser for N.A. 1.4) 
Zeiss, Oberkochen 
Zeiss Axiovert 200M Zeiss, Jena 
Zeiss CCD AxioCam MRm camera Zeiss, Jena 
 
3.2 Cell culture accessories 
Name of Item Company, Location 
Corning® 500 ml Polycarbonate Erlenmeyer Flask 
with Plug Seal Cap 
Corning Inc., Lowell (U.S.A.) 
Cell Scraper Greiner Bio-one, Munich 
Cellfectin® Reagent Invitrogen, Karlsruhe 
Centrifugation Tube (250 ml) with Plug Seal Cap Nalgene Labware, Rochester 
(U.S.A.) 
Corning® 2 L Polycarbonate Erlenmeyer Flask with 
Plug Seal Cap 
Corning Inc., Lowell (U.S.A.) 
Corning® 250 ml Polycarbonate Erlenmeyer Flask 
with Plug Seal Cap 
Corning Inc., Lowell (U.S.A.) 
Electrical Vacuum Pump BVC21 NT Vacuubrand, Wertheim 
Fetal Bovine Serum (FBS) USA origin, sterile-filtered, 
Cell Culture- and Hybridoma-tested 
Sigma-Aldrich, St. Louis (U.S.A.) 
Filter Syringe 0.22 µm Millex® GP (sterile) Millipore, Schwalbach 
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Gentamicin (10 mg/ml) c.c. Pro, Oberdorla 
Glass Erlenmeyer Flasks (0.2 L to 6L) Fisher Scientific, Schwerte 
Insulin (bovine) Sigma-Aldrich, St. Louis (U.S.A.) 
Leibovitz’s L-15 Medium Invitrogen, Karlsruhe 
Light-Microscope Labovert Leitz, Wetzlar 
Medium Sf-900 II SFM Gibco-Invitrogen, Karlsruhe 
Melanophores (Xenopus laevis), immortalized  kind gift from V. Gelfand, Chicago 
(U.S.A.) 
Melatonin Sigma-Aldrich, St. Louis (U.S.A.) 
Penicilin-Streptomycin Invitrogen, Karlsruhe 
Sf9 Cells, SFM Adapted Invitrogen, Karlsruhe 
Six-Well Plate Multiwell Becton-Dickinson, Franklin (U.S.A.) 
Syringes 2 ml (sterile) Braun, Melsungen 
Trypsin/EDTA Promega, Mannheim 
Vent-cap Cell Culture Flasks, 25-175 cm2, PS Greiner, Munich 
Water Bath Preservative Roth, Karlsruhe 
α-Melanocyte Stimulating Hormone (α-MSH) Sigma-Aldrich, St. Louis (U.S.A.) 
 
3.3 Plasmids and vectors 
Description Distributor, Location 
p2bac/pfastbac (containing HMM-like Myosin 
Va+CaM) 
J. Spudich, Stanford (U.S.A.)  
pBluescript SK (-) (containing CaMKII-α coding 
sequence) 
Y. Hayashi, Saitama (Japan) 
pFastBac™Dual Invitrogen, Karlsruhe 
pFastBac™ 1 Invitrogen, Karlsruhe 
 
3.4 Oligonucleotides (Primers) 
3.4.1 Cloning primers 
Primer ID Primer Sequence Rest.site 
 HMM-like Myosin Va (N’ FLAG-tag)  
HMM-M5_Fw01 5’-atagcggccgcatggactacaaggacgacgatgacaagggc-3’ NotI 
HMM-M5_Rv01 5’-atagtcgactcgactcactccccgacaagcttcttaagt-3’ SalI 
 Calmodulin (no tag)  
CaM_Fw01 5’-atagctagcatggcagatcaactgacagaagagc -3’ NheI 
CaM_Rv01 5’-atagcggtactcacttcgctgtcatcatctg -3’ KpnI 
 CaMKII-α  (N’ FLAG-tag)  
CaMKII-
FLAG_Fw1 5’-cgataactagtatggactacaaggacgacgatgacaagggcgcacctgctaccatcacctgcacc-3’ SpeI 
CaMKII_Rv1 5’-cgcttgcggccgctcaatggggcaggacggagg-3’ NotI 
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 CaMKII-α  (C’ FLAG-tag)  
CaMKII_Fw2 5’-cgataactagtatggctaccatcacctgcacccg-3’ SpeI 
CaMKII-
FLAG_Rv2 5’-cgcttgcggccgctcacttgtcatcgtcgtccttgtagtcaggtgcgccatggggcaggacggagggc-3’ NotI 
 CaMKII-α  (No FLAG-tag)  
CaMKII_Fw2 5’-cgataactagtatggctaccatcacctgcacccg-3’ SpeI 
CaMKII_Rv1 5’-cgcttgcggccgctcaatggggcaggacggagg-3’ NotI 
 Full-length Xenopus l. Myosin Va (N’ FLAG-tag)  
FLXM5_NheIFL
AG-Fw 5’-gcgctagcatggactacaaggacgacgatgacaagggcgcacctgaaaacaatttagattttgc-3’ NheI 
FLXM5_SphI-Rv 5’-gttgcatgctcagacgcgtgtgaggaacc-3’ SphI 
 Full-length Xenopus l. Myosin Va (C’ FLAG-tag)  
FLXM5_Nhe-
Fw2 5’-gcgctagcatggaaaacaatttagattttgc-3’ NheI 
FLXM5_SphIFL
AG-Rv 5’-gttgcatgctcacttgtcatcgtcgtccttgtagtcaggtgcgccgacgcgtgtgaggaacc-3’ SphI 
 Full-length Xenopus l. Myosin Va (No FLAG-tag)  
FLXM5_NheI-
Fw2 5’-gcgctagcatggaaaacaatttagattttgc-3’ NheI 
FLXM5_SphI-Rv 5’-gttgcatgctcagacgcgtgtgaggaacc-3’ SphI 
 Full-length Xenopus l. Myosin Va (intermediate products)  
 Phase A  
FLXM5_Fw#1 5’-atggaaaacaatttagattttgc-3’ − 
FLXM5_Rv5 5’-atttttcttgcctgctcctg-3’ − 
 Phase B  
FLXM5_Fw#5 5’-atgtatgttgttcgacagaagtaccg-3’ − 
FLGgM5_Rv412
6 5’-agccgggtgatctcatgctg-3’ 
− 
 Phase C  
FLXM5_Fw#7 5’-gaggaacttgacgtgcgtaaggaag-3’ − 
UPM (long) 5'-ctaatacgactcactatagggcaagcagtggtatcaacgcagagt-3'  − 
UPM (short) 5'-ctaatacgactcactatagggc-3'  − 
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3.4.2 Sequencing primers 
Primer ID Primer Sequence 
 Full-length Xenopus l. Myosin Va-specific 
FLXM5_Seq#1 5’-atggaaaacaatttagattttgc-3’ 
#2 5’-atacattgaaattggctttgataaac-3’ 
#3 5’-gctttgaacagttttgtatcaactatg-3’ 
#4 5’-agaaattcccttcaccttctgatg-3’ 
#5 5’-atgtatgttgttcgacagaagtaccg-3’ 
#6 5’-ttaatccaggagcaggcaag-3’ 
#7 5’-gaggaacttgacgtgcgtaaggaag-3’ 
#8 5’-gccacctgaagcaagaattg-3’ 
#9 5’-agctggaagtgggtcaaatg-3’ 
#10 5’-ttgttcatgtgtttgcgtca-3’ 
#11 5’-actgtcagtggttctgccagtg-3’ 
#12 5’-atttccagattacaagccaccaatgc-3’ 
#13 5’-gttgccgagctgagagaacagaatgc-3’ 
#14 5’-ccataccgaaatgaggagcctgctg-3’ 
#15 5’-agctggaagtgggtcaaatg-3’ 
#16 5’-accgatgaagatgcagaagc-3’ 
 HMM-like Myosin Va-specific 
HMM-M5_Seq#1 5’-ggggcaggaaagacggtttctgcc-3’ 
#2 5’-gggcaacgtggagtttgcatctcggg-3’ 
#3 5’-ggatctgttagatgaggaatgcaagatgcc-3’ 
#4 5’-ggacataccaagagttcttcagccg-3’ 
#5 5’-ggctggctggctcgagtgc-3’ 
 CaMKII-α-specific 
CaMKII_Seq#1 5’-cgacctgaagcctgagaatc-3’ 
#2 5’-aaactgaagggagccatcct-3’ 
 Calmodulin-specific 
CaM_Seq#1 5’-ggatcagctgaccgaagaac-3’ 
 Baculovirus transfer vector-specific 
pPolyhedrin_Seq 5’-cctataaatattccgg-3’ 
pP10_Seq 5’-cggacctttaattcaaccc-3’ 
M13_Seq (reverse) 5’-caggaaacagctatgac-3’ 
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3.5 Microorganisms 
Description of Cells Company, Location 
MAX Efficiency® DH10Bac Competent E. coli Invitrogen, Karlsruhe 
XL1-Blue Subcloning-Grade Competent Cells Stratagene, La Jolla (U.S.A.) 
 
3.6 Mediums and agars for microorganisms 
LB-Ampicillin Agar 
1.5 % (w/v) Agar 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast Extract 
1 % (w/v) NaCl 
0.1 % (v/v) Ampicillin-Solution (100mg/ml) 
 
LB-Ampicillin Medium 
1 % (w/v) Tryptone 
0.5 % (w/v) Yeast Extract 
1 % (w/v) NaCl 
0.1 % (v/v) Ampicillin-Solution (100mg/ml) 
 
S.O.C Medium 
2 % (w/v) Tryptone 
0.5 % (w/v) Yeast Extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
2 % (v/v) 1 M Glucose 
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3.7 Antibodies and peptides 
 Antibody Name Isotype/host Company, Location 
Anti-FLAG® M2 affinity gel IgG1/Mouse Sigma-Aldrich, St. Louis (U.S.A.) 
Anti-FLAG® Biotinylated M5, 
monoclonal IgG1/Mouse 
Sigma-Aldrich, St. Louis 
(U.S.A.) 
Anti-Myosin Va (LF-18), 
polyclonal IgG/Rabbit 
Sigma-Aldrich, St. Louis 
(U.S.A.) 
Anti-FLAG® M2-Cy3™, 
monoclonal IgG1/Mouse 
Sigma-Aldrich, St. Louis 
(U.S.A.) 
Anti-α-Tubulin (YL 1/2), 
monoclonal IgG/Rat R. Gräf, Postdam 
Anti-β-Tubulin (SAP.4G5), 
monoclonal IgG1/Mouse 
Santa Cruz Biotech., 
Heidelberg 
Anti-total CaMKII (6G9), 
monoclonal IgG1/Mouse Thermo Scientific, Bonn 
Anti-Phospho (Thr286)-CaMKII 
(22B1), monoclonal IgG1/Mouse Thermo Scientific, Bonn 
Anti-Kinesin-2 (K2.4), monoclonal IgG1/Mouse Covance, Princeton (U.S.A.) 
Anti-GAPDH (6C5), monoclonal IgG1/Mouse Merck-Millipore, Darmstadt 
Pr
im
ar
y 
Anti-Trp1 (TA99), monoclonal IgG2a/Mouse Abcam, Cambridge (U.K.) 
    Anti-Mouse IgG Microbeads IgG/Goat Miltenyi Biotec, B. Gladbach 
Anti-Rat IgG (Whole Molecule)-
Peroxidase IgG/Rabbit 
Sigma-Aldrich, St. Louis 
(U.S.A.) 
Anti-Mouse IgG (Fc-specific) 
Peroxidase Conjugate IgG/Goat 
Sigma-Aldrich, St. Louis 
(U.S.A.) 
Se
co
nd
ar
y 
Anti-Rabbit IgG (Whole Molecule) 
Peroxidase Conjugate IgG/Goat 
Sigma-Aldrich, St. Louis 
(U.S.A.) 
 FLAG® peptides  Sigma-Aldrich, St. Louis (U.S.A.) 
 
3.8 Chemicals and ready-to-use solutions 
Name of Chemical/Solution Company, Location 
1-Brom-3-Chloropropane Merck, Darmstadt 
Acetic Acid (99.5% p. A.) Roth, Karlsruhe 
Acteone Sigma-Aldrich, St. Louis (U.S.A.) 
Agarose NEEO Ultra-Quality Roth, Karlsruhe 
AMP-PNP (Adenosine 5’-(β,γ-imido) triphosphate 
lithium salt hydrate) 
Sigma-Aldrich, St. Louis (U.S.A.) 
Ampicillin (No Salt) Roth, Karlsruhe 
APS Biorad, Hercules (U.S.A.) 
Apyrase from Potato grade IV Sigma-Aldrich, St. Louis (U.S.A.) 
Betaine Sigma-Aldrich, St. Louis (U.S.A.) 
Bio-Rad Protein Assay Dye Reagent Concentrate Biorad, Hercules (U.S.A.) 
Biotin Bovine Serum Albumin  Sigma-Aldrich, St. Louis (U.S.A.) 
Bovine Serum Albumin 99% purity Sigma-Aldrich, St. Louis (U.S.A.) 
Bromophenol Blue Sigma-Aldrich, St. Louis (U.S.A.) 
CaCl2 x 2H2O Merck, Darmstadt 
Calmodulin from Bovine Brain, High Purity Merck-Millipore, Darmstadt 
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Casein from Bovine Milk Sigma-Aldrich, St. Louis (U.S.A.) 
Collodion solution, 2% in amyl acetate Sigma-Aldrich, St. Louis (U.S.A.) 
Coomassie Brilliant Blue R-250 Sigma-Aldrich, St. Louis (U.S.A.) 
cθmplete, Mini Protease Inhibitor (EDTA-free) Roche Applied Science, Penzberg 
DEPC (Diethyl pyrocarbonate) Sigma-Aldrich, St. Louis (U.S.A.) 
DMSO  Roth, Karlsruhe 
dNTPs (100 mM) PeqLab, Erlangen 
DTT  Sigma-Aldrich, St. Louis (U.S.A.) 
EDTA Sigma-Aldrich, St. Louis (U.S.A.) 
EGTA Sigma-Aldrich, St. Louis (U.S.A.) 
Ethanol (99.8% p.a.) Roth, Karlsruhe 
Ethidium Bromide Roth, Karlsruhe 
Gelsolin from Bovine Plasma Sigma-Aldrich, St. Louis (U.S.A.) 
Gene Ruler 100 bp Plus DNA Ladder (0.1 µg/µl) 
#SM0328 
Fermentas, St. Leon Roth 
Gentamicin Sulfate Sigma-Aldrich, St. Louis (U.S.A.) 
Glacial Acetic Acid (99%) Roth, Karlsruhe 
Glucose Roth, Karlsruhe 
Glycerol Rotipuran®  (99.5% p.a.) Sigma-Aldrich, St. Louis (U.S.A.) 
Goat Anti-Mouse IgG Microbeads Miltenyi Biotec, B. Gladbach 
GTP Sigma-Aldrich, St. Louis (U.S.A.) 
Guanidinium-HCl Solution (8 M in H2O, filtered) Sigma-Aldrich, St. Louis (U.S.A.) 
HCl  Merck, Darmstadt 
Hepes Merck, Darmstadt 
High Molecular Weight Protein Ladder Sigma-Aldrich, St. Louis (U.S.A.) 
Imidazole Sigma-Aldrich, St. Louis (U.S.A.) 
Isoamylalcohol (99.8% p.a.) Sigma-Aldrich, St. Louis (U.S.A.) 
Isopropanol (99% p.a.) Roth, Karlsruhe 
K-Acetate Merck, Darmstadt 
Kanamycin Monosulfate Sigma-Aldrich, St. Louis (U.S.A.) 
KCl Merck, Darmstadt 
KH2PO4 Merck, Darmstadt 
KOH Merck, Darmstadt 
Luminol (3-Aminophtalhydrazide) Sigma-Aldrich, St. Louis (U.S.A.) 
Methanol (99.5% p.a.) Roth, Karlsruhe 
Mg-Acetate x 4 H2O Merck, Darmstadt 
MgCl2 x 6 H2O Merck, Darmstadt 
MgSO4 x 7 H2O Merck, Darmstadt 
Milkpowder Roth, Karlsruhe 
N-Phenylthiourea (PTU) Sigma-Aldrich, St. Louis (U.S.A.) 
Na2ATP  Sigma-Aldrich, St. Louis (U.S.A.) 
Na2HPO4 Merck, Darmstadt 
NaCl  Sigma-Aldrich, St. Louis (U.S.A.) 
NaHCO3 Merck, Darmstadt 
NaN3 Merck, Darmstadt 
p-Coumaric Acid Sigma-Aldrich, St. Louis (U.S.A.) 
P11 Cellulose Phosphate Material Merck, Darmstadt 
Paclitaxel from Taxus brevifolia Sigma-Aldrich, St. Louis (U.S.A.) 
Page Ruler Prestained Protein Ladder #SM0671 Fermentas, St. Leon Roth 
Phalloidin from Amanita phalloidies Sigma-Aldrich, St. Louis (U.S.A.) 
Phalloidin-Atto 488 Sigma-Aldrich, St. Louis (U.S.A.) 
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Phalloidin-TRITC Invitrogen, Karlsruhe 
Phenylmethanesulfonyl fluoride (PMSF) Premium Sigma-Aldrich, St. Louis (U.S.A.) 
Phospho(enol)pyruvic acid trisodium sulfohydrate  Sigma-Aldrich, St. Louis (U.S.A.) 
PIPES Sigma-Aldrich, St. Louis (U.S.A.) 
Ponceau Red S Sigma-Aldrich, St. Louis (U.S.A.) 
Protector RNase-inhibitor Roche Applied Science, Penzberg 
QDot® 525 Streptavidin Conjugate Life Technologies, Grand Island 
(U.S.A.) 
Rotiphorese Gel 30 Roth, Karlsruhe 
SDS  Sigma-Aldrich, St. Louis (U.S.A.) 
Streptavidin from Streptomyces avidinii Sigma-Aldrich, St. Louis (U.S.A.) 
Sucrose Merck, Darmstadt 
Taq Polymerase Reaction Buffer (10X) PeqLab, Erlangen 
Temed  Sigma-Aldrich, St. Louis (U.S.A.) 
Tetracyclin Sigma-Aldrich, St. Louis (U.S.A.) 
TRI-reagent® Molecular Research Center, 
Cincinatti (U.S.A.) 
Triton-X 100 Fluka, Buchs (Switzerland) 
Trizma Base Sigma-Aldrich, St. Louis (U.S.A)  
Trypan Blue Solution Invitrogen, Karlsruhe 
Tryptic Soy Broth (Tryptone, microbiologically tested) Sigma-Aldrich, St. Louis (U.S.A.) 
Tween® 20 Premium Sigma-Aldrich, St. Louis (U.S.A.) 
Yeast Extract Agar Sigma-Aldrich, St. Louis (U.S.A.) 
β-Mercaptoethanol Sigma-Aldrich, St. Louis (U.S.A.) 
β-Nicotinamide-adenine-dinucleotide (NADH), 
reduced disodium salt  
Sigma-Aldrich, St. Louis (U.S.A.) 
 
3.9 Buffers and ready-to-use solutions 
12A25 Buffer (1X): 
12.5 mM KOH (pH 6.8) 
2 mM Mg-Acetat 
25 mM K-Acetat 
1 mM EGTA 
 
ABSA Buffer (1X, 10 ml): 
1 ml BSA (10 mg/ml) 
9 ml AB Buffer (1X) 
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Agarose Gel Loading Buffer: 
20% Glycerol 
0.1 M EDTA 
1% SDS 
0.25% Bromophenol Blue 
 
APS Solution (100X): 
10% (w/v) APS in Water 
Assay Buffer AB (1X): 
25 mM Imidazole, pH 7.4 
25 mM KCl 
4 mM MgCl2 
1 mM EGTA 
10 mM DTT 
 
ATP Solution (0.1 M, pH 7.0): 
100 mM Na2ATP in Water 
BBSA Solution (10 ml): 
10 mg BBSA 
10 ml PBS 
BRB80 Buffer (1X): 
80 mM Pipes 
2 mM MgCl2 
1 mM EGTA 
1 mM DTT 
 
BRB80-Tx (1X): 
+5 µM Paclitaxel (4 mM in DMSO) 
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Brickey Buffer (1X): 
10 mM TrisCl, pH 7.5 
1 mM EGTA 
1 mM EDTA 
2.5% (v/v) Betaine 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free, Roche) 
 
BSA Solution (10 ml): 
100 mg BSA 
10 ml Water 
 
Buffer A (pH 6.9): 
0.1 mM Pipes 
2 mM EGTA 
1 mM MgSO4 
0.1 mM Na2ATP  
1 mM DTT 
 
Buffer B (pH 6.94): 
0.5 M Pipes 
2 mM EGTA 
1 mM MgSO4 
 
Buffer C: 
0.1 M Pipes 
1 mM EGTA 
1 mM MgSO4 
1 mM Na2ATP 
1 mM DTT 
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Buffer D: 
0.1 M Pipes (pH 6.94) 
1 mM EGTA 
1 mM MgSO4 
0.05 mM Na2ATP 
0.022 mM GTP (pH 7.0) 
1 mM DTT 
 
Catalase Solution (100X): 
170000 U/ml Catalase in O2 Quench Buffer (1X) 
50% (v/v) Glycerol 
 
Coomassie Brilliant Blue Solution: 
0.25% (w/v) Brilliant Blue R-250 
50% (v/v) Methanol 
10% (v/v) Glacial Acetic acid 
 
DB-CK (1X): 
150 mM KCl 
10 mM Hepes, pH 7.4 
0.1 mM EGTA 
10% (v/v) Gylcerol 
 
DB-HMM-M5 (1X): 
Assay Buffer (1X) 
50% (v/v) Glycerol 
 
EB-CK (1X): 
500 mM NaCl 
40 mM Hepes, pH 7.4 
1 mM EGTA 
+ 400 µg/ml FLAG peptides (in TBS) 
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EB-HMM-M5 (1 ml): 
300 µg FLAG® Peptides in TBS  
940 µl Wash Buffer (1X) 
 
EB-XM5 (1X): 
1.25 mg FLAG® Peptides (in TBS) 
750 µl Wash Buffer (1X) 
 
ECL- Solution (1 ml): 
0.5 ml Solution A 
0.5 ml Solution B 
0.01% H2O2 
 
EDTA Solution (pH 7.0): 
200 mM EDTA in TAE (50X) 
EGTA Solution (pH 7.0): 
200 mM EGTA in TAE (50X) 
Electrophoresis Buffer (10X, pH 8.8): 
3% (w/v) Tris Base  
1% (w/v) SDS 
14% (w/v) Glycine 
 
Ethanol (1 L, 70% Vol.): 
700 ml Ethanol (99.9%) 
300 ml Water 
 
FLAG® Peptides (1 ml of 5 µg/µl Aliquots):  
5 mg FLAG® Peptides  
1 ml TBS (1X) 
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G Buffer: 
2 mM TrisHCl 
0.2 mM CaCl2 
0.2 mM ATP 
0.2 mM DTT 
0.005% (v/v) NaN3 (20% Stock Solution) 
 
Gentamicin Solution (100 ml): 
50 mg Gentamicin Sulfate  
100 ml Water 
 
Glucose Oxidase Solution (100X): 
2600 U/ml Glucose Oxidase in O2 Quench Buffer (1X) 
50% (v/v) Glycerol 
 
Glucose Solution (100X, 1 ml): 
500 mg Glucose 
1 ml Water 
 
GTP Solution (pH 7.0): 
0.1 M GTP in Water 
Guanidine Hydrochloride (6.6 M): 
6.6 M Guanidinium Hydrochloride Solution (8 M) 
Water 
 
Hepes Buffer (1X): 
100 mM Hepes (pH 7.0) 
1 mM MgCl2 
0.5 mM EGTA 
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High Ca2+ Reaction Mix (2.5X): 
125 mM Tris Base, pH 7.1 
>2.5 mM MgCl2 (included in 0.5 M TrisCl / 0.01 MgCl2) 
1 mM EGTA 
1.75 mM CaCl2 
1 mg/ml BSA (in H2O) 
 
High Molecular Weight (HMW) Protein Ladder-Aliquots: 
3 mg HMW 
1.5 ml SDS Sample Buffer (1X) 
 
High Salt Buffer (pH 8.5): 
10 mM Tris Base (pH 8.0) 
0.25 mM CaCl2 
0.1 mM EGTA 
0.2 mM DTT 
2 M NaCl 
 
Kanamycin Solution (100 ml): 
50 mg Kanamycin Monosulfate 
100 ml Water 
 
KMg50 Buffer (1X): 
50 mM KCl 
1 mM EGTA 
1 mM MgCl2 
1 mM DTT 
10 mM Imidazole (HCl, pH 7.0) 
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LB-HMM-M5 (1X): 
200 mM NaCl 
4 mM MgCl2 
20 mM Imidazole, pH 7.5 
0.5 mM EDTA 
7% (w/v) Sucrose 
5 mM DTT 
2 mM ATP 
0.5% (v/v) Triton-X 100 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free) 
 
LB-XM5 (1X): 
200 mM NaCl 
20 mM Imidazole, pH 7.5 
mM MgCl2 
1 mM EGTA 
1 mM EDTA 
7% (w/v) Sucrose 
1 mM PMSF (in Isopropanol) 
3 mM ATP 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free, Roche) 
 
Low Ca2+ Reaction Mix (2.5X): 
125 mM Tris Base, pH 7.1 
>2.5 mM MgCl2 (included in 0.5 M TrisCl / 0.01 MgCl2) 
1 mM EGTA 
1 mM CaCl2 
1 mg/ml BSA (in H2O) 
 
MgATP Solution (90 mM): 
90 mM ATP 
9 mM MgCl2 
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Na2ATP Solution (0.1 M for Tubulin-Prep, pH 6.9): 
100 mM Na2ATP in Buffer A (no DTT) 
NHB 1X: 
300 mM KCl 
25 mM Imidazole, pH 7.0 
1 mM EGTA 
1 mM MgCl2 
1 mM DTT 
 
Nitrocellulose solution (0.1%): 
0.1% (final concentration) Collodion solution (2% in Amyl Acetate) 
dilute into Isoamylalcohol (99.8% p.a.) 
 
No Salt Buffer (pH 8.5): 
10 mM Tris Base (pH 8.0) 
0.25 mM CaCl2 
0.1 mM EGTA 
0.2 mM DTT 
 
O2 Quench Buffer (1X): 
24 mM Pipes 
4 mM MgCl2 
4 mM EGTA 
 
Oxygen-scavenging system (25X), 20 µl: 
10 µl Catalase Solution (100X) 
10 µl Glucose-oxidase Solution (100X) 
(Glucose (100X in H2O) is added directly to assay) 
 
Paclitaxel (4 mM in DMSO): 
25 mg Paclitaxel 
7.3 ml DMSO 
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PBS (1X, pH 7.4): 
140 mM NaCl 
2.7 mM KCl 
1.8 mM KH2PO4 
10 mM Na2HPO4 
 
PBS for MACS (1X, pH 7.4): 
75 mM NaCl 
16.2 mM Na2HPO4 
3.8 mM NaH2PO4 
 
PEB (1X): 
PBS for MACS (1X) 
2 mM EDTA 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free, Roche) 
 
SDS Protein Sample Buffer (6X): 
300 mM Tris Base (pH 6.8) 
15 mM EDTA 
12% (w/v) SDS 
30% (v/v) Glycerol 
0.06% (v/v) Bromophenol blue 
15% (v/v) β-Mercaptoethanol 
 
Separating Gel (10%, 10 ml): 
3.3 ml Rotiphorese Gel 30 
2.5 ml Separating Gel Buffer 
4.2 ml Water 
10 µl Temed 
100 µl APS 
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Separating Gel Buffer (10X): 
0.5 M Tris Base (pH 6.8) 
0.4% (w/v) SDS 
 
Solution A (100 ml): 
9 ml Tris Base (1 M), pH 8.5 
1 ml Luminol (0.25 M) 
90 ml H2O 
 
Solution B (100 ml): 
9.6 ml Tris Base (1 M), pH 8.5 
440 µl Coumaric Acid (90 mM) 
90 ml H2O 
 
Solution I (1X, pH 6.5): 
100 mM KCl 
150 mM KH2PO4 
 
Solution II (1X, pH 7.4): 
50 mM NaHCO3 
Solution III (1X, pH 7.0): 
1 mM EDTA  
Stacking Gel (10%, 10 ml): 
1.3 ml Rotiphorese Gel 30 
2.5 ml Stacking Gel Buffer 
6.2 ml Water 
10 µl Temed 
100 µl APS 
 
Stacking Gel Buffer (10X): 
1.5 M Tris Base (pH 8.8) 
0.4% (w/v) SDS 
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Streptavidin Solution (10 ml): 
10 mg Streptavidin 
10 ml PBS 
 
Sucrose Solution (20%): 
20% (w/v) Sucrose in Water 
TAE Buffer (50X): 
24.2% (w/v) Tris Base 
5.7% (v/v) Glacial Acetic acid 
50 mM EDTA, pH 7.0 
 
TBS Buffer (1X, pH 7.2): 
20 mM Tris Base 
150 mM NaCl 
 
TBST (1X): 
TBS (1X) 
0.05% (v/v) Tween-20 
 
TE Buffer  (pH 8.0): 
10 mM Tris Base 
1 mM EDTA 
Tetracycline Solution (100 ml): 
50 mg Tetracycline  
100 ml Water 
 
TrisCl (0.5 M / 0.01 M MgCl2 ), 50 ml: 
5 ml 0.5 M Tris Base / 0.1 M MgCl2 
45 ml 0.5 M Tris Base, pH 7.1 
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WB-CK (1X): 
100 mM NaCl 
40 mM Hepes, pH 7.4 
1 mM EGTA 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free, Roche) 
 
WB-HMM-M5 (1X): 
150 mM KCl 
20 mM Imidazole, pH 7.5 
5 mM MgCl2 
1 mM EGTA 
1 mM EDTA 
10 mM DTT 
3 mM ATP 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free, Roche) 
 
WB-XM5 (1X): 
150 mM KCl 
20 mM Imidazole, pH 7.5 
5 mM MgCl2 
1 mM EGTA 
1 mM EDTA 
2 mM DTT 
1 mM PMSF (in Isopropanol) 
3 mM ATP 
1 Tablet/50 ml cθmplete, Mini Protease Inhibitor (EDTA-free, Roche) 
 
Zero Ca2+ Reaction Mix (2.5X): 
125 mM Tris Base, pH 7.1 
>2.5 mM MgCl2 (included in 0.5 M TrisCl / 0.01 MgCl2)1 mM EGTA 
1 mg/ml BSA (in H2O) 
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3.10 Enzymes and kits for biochemistry & molecular biology 
Name of Item Company, Location 
Antarctic Phosphatase (Kit) New England Biolabs, Frankfurt a. 
Main 
Bac-to-Bac® Baculovirus Expression System Invitrogen, Karlsruhe 
Catalase from Bovine Liver Sigma-Aldrich, St. Louis (U.S.A.) 
First Strand cDNA Synthesis Kit for RT-PCR (AMV)  Roche Applied Science, Penzberg 
Glucose Oxidase Type VII from Aspergillus Niger  Sigma-Aldrich, St. Louis (U.S.A.) 
Peq Gold DNA Taq DNA Polymerase (5 U/µl) PeqLab, Erlangen 
Platinum® Pfx Polymerase (Kit) Invitrogen, Karlsruhe 
Platinum® Taq HF Polymerase (Kit) Invitrogen, Karlsruhe 
Pyruvate Kinase/Lactic Dehydrogenase from Rabbit 
Muscle; PK (700 U/ml) and LDH (1000 U/ml) 
Sigma-Aldrich, St. Louis (U.S.A.) 
Qiaprep® Midiprep Kit Qiagen, Hilden 
Qiaprep® Miniprep Kit Qiagen, Hilden 
Qiaquick® Purification Kit Qiagen, Hilden 
Restriction Enzymes New England Biolabs, 
Frankfurt/Main 
SMARTer™ RACE-PCR Kit BD-Clontech, Heidelberg 
SubtilisinA, bacterial, Type VIII from Bacillus 
licheniformis 
Sigma-Aldrich, St. Louis (U.S.A.) 
T4 DNA Ligase (Kit) New England Biolabs, Frankfurt a. 
Main 
 
3.11 Software for data acquisition and analysis 
Software Name Company, Location 
CellR Olympus Biosystems, Planegg 
ImageJ Plugins + Macros NIH, Bethesda (U.S.A.) 
ImageJ Plugins MTrackJ and MultipleKymograph NIH, Bethesda (U.S.A.) 
ImageJ Version 1.46j NIH, Bethesda (U.S.A.) 
ImageQuant, Version TL 7.0 GE Healthcare, Munich 
Igor Pro Version 6.1.2 WaveMetrics, Inc., Lake Oswego 
(U.S.A.) 
Megalign Version 2.1.0.97 DNAStar, Madison, (U.S.A.) 
Kaleidagraph Version 4.0.3 Synergy, Pittsburgh, (U.S.A.) 
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4 Methods 
4.1 Cell culturing 
4.1.1 Culturing of immortalized Xenopus l. melanophores 
Immortalized Xenopus laevis melanophores (kind gift of Prof. V. Gelfand, 
Northwestern University, Chicago, U.S.A.) were cultured as previously described 
66 at 28°C in 0.7X Leibovitz-15 (L-15) medium supplemented with 10% fetal 
bovine serum, 5 µg/ml insulin, 100 U/ml penicillin/streptomycin. Depending on the 
experiment to be performed, cells were cultured in small (25 cm2), medium (75 
cm2) or large (175 cm2) sterile tissue culture-treated flasks with vent-cap. 
Typically, the cells were split by trypsinization once a week when confluency was 
reached. 
To hormone-induce pigment aggregation or dispersion, first the cells had to be 
transferred into serum-free medium 24 hours prior to hormone stimulation. One 
hour prior melanosome purification, aggregation or dispersion of pigment 
granules was stimulated by adding 50 nM melatonin or 100 nM α-melanocyte 
stimulating hormone α-MSH to the serum-free culture medium, respectively. 
4.1.2 Preparation of cryo-cultures from Xenopus l. melanophores 
For the preparation of melanophore cryo-cultures, at first melanosomes had to be 
eliminated by the tyrosinase inhibitor phenylthiourea (PTU). That is because upon 
freezing melanin, as the main component of melanosomes, is released from 
accidentally freeze-ruptured cells, leading to low efficiency in the successful re-
culturing of the frozen cell stocks.   
For the actual elimination, the medium was supplemented with PTU at a final 
concentration of 1 mM and was maintained in this medium for about 4 weeks. The 
effect of PTU is completely reversible and non-toxic for the cells 63. 
Once the melanophores were made devoid of melanosomes, cells from one 
confluently-grown medium-size (75 cm2) flask were trypsinized into 0.7X L-15 
medium (containing additives and 10% serum) and pelleted at 150 × g for 5 
minutes at room temperature (Rotina 420, Hettich). The cell pellet was 
resuspended in 1.5 ml 0.6X L-15 Medium (containing 40% serum) and incubated 
Methods 
________________________________________________________ 
 61 
for 5 minutes on ice. As a next step, in total 1.5 ml of 0.5X L-15 medium 
(containing 30% serum, 20% DMSO) were added drop-wise to the cell 
suspension while gently stirring. The suspension was kept on ice for an additional 
15 minutes. This way a final concentration of 10% DMSO, 35% FBS was 
reached. At last, 0.5 ml aliquots were prepared and kept overnight at -70°C before 
storage in liquid nitrogen. 
4.1.3 Thawing and propagating melanophore cryo-cultures 
To take cryo-cultures of melanophores back into culture, the cells were thawed 
quickly, mixed with 10 ml of 0.7X L-15 medium (containing additives and 10% 
serum) and pelleted at 150 × g for 5 minutes at room temperature (Rotina 420, 
Hettich) to remove the DMSO. The cell pellet was resuspended gently in 10 ml of 
0.7X L-15 medium (containing additives and 10% serum), followed by transfer 
into a small (25 cm2) culturing flask for subsequent propagation at 28°C. 
4.1.4 Protocol for MACS-bead assisted melanosome purification 
The first part of the melanosome isolation procedure was performed as described 
previously by Rogers et al. (1997)61 and Kashina et al. (2004)65,93, except that 
PBS 0.7X instead of AB 1X was used. In brief, before harvesting of the cells with 
a cell-scraper, 5 flasks of confluent melanophores were rinsed once with an 
appropriate amount of PBS 0.7X. Typically, cells were scraped into 2 ml PBS 
0.7X (containing protease inhibitor) before cell lysis via Balch-homogenization (1 
ml-syringes and 0.6 micron ball diameter). It was important not to lyse for more 
than 10 up-and-down cycles and to keep the Balch device on ice at all times. 
Membrane fractions and cell debris were pelleted at 750 × g for 7 minutes and 
4°C (Hettich Rotanta 460R), with the melanosomes remaining in the supernatant. 
After pelleting the melanosomes at 3,000 × g for 5 minutes and 4°C (Hettich 
Rotanta 460R), pellets were resuspended in 800 µl of PBS 0.7X (plus protease 
inhibitor). 
For the subsequent purification by MACS bead technology, 400 µl of the 
melanosome solution was incubated rolling with 1 to 2 µg anti-Tyrosinase related 
protein Trp1 (mouse monoclonal, clone TA99) or anti-Kinesin-2 antibody (mouse 
monoclonal, clone K2.4) (in PBS 1X) at 4°C for 20 minutes. Subsequently, 35 µl 
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of anti-mouse IgG conjugated MACS® beads (Miltenyi Biotec) were added. 
Following an incubation of 40 minutes at 4°C, the reaction volume was expanded 
by adding 500 µl PBS 1X (containing protease inhibitors), while incubating for 
additional 20 minutes at 4°C.  
The melanosome-MACS bead mixture was applied dropwise onto a MACS LS-
column, equilibrated with 3 ml PEB 1X (containing protease inhibitors). Still 
attached to the magnet, the column to which the melanosomes are now bound 
was washed three times with 3 ml of PEB 1X (containing protease inhibitors) 
each. Then the column was detached from the magnet and elution was carried 
out twice with 3 ml PEB 1X (containing protease inhibitors) each. To yield a more 
concentrated solution of purified melanosomes, an additional pelleting step of the 
sample at 3,000 × g for 5 minutes and 4°C (Hettich Rotanta 460R) with 
subsequent resuspension in 100 to 200 µl PBS 1X (containing protease inhibitors) 
was included. For Western-blot analysis, samples were run on a 10% SDS-
PAGE. 
4.1.5 Culturing of Sf9 insect cells 
For the expression of recombinant proteins from the baculovirus-expression 
system, the Sf9 insect cell line (Invitrogen) was used. This cell line is a clonal 
isolate derived from the parental Spodoptera frugiperda (fall armyworm) cell line 
IPLB-Sf-21-AE 133,134,135, that itself originated from a population of cells that was 
isolated from S. frugiperda ovarian tissue 126. Sf9 cells are adapted to serum-free 
suspension growth in Sf-900 II SFM (Invitrogen), which is a serum-free medium 
that is optimized for growth of Sf9 but also other invertebrate cell lines. 
Sf9 cells were suspension-cultured in Sf-900 II SFM medium (supplemented with 
10% vol. FBS and 0.5 mg/ml Gentamicin). The actual culturing took place at 28°C 
and 110 rpm in spinner flasks that contained a final volume of 100 to 500 ml cell 
suspension at a cell density of 0.5 to 6*106 cells/ml. Typically, cells were split 
every other day. For the purpose of protein expression with subsequent 
purification, cells were brought to a density of 2*106 cells/ml, while for virus 
amplification cells were diluted to a density of 0.5*106 cells/ml. 
In general, cells were propagated up to 30 passages. To start a new round of Sf9 
cell propagation, liquid nitrogen-stored cell stocks were thawed and expanded 
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according to the manufacturer’s protocol (Invitrogen). Aliquots of cells to be stored 
in liquid nitrogen were prepared and handled as proposed by the manufacturer. 
 
4.2 Molecular biological methods 
4.2.1 RNA 
4.2.1.1 Isolation of cellular total RNA 
RNA was isolated via Total RNA Isolation (TRI)-reagent-mediated cell lysis. TRI-
reagent (same as TRIzol) contains phenol and thiocyanate and reacts strongly 
with chloroform, thus is used for RNA isolation. 
Typically, RNA from approx. 106 melanophores was isolated. For this, cells were 
harvested by trypsinization as described in Section 4.1.1, collected in 10 ml 0.7X 
L-15 medium (no additives) and pelleted twice at 800 × g for 5 minutes at room 
temperature (Swinging-bucket centrifuge Rotina 420, Hettich). Between 
centrifugation steps, one washing step of the pellet with 1 ml 0.7X L-15 medium 
(no additives) was included. 
To lyze the plasma and organelle membranes, the cell pellet was resuspended in 
200 µl TRI-reagent while pipetting the suspension 10 times up and down. The 
following incubation (for 8 minutes at room temperature) causes the dissociation 
of any nucleo-protein complexes that might have formed during the procedure. In 
cases where the actual RNA extraction was performed at a later time point, the 
obtained cell lysate was stored at -20°C. 
RNA extraction was carried out by adding 40 µl (i.e., 20% vol. of the lysate 
volume) 1-Brom-3-Chloropropane, followed by intense vortexing for 15 seconds.  
After incubation for 10 minutes at room temperature, the suspension was 
centrifuged at 12,000 × g for 15 minutes at 4°C (Eppifuge 5415D, Eppendorf), 
yielding three phases. The RNA fraction is found in the upper phase, while the 
interphase and lower phase contain the respective factions with DNA and 
proteins. To avoid contamination with traces of DNA, instead of retrieving the 
entire upper phase only 90 µl were taken off and used for RNA-precipitation by 
adding 100 µl (approx. one vol. of RNA phase suspension) of isopropanol (99% 
p.a.). After incubation for 10 minutes on ice, the precipitated RNA was pelleted at 
12,000 × g for 12 minutes at 4°C (Eppifuge). Sedimented RNA was washed with 
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0.5 ml ice-cold ethanol (75% in DEPC-water) while vortexing. A final 
centrifugation step at 12,000 × g for 12 minutes at 4°C (Eppifuge) was added, the 
supernatant carefully discarded, and the RNA-pellet was air-dried for 3 minutes at 
room temperature and dissolved for 10 minutes at 55°C in 20 µl RNase-free 
water. Concentration of RNA content was measured at 260 nm (Section 4.2.2.7) 
before the extracted RNA was put to -70°C for storage. 
4.2.1.2 cDNA synthesis via reverse transcriptase (RT)-PCR 
The extracted RNA was used for subsequent reverse transcription into cDNA. In 
this process, the reverse transcriptase (RT) allows transcription of single-stranded 
copy DNA (or cDNA) from an RNA template by executing its RNA-dependent 
DNA polymerase activity. Furthermore, being a multifunctional enzyme, the 
reverse transcriptase is capable of acting as well as an RNase. Thereby the RNA 
from the RNA/DNA hybrids that have formed upon reverse transcription is 
degraded, yielding pure cDNA 136. A schematic overview on this process is given 
in Figure 10.  
cDNA synthesis was carried out according to the manufacturer’s protocol using 
the first-strand cDNA synthesis kit from Roche Applied Sciences (Penzberg, 
Germany).  For this protocol, a so-called Oligo-d(T) primer (kit-included) was used 
that anneals to the 3’-Poly-A ends (poly A+) of the mRNA to be transcribed and is 
needed for the initiation of the transcription process. RT-PCR was carried out in a 
20 µl reaction volume and was set up as described in Table 1. The reaction was 
incubated for 10 minutes at 25°C followed by incubations at 42 and 99°C for 60 
and 5 minutes, respectively. 
Figure 10. Reverse transcriptase in 
first-strand cDNA synthesis. 
A kit-provided Oligo-d(T) primer anneals 
at the 3’-poly A+ ends of the before 
isolated mRNA. The reverse 
transcriptase (RT) allows for the 
transcription of single-stranded copy-
DNA (cDNA) by executing its RNA-
dependent DNA polymerase activity. In 
addition the RT possess RNAse activity 
and thereby degrades any RNA/DNA 
hybrids that have formed upon reverse 
transcription, leaving over cDNA only. 
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Component (concentration) Final concentrations 
Applied 
volume (µl) 
Reaction Buffer 10X 1X 2 
RNA ~ 1 µg variable 
MgCl2 (25 mM) 5 mM 4 
dNTP-Mix (10 mM) 1 mM 2 
Oligo-p(dT)15-Primer (0.8 µg/µl) 0.08 µg/µl 2 
RNase-inhibitor (1000 U) 50 U 1 
RT (500 U) 20 U 0.8 
Sterile H2O (RNase-free) - Δ 20 
Total reaction volume  20 
 
 
4.2.1.3 RACE-PCR on isolated RNA 
The specialized PCR technique of Rapid Amplification of cDNA Ends (RACE-
PCR) is ideally suited for the purpose of retrieving and amplifying a specific 
portion that is encoded by the isolated poly A+ mRNA.  
Here, the SMARTer RACE cDNA Amplification Kit (ClontechLaboratories) was 
used. This technology combines the generation of full-length cDNAs via reverse 
transcription with primer-specific amplification of the desired region on the 
generated cDNA. The reverse transcriptase (RT) used in this kit is a variant of the 
Moloney Murine Leukemia Virus (MMLV) RT and upon reaching the end of an 
RNA template, exhibits terminal transferase activity, which in turns leads to the 
addition of three to five nucleotides to the 3’ end of the first-strand cDNA 
(SMARTer sequence). Those added residues then serve as annealing sites for 
the SMARTer Oligo, which contains a terminal stretch of modified bases that are 
complementary to the SMARTer sequence that was added by the RT. The 
annealed oligo in turn serves as template for the RT, which itself is then able to 
switch templates from the mRNA to the oligo, thereby generating a complete 
cDNA copy of the original RNA with the specific SMARTer sequence added at its 
end (referred to RACE-ready cDNA) (Figure 11). 
 
 
 
 
Table 1. Reaction setup for reverse transcriptase (RT)-mediated 
first-strand cDNA synthesis. 
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To generate RACE-ready cDNA, 1 µg of extracted RNA was mixed with the 
SMARTer Oligo (Mix 1, Table 2) and briefly centrifuged (Eppifuge) before 
incubation for two minutes at 70°C with subsequent chilling for 2 minutes on ice 
took place. Subsequently, Mix 1 was added to Mix 2 (Table 2) and incubated in a 
hot-lid thermo-cycler for 90 minutes at 42°C. Due to the large amount of initially 
applied RNA (greater than 200 ng), following cDNA synthesis 100 µl Tricine-
EDTA Buffer was added. 
 
 
Figure 11. Overview of the 3’-RACE PCR mechanism. 
RACE PCR combines in four steps the generation of full-length cDNAs via reverse 
transcription and subsequent primer-specific amplification of the desired region on the 
generated cDNA. Step one: Upon reaching the end of an RNA template, the RT exhibits 
terminal transferase activity. Thereby three to five nucleotides are added to the 3’ end of the 
first-strand cDNA (SMARTer III A sequence). Step two: The added residues subsequently 
serve as annealing sites for the SMARTer Oligo, which is complementary to the SMARTer 
sequence that was added by the RT. Upon annealing, this oligo in turn provides the template 
for the RT, which upon switching templates (from the mRNA to the oligo) generates a 
complete DNA copy of the original RNA with the specific SMARTer sequence added at its end 
(referred to as 3’-RACE-Ready cDNA). Steps three and four: Using a gene-specific primer 
(GSP) along with short and long kit-provided universal primers (UP) actual RACE PCR is 
carried out. This way a gene-specific double-stranded DNA fragment composing the sequence 
up to and including the poly A+ ends of the initial applied RNA template is obtained. Figure 
adapted from SMARTer™ RACE cDNA amplification manual (Clontech Laboratories Inc., CA, 
U.S.A.). 
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 Component (concentration) Final concentrations 
Applied 
volume (µl) 
RNA ~ 1 µg variable 
3’ coding sequence Primer A 
(12 µM) 1.2 µM 1 M
ix
 1
 
Sterile H2O (RNase-free) - Δ 5 
    First-strand buffer (5X) 1X 2 
DTT (20 mM) 2 mM 1 
dNTPs (10 mM) 1 mM 1 M
ix
 2
 
SMARTscribe RT (100 U/µl) 10 U/µl 1 
 Total reaction volume  10 
 
 
 
As outlined in Table 3, for RACE-PCR a Polymerase and Primer Mix was 
prepared. The Advantage 2 Polymerase used here is comprised of a Titanium® 
Taq and a proofreading polymerase. The Primer Mix contained the RACE-ready 
cDNA, a so-called universal primer mix (UPM) and a gene-specific primer (in this 
case FLXM5_Fw#7 was used).  
 
 
 Component (concentration) 
Final 
concentrations 
Applied 
volume (µl) 
Advantage 2 Buffer (10X) 1X 5 
dNTPs (10 mM) 0.2 mM 1 
Advantage 2 Polymerase Mix (50X) 1X 1 
P
ol
ym
er
as
e 
M
ix
 
H2O - Δ 41.5 
    RACE-ready cDNA - 2.5 
UPM (10X) 1X 5 
P
rim
er
  
M
ix
 
FLXM5_Fw#7 (10 µM) 0.2 µM 1 
 Total reaction volume  50 
 
 
 
After both mixes were combined, RACE-PCR was carried out according to the 
thermo-cycler program that is outlined in Table 4. Note, here no touchdown 
thermo-cycling program was required.  
 
 
 
 
Table 2. Reaction setup for SMARTer RACE cDNA synthesis. 
 
Table 3. Reaction setup for SMARTer 3’-RACE PCR with gene-specific and 
universal primers. 
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Temperature (°C) Cycle Time (s) Cycles 
94 30 
68 30 
72 180 
35 × 
 
 
 
The product obtained by RACE-PCR was purified (Section 4.2.2.5) and 
sequenced as described in Section 4.2.2.6. 
4.2.2 DNA 
4.2.2.1 Polymerase chain reaction (PCR) 
By applying specifically designed oligonucleotides (primers), via polymerase 
chain reaction (PCR) it is possible to in vitro amplify a part of a known sequence 
from a DNA template 137. Via their complementary sequence the primers flank at 
5’ and 3’ of the region of interest on the single-strands of the template DNA. The 
PCR cycle starts with heat-denaturation of the double-stranded DNA, is followed 
by hybridization of the single strands and added primers, and is completed by the 
eventual synthesis of the complementary strand via DNA polymerase. By 
repeating those three phases for a certain number of cycles (30 to 50 times), 
exponential amplification of the synthesized DNA product takes place, yielding 
large amounts of specific DNA fragments. 
4.2.2.2 PCR protocols 
4.2.2.2.1 PCR for the cloning of HMM-like Myosin Va and CaMKII-α 
PCR was performed as outlined in Table 5 and Table 6 using the Platinum® Pfx 
DNA Polymerase (Invitrogen) along with a specific combination of forward and 
reverse primers (for a complete list of primers, see Section 3.4) and the purified 
insert DNA obtained before as template.  
 
 
 
 
Table 4. Thermal cycling program of SMARTer 3’-
RACE PCR. 
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Component (concentration) Final concentrations 
Applied 
volume (µl) 
Reaction Buffer 10X 1X 5 
Insert-DNA - 1 
dNTP-Mix (10 mM) 0.4 mM 2 
Forward Primer (10 µM) 0.5 µM 2.5 
Reverse Primer (10 µM) 0.5 µM 2.5 
Platinum® Pfx Pol. (250 U) 2.5 U 1 
Sterile H2O - Δ 50 
Total reaction volume  50 
 
 
Temperature (°C) Cycle Time (s) Cycles 
94 120  
94 15 
55 45 
68 180 
35 
68 420  
 
 
4.2.2.2.2 PCR for determining the full-length Xenopus l. Myosin Va 
All PCR reactions were carried out with Platinum® Taq DNA Polymerase High 
Fidelity (HF). The reaction setup (Table 7) always was the same. Depending on 
the primer combination and the size of the product to be expected, annealing 
temperatures as well as extension times were slightly modified (Table 8). In Table 9, 
the forward and reverse primers that yielded products of approximate correct 
sizes are listed along with the respective product size and PCR phase of each 
primer combination. For the specific primer sequences, please refer to Section 
3.4.1. 
 
 
 
 
 
 
Table 5. PCR reaction setup using Platinum Pfx polymerase. 
 
Table 6 Thermal cycling program for PCR reactions 
using Platinum Pfx polymerase. 
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Component (concentration) Final concentrations 
Applied 
volume (µl) 
Reaction Buffer 10X 1X 5 
cDNA - 1 
MgSO4 (50 mM) 4 mM 4 
dNTP-Mix (10 mM) 0.3 mM 1.5 
Forward Primer (10 µM) 0.3 µM 1.5 
Reverse Primer (10 µM) 0.3 µM 1.5 
Platinum® Taq HF Pol. (250 U) 1.5 U 0.3 
Sterile H2O - Δ 50 
Total reaction volume  50 
 
 
Temperature (°C) Cycle Time (s) Cycles 
94 120  
94 30 
50 to 52 30 
72 300 to 420 
30 to 50 
72 600  
. 
 
 
PCR 
Reaction (Phase) 
Forward Primer 
(name) 
Reverse Primer 
(name) 
Size of PCR 
Product (bp) 
A FLXM5_Fw#1 FLXM5_Rv5 3146 
B FLXM5_Fw#5 FLGgM5_Rv4126 1633 
C  
(RACE)* FLXM5_Fw#7 UPM (RACE-kit) 2500 (approx.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. PCR reaction setup using Platinum Taq High-Fidelity 
polymerase. 
Table 8. Thermal cycling program for PCR reactions 
using Platinum Taq High-Fidelity polymerase 
Table 9. Summary of PCR primers used to obtain the full-length sequence of 
Xenopus l. Myosin Va. 
Listed are the forward and reverse primers that were used to obtain the final 
products of Phases A, B, C as well as of the full-length coding sequence (Figure 
52). (*) for details on RACE-PCR, refer to Section 4.2.1.3. 
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4.2.2.2.3 PCR-mediated preparation of the full-length Xenopus l. 
Myosin Va gene for vector cloning 
To subsequently clone the gene encoding for the full-length protein of Xenopus l. 
Myosin Va into a suitable transfer vector (pFastBac Dual) the full-length coding 
sequence DNA was obtained and prepared for further cloning. To either yield 5’ 
(N’ in protein sequence) or 3’ (C’ in protein sequence) FLAG-tagged full-length 
Xenopus l. Myosin Va PCR products, the sequence coding for the FLAG-tag was 
fused to the 3’- and 5’-ends of the gene. In addition, the forward and reverse 
primers used in this step likewise contained an NheI and SpeI restriction enzyme 
recognition sequence, respectively. PCR reactions were performed according to 
the protocol in Section 4.2.2.2.2 (Table 7 and Table 8). The PCR products were gel-
extracted, purified and digested with restriction enzymes NheI and SphI (HF) as 
described (Sections 4.2.2.4, 4.2.2.5 and 4.2.3.1). For a list of specific primer 
sequences, please refer to Section 3.4.1. 
 
Product Primer Names 
FLXM5_NheIFLAG-Fw 
N
’ F
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G
-
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FL
X
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a 
FLXM5_SphI-Rv 
FLXM5_Nhe-Fw2 
C
’ F
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G
-
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X
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FLXM5_SphIFLAG-Rv 
FLXM5_NheI-Fw2 
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a 
FLXM5_SphI-Rv 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. PCR primer list. 
Forward and reverse primers used for the cloning  
of untagged and FLAG-tagged full-length Xenopus 
l. Myosin Va into the pFastBac Dual vector. 
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4.2.2.3 DNA analysis by agarose gel electrophoresis 
Unless mentioned otherwise, DNA fragments were separated via (1%) agarose 
gel electrophoresis. For this, the required amount of agarose was dissolved in 
TAE buffer (1X). All gels were supplemented with 1% ethidium bromide (10 
mg/ml) to easily visualize the acquired DNA products on the gel. Typically, prior 
loading, the samples were mixed with loading buffer (6X) in a 1:6 ratio. 
Electrophoresis was performed at 90 V for 10 to 30 minutes. DNA was detected 
by using a UV light source. To determine the correct size of the product, in 
addition to the samples a standard 1 kb DNA ladder was always loaded. 
4.2.2.4 Gel-extraction of DNA fragments 
For the extraction of DNA fragments (e.g., PCR products) from agarose gels post 
gel electrophoresis, bands of interest were excised with a clean scalpel and 
subsequently gel-extracted with the Qiaquick® Gel Extraction kit (Qiagen) 
according to the manufacturer’s protocol. Depending on the yield in DNA 
concentration to be expected, elution of the sample took place in 30 to 50 µl 
Qiagen Elution Buffer. Samples were stored at -20°C. 
4.2.2.5 Purification of PCR and restriction-digest products 
PCR and restriction enzyme-digested DNA products were purified from any left-
over enzymes, nucleotides and salts by using the Qiaquick® PCR Purification kit 
(Qiagen) according to manufacturer’s protocol. Typically, purified samples were 
eluted in 30 µl Qiagen elution buffer. Samples were stored at -20°C. 
4.2.2.6 DNA Sequencing 
All plasmids and PCR products were purified before sequencing at the 
Sequencing Service Unit of the LMU (Ludwig-Maximilians-University, Munich, 
Germany) was carried out. Typically 50 to 200 ng of gel-purified PCR product 
DNA was mixed with 3.3 pmol sequencing primer in DNA elution buffer (DNA-EB) 
1X (Table 11). In cases where purified plasmid DNA was prepared for sequencing, 
150 to 300 ng of DNA was required. Sequencing at the service unit was then 
performed with the “Cycle, Clean & Run” program using BigDye v3.1. 
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Component 
(concentration) Final concentration  
Applied volume 
(µl) 
DNA-EB (1X) - Δ 7 
Sequ. Primer (3.3 µM) 3 pmol 1 
DNA 50 to 200 ng variable 
Total reaction volume  7 
 
 
 
4.2.2.6.1 Sequencing reactions of full-length Xenopus l. Myosin Va 
All products that were obtained either by RACE- or conventional PCR and that 
yielded products of approximately the right size (estimated via sequence 
homology comparison to full-length chicken Myosin Va) were prepared for DNA 
sequencing (for details on the reaction setup, refer to Table 11). 
A list of all the primers that were used to step-by-step sequence the respective 
PCR products obtained in Phases A through C is provided in Table 12. For a list of 
the specific primer sequences, please refer to Section 3.4.2.  
Table 11. Reaction setup for “Cycle, Clean & Run” DNA sequencing with 
BigDye v3.1. 
 
Table 12. List of sequencing primers used for 
the conformation of partial and full-length 
Xenopus l. Myosin Va PCR products. 
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4.2.2.7 Determination of DNA concentration 
The concentration (c) of purified DNA and RNA was measured spectroscopically 
by determining the optical density (OD) at wavelength (λ) 260. The optical density 
is a unit-less measure of the transmittance of an optical element for a given length 
and wavelength. The transmittance is expressed as the fraction of the intensity of 
the transmitted (I) and incident (I0) light beam. For liquids the measure of the OD 
is also referred to as absorbance (A).  
Depending on the yield to be expected, 1:100 or 1:200 dilutions of the DNA or 
RNA sample (in (DEPC)-water) were targeted for concentration determination.  
The concentration was calculated according to Equation 2 and Equation 1: 
 
4.2.2.8 DNA sequence synthesis of HMM-like Myosin Va loop 2 
constructs 
The plasmid DNA provided by Purcell, T. J. and colleagues (Stanford University, 
Stanford, U.S.A.)138, containing the Wildtype HMM-like Myosin Va gene, was 
used as the template plasmid to perform custom DNA synthesis (carried out by 
SloningBio-Technology, Puchheim, Germany) of the three loop 2 mutations 
described above.  
The so-called Slonomics technology relies on a library of standardized DNA 
building blocks that can be combined to any desired sequence, instead of ligating 
gene product-specific and individually designed oligo-nucleotides. The loop 2 of 
Myosin Va is flanked by the two unique restriction sites, SphI and ApaI. This 
! 
cDNA/RNA =
0.05 or 0.04µg µl
FactorDilution
"OD260nm
! 
" withOD260nm =1 # 0.05µg µl DNA
and
" withOD260nm =1 # 0.04µg µl RNA
! 
OD" = A" = #log10T = #log10
I
I0
$ 
% 
& 
' 
( 
) 
Equation 2 
Equation 1 
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rather convenient circumstance was taken advantage of to cut out the loop 2 
sequence from the Wildtype version to then synthesize the mutant versions of 
loop 2.  
Eventually, the synthesized mutant versions of loop 2 were cloned back into 
p2bac/pfastbac transfer vector via the exact same restriction sites. Thereby all the 
HMM-like Myosin Va loop 2 constructs were cloned into the hybrid transfer vector 
p2bac/pfastbac138 and confirmed by DNA-sequencing (performed by 
SloningBiotechnology). 
4.2.3 Cloning techniques 
4.2.3.1 Restriction enzyme-mediated DNA digest 
Plasmid DNA or PCR fragments, containing restriction enzyme-specific restriction 
sites at their ends, were digested via restriction enzyme-mediated digestion 
according to the enzyme manufacturer’s protocol (New England Biolabs, NEB). 
Typically, digestion was carried out for 2 to 3 hours at the temperature optimum of 
the respective enzyme. Vector linearization was typically performed with ~ 5 µg of 
vector DNA in a 30 µl-reaction volume, while for digestion of PCR-products the 
entire PCR-reaction (50 µl) was applied (Table 13). In cases where simultaneous 
digestion with two different enzymes was carried out, the buffer suiting both 
enzymes best was used. Or, in cases where no suitable common buffer could be 
used, sequential digestion with the two enzymes took place.  
 
Component 
(concentration) Final concentration  
Applied volume  
-Vector 
linearization- 
(µl) 
Applied volume  
-Test or PCR 
Digest- 
(µl) 
Rest. Enzyme Buffer 
(10X) 1X 3 2 or 5.5 
DNA ~ 5 µg (vector DNA) variable 2 or 47 
BSA (10 mg/ml) 
-if required- ~ 0.1 mg/ml 0.3 0.2 or 0.6 
Enzyme 1 (10 to 20 U/µl) 0.3 to 0.5 U/µl 1 0.5 or 1 
Enzyme 2 (10 to 20 U/µl) 
-if double-digest is 
performed- 
0.3 to 0.5 U/µl 1 0.5 or 1 
H2O - Δ 30.3 Δ 20 or 55 
Total reaction volume  30.3 20 or 55 
 
 
 
Table 13. Reaction setup for restriction enzyme-mediated digest of plasmid DNA or 
PCR fragments. 
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Following DNA digestion, DNA purification of the product was carried out (Section 
4.2.2.5). 
4.2.3.2 Dephosphorylation of linearized DNA 
To prevent religation of linearized (i.e., restriction enzyme-specifically cut) vector 
DNA, Antarctic Phosphatase (AP; NEB) was used to dephosporylate the 5’ ends 
of the DNA. For this, typically 1 µg of linearized DNA was incubated with 5 units 
AP in AP-Buffer (10X) for 1 hour at 37°C (Table 14). It was crucial to heat-
inactivate AP by incubating for 5 minutes at 65°C. DNA treated this way can be 
used for subsequent ligation without any additional purification. 
 
Component (concentration) Final concentration  
Applied volume  
(µl) 
AP Buffer (10X) 1X 3 
Linearized DNA ~ 1 to 2.5 µg 26 
AP (5 U/µl) ~ 0.17 U/µl 1 
Total reaction volume  30 
 
 
4.2.3.3 Ligation of DNA fragments into linearized vectors 
Once linearized by specific restriction enzyme-mediated digestion, those vectors 
typically now containing so-called sticky (3’ and 5’ overhangs) ends can be ligated 
with DNA fragments (inserts) that contain the exact same sticky ends. For the 
efficient and successful ligation it is crucial that the linearized vector (or insert) is 
dephosphorylated at the 5’ end (Section 4.2.3.2). The ligation reaction is then 
carried out by T4 DNA Ligase, which catalyzes the formation of a phosphodiester 
bond between juxtaposed 5' phosphate and 3' hydroxyl termini in duplex DNA (or 
RNA)139. 
Typically, ligation was carried out by mixing vector and insert in a 1:3 or 1:5 ratio, 
with subsequent ligation by 40 units T4 DNA Ligase in Ligase Buffer (10X) 
overnight at 16°C (Table 15).  
 
 
 
Table 14. Reaction setup for the dephoshorylation of linearized 
DNA via alkaline phosphatase. 
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Component (concentration) Final concentration  
Applied volume  
(µl) 
Ligase Buffer (10X) 1X 1 
Vector DNA ~ 100 ng 1 
Insert DNA variable 3 to 5 
T4 DNA Ligase (400 U/µl) 40 U/µl 1 
H2O - Δ 10 
Total reaction volume  10 
 
 
 
4.2.3.4 Transformation of chemically competent E.coli XL1-Blue cells 
To amplify plasmid-DNA that contains the genes encoding the different constructs 
used in this work, transformation of the plasmid of interest into chemically 
competent XL1-Blue cells was carried out. Prior transformation, the cells were 
slowly thawed on ice. Typically, 30-50 µl of DNA (in general from ligation 
reactions), were carefully mixed with 200 µl of XL 1-Blue competent cells and 
incubated on ice for 20 minutes. To transform the cells, a heat-shock for 45 
seconds at 42°C was performed, followed by 2 minutes of incubation on ice. 
Then, 200 µl S.O.C. medium was added and the mix was incubated for 1 hour at 
37°C on a shaker and afterwards plated on LB-Amp Petri-dishes, which were then 
kept overnight at 37°C.  
For the transformation of synthesis-generated genes from Sloning BioTech, 3 µg 
of the lyophilized plasmid DNA was dissolved in 10 µl TE Buffer (1X), before the 
transformation into chemically competent XL1-Blue cells. 
4.2.3.5 Selection and expansion of transformed E. coli 
To select for those cells that contained the plasmid coding for the protein of 
interest and as well the ampicilin-resistance cassette, transformation reactions 
were plated on LB-Ampicilin plates. Typically, after an overnight incubation at 
37°C, for Mini-Plasmid preparation (Mini-Prep) two to ten medium-size colonies 
were picked to inoculate 2 to 5 ml of LB-Amp liquid medium per tube. Incubation 
was carried out overnight in a shaker device at 220 rpm and 37°C. The following 
day, the cells were pelleted and plasmid isolation by using the Qiaprep® Miniprep 
kit (Qiagen) was carried out (for details, see below). 
Table 15. Reaction setup for the ligation of linearized vector and 
insert DNA via T4 DNA ligase. 
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4.2.3.6 Plasmid-DNA extraction from transformed bacteria 
As mentioned above, single colonies of the transformation reaction were selected 
for subsequent DNA isolation and used for the inoculation of a Mini-Prep 
(4.2.3.5). Cells were pelleted at 2,500 x g for 10 minutes at 4°C (Rotanta 460R 
swinging bucket centrifuge, Hettich), and plasmid DNA isolation was carried out 
with the QIAprep® Miniprep kit (Qiagen) according to the manufacturer’s protocol. 
Typically, DNA was eluted in 50 µl (pre-warmed) Qiagen Elution Buffer and stored 
at -20°C. 
 
4.3 Protein Biochemistry 
4.3.1 Analytical methods 
4.3.1.1 Protein analyis by SDS-polyacryl amide gel electrophoresis 
(SDS-PAGE) 
SDS-PAGE allows the separation of protein bands under denaturing conditions. 
The highly anionic character of SDS gives all proteins the same negative charge 
so that separation in an electric field occurs only by differences in size and not by 
individual native protein charges.  
Typically 10 to 12% polyacryl amide gels with 10 or 15 loading pockets were 
used. Before loading, samples were always boiled in a heat-block at 95°C in SDS 
6X sample buffer. Usually 20 to 25 µl of the sample in SDS sample buffer and 5 to 
10 µl of protein standard (unstained High Molecular Weight ladder or pre-stained 
Protein-marker IV) were loaded on the gel. The gels were run for 40 to 60 minutes 
in electrophoresis buffer (1X) at 20-60 mA with 240 V limit. Protein bands were 
stained with Coomassie Blue solution. For subsequent imaging or mass 
spectrometry analysis, Gels were stored in water at 4°C. 
4.3.1.2 Protein identification and conformation by mass spectrometry 
Expressed and purified proteins of interest but also those protein bands that were 
of still uncertain identity were confirmed by mass spectrometry analysis. This 
analytical technique measures the mass-to-charge ratio of charged particles. In 
principle, the mass spectrometer consists of the following three basic parts: First, 
an ion source that induces sample ionization; second, an electric or magnetic field 
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by which based on different ion masses, separation of those ions takes place; and 
third, a detector system that generates a mass spectrum with the collected mass 
data 140. Many different ion sources and analyzers are used for different 
applications. To identify peptide sequences, at first basic MALDI-TOF (Matrix-
asssisted laser desorption/ionization-Time of flight) mass spectrometry, and then 
later on Nanospray-Liquid Chromatography tandem mass spectrometry 
(Nanospray-LC-MS/MS) was performed by the Zentrallabor für Proteinanalytik 
(ZfP) of the LMU. Tandem mass spectrometry (MS/MS) involves multiple steps of 
mass spectrometry analysis, which makes possible multiple rounds of mass 
spectrometry with different types of analyzers, leading to exact and well-sorted 
mass data, whereas MALDI-TOF analysis makes only one round of mass 
spectrometry 141. For LC-MS/MS, an iontrap/orbitrap and quadrupol/time-of-flight 
(TOF) space-separated analyzer was used. Mass spectrometry was performed 
from in-gel-digested protein bands. 
4.3.1.3 Determination of protein concentration 
Unless mentioned otherwise, protein concentration was determined using a 
Bovine Serum Albumin (BSA)-standard that was included on those SDS-PAGE 
gels where the purified protein of interest was loaded. The principle of this method 
is to generate a calibration curve by loading different but defined concentrations 
of a high-grade pure protein of known molecular weight. Typically five different 
BSA concentrations (0.1, 0.2, 0.4, 0.6 and 0.8 mg/ml; in H2O) were loaded next to 
the protein(s) of interest on SDS-PAGE gels. The calibration curve was generated 
as follows: the respective TIFF-image of the gel was background-corrected and 
the intensity of the BSA-specific protein bands of the respective concentration 
was analyzed with ImageQuant imaging software. Likewise, the intensities of the 
protein bands of interest were determined and subsequently related to those 
values obtained from the calibration curve. Using Equation 3, the absolute 
concentration was converted into the molar concentration of the protein. 
! 
cmolar (Mol) =
cabsolute (mg ml)
MW (kDa)
" with 1 micromole protein of MW = x kDa # x mg
!
Equation 3 
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4.3.1.4 Determination of tubulin concentration 
To determine the concentration of polymerized microtubules, a 5-fold dilution into 
12A25 Buffer 1X supplemented with 20 µM Taxol, and a subsequent 10-fold 
dilution into Guanidine Hydrochloride (6.6 M) were carried out. Guanidine 
hydrochloride has chaotropic properties and depolymerizes the microtubule 
polymers 142. Calibration of the spectrophotometer was carried out at 280 nm with 
a 10-fold dilution of 12A25 Buffer (1X) supplemented with 20 µM Taxol into 
guanidine hydrochloride (6.6 M), before 100 µl of the microtubule dilution was 
measured at 280 nm. The concentration was calculated according to the law of 
Lambert-Beer (Equation 4). 
4.3.1.5 Western-blot analysis 
Western-blotting is an often-used technique to test for the presence or state of 
activity (phosphorylated versus non-phosphorylated) of proteins of interest. In 
brief, proteins that had been separated on a polyacryl amide gel are transferred 
onto a membrane, which is typically made of nitrocellulose (NC) or polyvinylidene 
difluoride (PVDF). The blotted proteins are probed with primary antibodies that 
are specific for the antigens of interest. Then, secondary antibodies, which are 
conjugated to either a reporter enzyme or a fluorophore and are reactive against 
the primary antibodies are used for detection. Depending on the detection 
method, photons emitted from either chemoluminescence or fluorescence are 
visualized by a photographic sheet of film or a CCD-camera, respectively.  
By using a semi-dry transfer apparatus, protein transfer after gel-electrophoresis 
was achieved by applying a current of 50 to 400 mA for 40 to 120 minutes. 
Efficiency of protein transfer was tested with Ponceau red. The membranes were 
blocked with 5% milk solution (in TBST) for 2 to 3 hours at room temperature. 
Incubation with primary and secondary antibodies (all conjugated to horseradish-
! 
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peroxidase) was performed overnight at 4°C or at room temperature for 1 hour, 
respectively. Before imaging, blots were always kept in TBS (1X) at 4°C. In-
between each step, membranes were washed three times with TBST (1X) for 20 
minutes each at room temperature.  
Chemiluminescence was generated by applying 1 ml freshly mixed ECL solution, 
containing cumaric acid and H2O2, onto the membrane. Signal detection took 
place wit a sheet of photographic film. 
Primary and secondary antibodies were all diluted in 1% milk solution (in TBST). 
For a complete list of antibodies, please refer to Section 3.7. 
4.3.2 Isolation, purification and handling of cytoskeletal Proteins 
4.3.2.1 G-actin purification from rabbit muscle tissue 
For the isolation of actin, skeletal muscle tissue of rabbits was cut in pieces, 
briefly washed with cold water to remove any remains of blood and ground with a 
pre-chilled meat grinder. The protocol refers to purification of G-actin from about 
350 g skeletal muscle meat, however it can be scaled-up proportionally. The 
ground tissue was mixed with 1 L Solution I and stirred for 10 minutes at 4°C. 
Filtration of the meat suspension through a gauze bandage was carried out and 
the remainder was dissolved in 2 L Solution II by stirring for 10 minutes at 4°C. 
After this suspension was filtrated, remainder II was dissolved in 1 L solution III, 
stirred for 10 minutes at 4°C and filtrated again. Remainder III was mixed with 2 L 
ice-cold water for 5 minutes and filtrated again. Extraction of the remaining water 
from the filtrate was accomplished by five times mixing and filtrating with 1 L 
acetone. To prepare the so-called acetone powder, the filtrate was air-dried on a 
sterile bench overnight and thereafter aliquots of 10 g were stored at -20°C. 
One aliquot of acetone powder was dissolved in 200 ml G Buffer, stirred for 30 
minutes at 4°C and afterwards was centrifuged at 35,000 x g for 30 minutes at 
4°C (J2-21M/E centrifuge and JA-14 Rotor, Beckman-Coulter). The supernatant 
of this extraction step was saved and the pellet was resuspended in 200 ml G 
Buffer and again stirred for 30 minutes at 4°C. The supernatant of this extraction 
was combined with the supernatant, which has been saved and the total solution 
was filtrated trough a gauze bandage. To polymerize G-actin, 50 mM KCl, 2 mM 
MgCl2 and 0.5 mM ATP was slowly applied to one volume of the combined filtrate 
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and the mixture was incubated for 30 minutes at room temperature. The 
polymerized mixture was stirred an additional 30 minutes at 4°C and centrifuged 
at 100,000 x g for 2 hours at 4°C (L8-70M Ultra-centrifuge and 45Ti Rotor, 
Beckman-Coulter). The pellet was resuspended in 30 ml G Buffer and 
homogenized. To depolymerize the actin, the homogenous solution was dialyzed 
in G Buffer for 46 to 48 hours with three buffer exchanges. Leftover polymerized 
actin was pelleted by centrifuging the solution at 100,000 x g for 2 hours at 4°C 
(L8-70M Ultra-centrifuge and 45Ti Rotor, Beckman-Coulter). The supernatant 
containing the G-actin was applied onto a Sephacryl G-300 HR column 
(Pharmacia, equilibrated with 5 L G Buffer) and eluted overnight in G Buffer with a 
flow-rate of 60 ml per hour. The concentration of the different fractions was 
determined spectroscopically at a wavelength of 290 nm (OD290 nm=1 equals 0.63 
mg/ml of G-actin) (for details on determination of protein concentration, refer to 
Section 4.3.1.3). The purity was confirmed via SDS-PAGE (10%). 1 mg of G-actin 
together with 2 mg sucrose was lyophilized and stored at -20°C. 
4.3.2.2 G-actin polymerization 
Purified G-Actin was polymerized by increasing the concentrations of monovalent 
and divalent cations in the buffer, which bind to sites with low affinity and hence 
promote polymerization 4. For the purpose of this work, actin filaments required 
stabilization, so that experimentation under constant conditions for a sufficient 
length of time was possible. F-actin polymerization was achieved by including the 
fungal toxin phalloidin into the polymerization reaction. By binding only to 
polymeric and oligomeric forms of actin, phalloidin is capable of strongly 
stabilizing actin filaments 143.  
As shown in Table 16, G-actin was mixed with Assay Buffer (AB, 10X) and 
phalloidin. The polymerization reaction-mix was incubated for 40 to 60 minutes at 
room temperature and was then kept on ice at all times. To visualize actin 
filaments for in vitro motility assays, fluorescently labeled tetramethylrhodamine-
isothiocyanate (TRITC)- or Atto488-labeled phalloidin instead of the unlabeled 
phalloidin (used for ATPase assays) was included into the polymerization 
reaction. 
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Component (concentration) Final concentration 
Applied  
volume (µl) 
G-actin (40 to 80 µM) 5 µM variable 
TRITC/Atto488-labeled  
or unlabeled Phalloidin (100 µM) 5 µM 2.5 
AB (10X) 1X 5 
H2O - Δ 50 
Total reaction volume  50 
 
 
 
4.3.2.3 Isolation and purification of porcine tubulin 
The tubulin used in this work was isolated from about 700 g of pig brain. For the 
proper isolation it was crucial to keep the brains on ice at all times. First, 
connective tissue and superficial capillaries were removed manually at 4°C. 350 g 
of the cleaned brain tissue together with 1 volume of Buffer A was homogenized 
by intense mixing until a homogenous consistency was obtained. The 
homogenate was then cleared by centrifugation at 26,000 × g for 70 minutes and 
4°C (J2-21M/E centrifuge and JA-14 Rotor, Beckman-Coulter). Together with 2 
mM Na2ATP, the supernatants from the first centrifugation step were gently mixed 
with a quarter of the final volume pre-warmed glycerol. By adding glycerol, the 
polymerization process even is enhanced. Polymerization took place in a water-
bath under constant shaking for 30 minutes at 35°C. The microtubules were then 
pelleted by centrifugation at 200,000 × g for 45 minutes and 32°C (L8-70M Ultra-
centrifuge and 45Ti Rotor, Beckman-Coulter). Microtubule pellets were then 
resuspended in 5 ml Buffer C, homogenized in ice-cold homogenizers and 
incubated on ice for 25 minutes while frequent homogenization in-between 
(enhances microtubule depolymerization) was carried out. The homogenate was 
cleared again by centrifugation at 150,000 × g for 30 minutes at 4°C (L8-70M 
Ultra-centrifuge and 42Ti Rotor, Beckman-Coulter). The collected supernatant 
was again polymerized by adding 2 mM Na2ATP and incubation at 35°C for 30 
min. Following sedimentation at 125,000 × g for 30 minutes at 35°C (L8-70M 
Ultra-centrifuge and 42.1 Rotor, Beckman-Coulter), the supernatants were 
discarded and pellets collected. To prevent the binding of microtubule-associated 
proteins (MAPs) to microtubules, tubulin pellets were resuspended and 
homogenized in Buffer B (high ionic strength) until a final volume of 50 ml was 
Table 16. Reaction setup for actin polymerization from monomeric G-actin. 
 
Methods 
________________________________________________________ 
 84 
reached. To further depolymerize the microtubules, the homogenate was 
incubated on ice for an additional 25 minutes. The homogenate was cleared once 
more by centrifugation at 150,000 × g for 30 minutes at 4°C (L8-70M Ultra-
centrifuge and 42.1 Rotor, Beckman-Coulter). The supernatant was mixed with 
one tenth of volume DMSO, 2 mM ATP and was incubated for 30 minutes at 37°C 
to induce polymerization. The polymerized microtubules were pelleted at 125,000 
× g for 60 minutes at 35°C (L8-70M Ultra-centrifuge and 42.1 Rotor, Beckman-
Coulter). By adding 5 ml of Buffer D to the pellet fraction and further 
homogenization on ice for 30 minutes depolymerization of microtubules was 
reached. Precipitates were removed by centrifugation at 135,000 × g for 30 
minutes at 4°C (L8-70M Ultra-centrifuge and 42.1 Rotor, Beckman-Coulter).  
To separate the pure tubulin from remaining MAPs, the material was loaded on a 
gravity-flow phosphocellulose P11 material-filled column. Equilibration took place 
in 100 ml Buffer D and tubulin was eluted dropwise in Buffer D. Protein content 
was checked by calorimetric determination via Bradford reagent. The main 
fractions of eluted tubulin were combined, mixed with 0.1 mM GTP and aliquots 
were snap-frozen in liquid nitrogen. For long-term storage aliquots of purified 
tubulin were kept at -70°C. 
4.3.2.3.1 Tubulin polymerization 
Taxol (4 mM), an established potent microtubule-stabilizing agent, was included 
into the polymerization reaction. By binding to the β-subunits, Taxol prevents the 
individual subunits from dissociating and thereby stabilizes microtubules 144. 
4.3.2.3.2 Polymerization of fluorescently labeled tubulin for in vitro 
motility assays 
For fluorescent labeling of microtubules, typically Atto488-labeled tubulin was 
included into the polymerization reaction. The actual labeling of tubulin was 
carried out exactly as described by Mitchison, T. et al. 
(http://mitchison.med.harvard.edu/protocols/label.html). 
In a 1:50 stoichiometry, Atto488-labeled tubulin was thoroughly mixed with tubulin 
and immediately centrifuged at 80,000 rpm for 5 minutes and 4°C (Optima-TL 
ultra-centrifuge and TLA120 Rotor, Beckman-Coulter) to pellet and remove 
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excess dye from the reaction. Polymerization was started upon adding 1 mM GTP 
to the tubulin-dye mixture and incubation for 20 minutes at 35°C. After this initial 
polymerization step, 20 µM Taxol was added and the reaction was incubated over 
night at 35°C. 
4.3.2.3.3 Polymerization of unlabeled tubulin for ATPase activity 
assays 
After in vitro polymerization, a fraction of tubulin always remains unpolymerized. 
However, for determining the exact rate of ATP-hydrolysis at a given microtubule 
concentration, it is crucial to also determine the exact concentration of 
polymerized tubulin in the assay. Therefore, after initial polymerization one 
additional centrifugation step at 200,000 × g for 15 minutes at 30°C (Optima-TL 
ultra-centrifuge and TLA120 Rotor, Beckman-Coulter) through a cushion of 
sucrose (40% in 12A25 Buffer 1X plus 20 µM Taxol) was included. Thereby the 
fraction of unpolymerized tubulin was separated from the polymerized 
microtubules. The pelleted microtubules were washed twice with 100 µl 12A25 
Buffer (1X) and dissolved in 100 to 200 µl 12A25 Buffer (1X). 
4.3.2.4 Microtubule E-hook removal via Subtilisin digest 
E-hooks represent the C-terminal ends (approx. the last 12-18 amino acids) of 
tubulin and are mainly composed of glutamic acid (E) residues, lending the E-
hook its name as well as its negative charge. In previous studies it has been 
shown that many different members of the kinesin family use those hook-like 
structures to interact via electrostatic attraction with the microtubule surface 
115,119,145,146,147. To test for the possible influence of microtubule E-hooks on 
Myosin Va’s ability to interact with microtubules, E-hooks were removed from α- 
and β-tubulin subunits via limited proteolysis by Subtilisin A, a non-specific 
protease that belongs to the family of Serine-endopeptidases 148. 
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Here, an established method 119 was optimized and adapted to the needs of this 
work (illustrated in Figure 122). In brief, tubulin (3.5 mg/ml) and Atto488 tubulin at a 
50:1 ratio was polymerized in BRB80 1X (plus 1 mM GTP) at 36°C for 90 min. 
Subsequently, microtubules were stabilized with 20 µM Taxol and incubated for 
an additional 40 minutes at 36°C. E-hooks were removed by incubation of 0.6 
mg/ml with Subtilisin A at 1:0.8 ratio in BRB80-Tx 1X for 45 minutes at 36°C. The 
reaction was stopped with 2 mM PMSF (dissolved in isopropanol) and incubation 
at room temperature for 10 minutes. Subtilisin-treated microtubules were pelleted 
at 27,000 × g for 25 minutes and 25°C (Optima-TL ultra-centrifuge and TLA120 
Rotor, Beckman-Coulter). Pellets were washed with and resuspended in BRB80-
Tx 1X (plus 1 mM GTP). To test for the efficiency of E-hook removal, samples 
were resolved on a 12% SDS-PAGE with subsequent Coomassie-staining or 
immunoblotting. Together with the HMM-Myosin Va constructs used here, those 
modified microtubules were then targeted for single-molecule motility assays and 
were visualized via TIRF microscopy (for schematics, see Figure 4, Figure 5 and 
Figure 6). 
 
 
 
 
 
Figure 12. Schematic of E-hook removal from intact microtubules via 
Subtilisin-treatment. 
Microtubules were polymerized in vitro from porcine brain tubulin. On intact 
microtubules (left), the highly acidic C’-terminal ends (E-hooks) of the α- and β-
tubulin dimer subunits prodrude from the microtubule surface and are known to 
serve as electrostatic tethers for a number of kinesins. If desired, said E-hooks can 
be removed via limited proteolysis with the Serine-endopeptidase Subtilisin A (right). 
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4.3.3 Protein expression using the baculovirus expression system 
Over the past decade the use of baculoviruses has become an important tool for 
overexpressing recombinant proteins in eukaryotic cells 149,150. Unlike the 
bacterial expression systems, this eukaryotic system uses most of the protein 
modification, processing, folding and transport machinery that is present also in 
higher eukaryotes. Thus, with this system, most of the over-expressed proteins 
exhibit proper biological activity and function 151.  
For the purpose of this thesis, the expression of the different protein constructs 
was carried out with the Bac-to-Bac® baculovirus expression system (Invitrogen) 
in the Sf9 insect cell line (Section 4.1.5). One of two major components of the 
Bac-to-Bac®-system is the vector into which the gene or genes of interest is/are 
cloned. In this thesis, vectors containing one or two promoters, and thus one or 
two expression cassettes, were used. Dual vectors, i.e., vectors that carry two 
such expression cassettes, allow for the expression of two different proteins that 
are encoded by two different genes while cloned into the same plasmid. Both, the 
polyhedrin (pPH) and the p10 promoter in the wildtype baculovirus AcMNPV 
promote transcription of two major late viral proteins. Both, the polyhedrin and 
p10 gene were replaced by a foreign gene in the here used recombinant 
baculoviruses. Thereby recombinant protein expresssion under the control of 
those two promoters was made possible. 
The second major component of the Bac-to-Bac® system is represented by an E. 
coli strain (DH10Bac Competent E. coli) that is used as host for the before 
generated plasmid, consisting of transfer vector and gene(s) of interest. 
DH10Bac Competent E. coli cells contain a baculovirus shuttle vector, referred 
to as bacmid. After transformation into these cells, transposition between 
transposons of the vector and the bacmid occurs. This recombinant bacmid is the 
basis to then generate the recombinant baculovirus. 
An overview of the key steps for baculovirus protein expression is given               
in Figure 13. 
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4.3.3.1 Construction of the recombinant transfer vector for protein 
expression 
In this thesis two dual vectors and one mono vector were used to generate 
recombinant transfer vectors for the expression of the herein used protein 
constructs (vector maps are provided in Section 7). The two dual vectors, named 
hereafter p2bac/pfastbac and pFastBacDual, mainly differ in their multiple 
cloning sites downstream of the p10 and polyH promoter. The presence of these 
two strong promoters allows for the simultaneous expression of two different 
proteins encoded on the same plasmid. The expression cassette is flanked by the 
left (L) and right (R) arms of Tn7, which are mini Tn7 elements that permit site-
specific transposition of the gene of interest into the baculovirus genome 152. It 
also contains a SV40 polyadenylation signal, which permits efficient transcription 
termination and polydenylation of mRNA 153. In addition the vectors contain an 
ampicillin and gentamicin resistance gene, where the first one allows selection of 
the plasmid in E. coli XL 1-Blue cells, while the latter one permits selection of the 
recombinant bacmid in E. coli DH10Baccells. 
Except for the fact that the mono vector pFastBac1 possesses the polyH 
promoter only, all the genes and regions that were described for both the dual 
vectors are present also in the pFastBac1 vector (vector maps are provided in 
Section 7). 
Figure 13. Protein expression via the Baculovirus Bac-to-Bac® system −  An overview. 
The flowchart illustrates the required steps for the successful protein expression via the Bac-
to-Bac® system. 
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4.3.3.2 Generation of the recombinant bacmid 
Once the recombinant vector was generated, for transposition into the baculovirus 
shuttle vector (bacmid) the amplified and purified DNA was transformed into 
DH10Bac E. coli cells. This strain of E. coli cells contains the bacmid with a 
mini-attTn7 attachment site, which is inserted in a segment of DNA encoding the 
LacZα peptide, and a helper plasmid. Generation of the recombinant bacmid is 
achieved via site-specific transposition between the mini-Tn7 element of the 
donor vector and the mini-attTn7 attachment site on the bacmid (Figure 14). 
For transformation, chemically competent DH10Bac E. coli cells (aliquots of 50 
µl) were thawed on ice and incubated with 10 ng DNA (in 5 µl TE buffer) 30 
minutes on ice. The heat shock was performed for 45 seconds at 42°C, followed 
by immediate incubation on ice. Subsequently, 900 µl of S.O.C. medium was 
added and the suspension was incubated in a shaker device at 225 rpm, for 4 
hours at 37°C.The Tn7 transposition functions are provided by a helper plasmid, 
which encodes for the transposase and confers resistance to tetracycline. Thus, 
successful recombination leads to the disruption of the LacZ gene on the bacmid, 
which in turn allows for blue-white screening in the presence of the chromogenic 
substrate Bluo-gal and the inducer IPTG.  
Therefore, 100 µl of dilutions 1:10, 1:100 and 1:1000 in S.O.C medium were 
plated on LB plates supplemented with (100 µg/ml) Bluo-Gal, (40 µg/ml) IPTG, 
Figure 14. Generation of recombinant bacmid by site-specific transposition. 
Left: before transformation of transfer vector into DH10Bac cells; middle: transposition of the 
gene of interest and the gene encoding for gentamicin resistance into the bacmid (black 
arrows); right: recombinant bacmid with Tn7-element of transfer vector. LacZ gene and genes 
encoding resistance for indicated antibiotics are color-coded. 
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(50 µg/ml) kanamycin, (7 µg/ml) gentamicin and (10 µg/ml) tetracycline. The 
plates were incubated for 48 hours at 37°C to grow single colonies. Two to ten 
single large and white colonies were picked and re-streaked to confirm the white 
(i.e., recombined bacmid) phenotype on new LB plates supplemented with same 
concentrations of kanamycin, gentamicin, tetracycline, Bluo-Gal and IPTG. 
4.3.3.3 Isolation of the recombinant bacmid DNA 
Single large and white colonies from the re-streak plates were picked and grown 
to saturation overnight in culturing tubes containing 6 ml LB medium 
supplemented with kanamycin, gentamicin, tetracycline at the same respective 
concentrations as the ones applied before. Cells were pelleted at in a Rotanta 
460R swinging bucket centrifuge (Hettich) at 2,500 x g for 15 minutes at 4°C 
(Rotanta 460R swinging bucket centrifuge, Hettich). 
Plasmid isolation and purification was performed with buffers P1, P2 and P3 from 
the Qiagen® Midiprep kit, using the following protocol, while all centrifugation 
steps were carried out at 16,000 × g for 1 minute at room temperature in an 
Eppifuge.  
Pelleted cells were resuspended in 500 µl of P1 buffer and then lysed by adding 
500 µl P2 buffer, followed by incubation for 5 minutes at room temperature. 500 µl 
of P3 buffer was added and incubated for additional 10 minutes on ice. The 
solution was cleared by centrifugation for 15 minutes. The supernatant containing 
the plasmid DNA was briefly mixed with 1.6 ml ice-cold isopropanol and incubated 
for 30 minutes on ice. The precipitated DNA was pelleted by centrifugation for 15 
minutes, followed by a wash step with 1 ml of ethanol (70%) before again pelleted 
by centrifugation for 5 minutes. The pellets were then air-dried for 15 minutes and 
subsequently dissolved in 40 to 50 µl of double-distilled water. Before storage at -
20°C, the DNA concentration of all purified plasmids was determined (Section 
4.2.2.7). 
The insertion of the gene of interest was confirmed by PCR using promoter- and 
gene-specific primers. The correct orientation of the transposon inserted into the 
bacmid was checked by combining a (gene-) internal forward and an external 
reverse primer. 
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4.3.3.4 Transfection of Sf9 insect cells with recombinant bacmid 
For transfection it is crucial that the bacmid DNA is clean and free from any salts, 
as contaminants will kill the cells and salt will interfere with lipid complexing, 
eventually leading to low levels in transfection efficiency (Invitrogen, 2004).  
For transfection, per probe 2 ml of freshly diluted Sf9 cells at a density of 0.5*106 
cells/ml were seeded into one well of a 6-well tissue culture plate. The cells were 
incubated light protected for 15 to 20 minutes at 28°C, allowing the cells to attach 
to the surface of the tissue culture plate. 
In the following, 1 to 10 µl of recombinant bacmid DNA solution was mixed with 5 
µl of the cationic lipid Cellfectin® reagent (Invitrogen) into 200 µl Sf-900 II SFM 
medium (no additives). Cellfectin® is a 1:1.5 (m/m) liposome formulation of the 
cationic lipid N, NI, NII, NIII-tetramethyl-N, NI, NII, NIII-tetrapalmitylspermine (TM-
TPS) and dioleoyl phosphatidylethanolamine (DOPE), which coats the DNA and 
thereby facilitates transfection (Figure 15).  
The mixture was incubated for 15 minutes at 28°C before 1 ml Sf-900 II SFM 
medium was added. As a next step, the medium from the seeded cells was 
removed and the cells were washed twice with 2 ml Sf-900 II SFM medium (no 
additives). Subsequently, the cells were overlaid with the Cellfectin®-DNA 
suspension, before culture plate was tightly sealed and incubated light protected 
for 5 hours at 28°C. During this time the lipid-coated DNA enters the cells. 
Figure 15. Preparing the bacmid for transfection into insect cells via Cellfectin® reagent. 
The cationic lipid (Cellfectin® reagent) coats the bacmid DNA for the subsequent chemical 
transfection into insect cells. 
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Then the transfection mix was removed and supplemented with 3 ml of fresh Sf-
900 II SFM medium (containing 10% serum and 1% gentamicin, 10 mg/ml), 
followed by further incubation for two to three days at 28°C. 
Virus-infected insect cells are characterized by increased cell size. In addition, 
after transfection the formerly surface-adhered cells detach from the plate they 
were seeded on and eventually undergo cell lysis, resulting in the release of virus 
into the medium (Figure 16). 
48 to 60 hours after transfection, the initial virus (V0 generation) was harvested, 
sterile-filtered using a 0.22 µm syringe filter and stored light-protected at 4°C. 
4.3.3.5 Amplification of baculovirus V0 generation 
The V0 viral stock is a small-scale, low-titer stock and is used to infect a larger 
volume of yet uninfected cells to generate a high-titer V1 (or higher) virus 
generation. For viral amplifications always cells from suspension culture were 
used. For an efficient amplification, prior infection the viability of the cell stock was 
supposed to be greater than 95%, while a cell density of 0.5*106 cells/ml was 
Figure 16. Schematic showing the time course from cell transfection until harvesting of 
released virus. 
Top left: Cellfectin-mediated transfection of insect cells with bacmid DNA; top right: following 
transfection, within approx. 48 to 60 hours cells produce viral proteins, that eventually 
assemble into intact lytic viral particles; free virus is eventually harvested and used for further 
virus amplification. 
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desired. Typically, 100 ml of uninfected cells were infected with 100 to 300 µl of 
V0 virus. Amplifications were incubated shaking at 110 rpm and 28°C. To 
determine the progress of the individual amplification cell viability and density was 
determined daily. As long as the cell density was higher than 0.5*106 cells/ml, the 
cell suspension was diluted to 0.5*106 cells/ml, while keeping the volume 
constant. Virus was harvested when the cell density stayed below 0.5*106 cells/ml 
for additional 48 hours. The harvested V1+x generations can be stored light 
protected at 4°C up to several months. 
4.3.3.6 Protein expression in Sf9 insect cells 
For all proteins over-expressed via the baculovirus expression system, 
expression was carried out in insect Sf9 cells from suspension culture.   
300 ml to 800 ml freshly diluted Sf9 cells at a density of 2*106 cells/ml (viability 
greater than 95%) were used for protein expression from suspension culture in 1 
to 6 L-glass spinner flasks. Typically, 2 to 5% vol. of recombinant virus encoding 
for the gene(s) of interest, were used to transfect the cells. Depending on the 
protein to be expressed, the suspension of transfected cells was incubated for 45 
to 80 hours in a shaker device at 110 rpm and 28°C. 
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4.3.4 FLAG-tag affinity protein purification 
All proteins expressed in this thesis contained either a C- or an N-terminal FLAG-
tag. The FLAG-tag itself is an octapeptide, which is made up of the amino acid 
sequence DYKDDDDK (Figure 17). 
As for other tags used in molecular biology, the FLAG-tag with its rather unique 
peptide sequence, is used to affinity-purify only those proteins that contain a 
FLAG-tag and are over-expressed in Sf9 cells. For this, a commercially available 
resin that contains agarose-beads to which multiple copies of monoclonal anti-
FLAG antibody are attached (Anti-FLAG M2® Affinity Gel, SIGMA) was used 
(Figure 18). 
The size of the beads keeps the bound proteins from passing through the 
membrane of the column. Via competitive elution, where synthetic FLAG-Peptides 
are applied in excess amount to the solution of antibody-bound protein, the 
protein of interest is eventually eluted from the column. Statistically the antibody 
will bind more likely to the highly concentrated FLAG peptides than to the much 
lower concentrated proteins of interest (Figure 19). This way high yields of 
relatively clean protein fractions are achieved. 
Figure 17. Schematic of FLAG-affinity protein purification −  
Part 1. 
Depicted is the cell lysate fraction containing the overexpressed 
FLAG-tagged protein of interest (depicted is a double-headed 
motor protein, e.g. Myosin V). 
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Figure 18. Schematic of FLAG-affinity protein purification −  Part 2. 
Upon incubation with anti-FLAG® M2 agarose resin, FLAG-tagged proteins 
bind to the resin. Thereby highly efficient separation of the FLAG-tagged 
protein from other unwanted cytoplasmic protein fractions is achieved. 
Figure 19. Schematic of FLAG-affinity protein purification −  Part 3. 
FLAG-tagged protein fraction is eluted from the column by competitive 
elution applying an excess amount of FLAG-peptides. 
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4.3.4.1 General FLAG-tag affinity purification protocol 
All steps were carried out on ice at all times. Before harvesting of the cells, 
viability and density was determined for comparison of infection rates. The cells 
were harvested by centrifugation at 1,500 x g for 15 minutes at 6°C. The pelleted 
cells were resuspended in approx. 9% vol. (of the initial cell suspension volume) 
Lysis Buffer (LB) 1X and homogenized in a glass-bounce homogenizer for 5 
minutes on ice. The homogenate was cleared by centrifugation at 69,000 × g for 
15 minutes at 4°C (L8-70M Ultra-centrifuge and 42.1 Rotor, Beckman-Coulter). 
The supernatant, containing most of the soluble proteins, was mixed with 3% vol. 
(of lysis solution volume) anti-FLAG agarose resin (Anti-FLAG M2® Affinity Gel). 
This mixture of anti-FLAG resin and cellular proteins was then incubated rotating 
for 90 to 120 minutes at 4°C. As a next step, the mixture now containing the 
antibody-bound FLAG-tagged proteins of interest was applied onto a PolyPrep® 
chromatography column, which was equilibrated with 2 to 3 ml of LB 1X 
beforehand. The cushion of anti-FLAG resin on the column was washed 8 to 10 
times with 2 ml of Wash Buffer (WB) 1X by constant stirring the suspension with a 
glass-stick. Protein elution from the column took place in 0.5 to 1.5 % vol. (of lysis 
suspension volume) of Elution Buffer (EB). Before the actual elution was carried 
out and under constant stirring, EB and the resin mixture were incubated for 30 
minutes at 4°C (chromatography column sealed-up). By gently applying air 
pressure onto the unsealed column, protein elution was carried out. Immediately 
after elution, via Slide-A-Lyzer® dialysis cassettes (0.1 - 0.5 ml or 0.5 - 3 ml 
capacity, 10 kDa molecular weight cut-off) samples were dialyzed for 60 to 120 
minutes at 4°C into 500 ml dialysis buffer (DB, containing 50% glycerol). This step 
was included to make the purified proteins suitable for long-term storage at -20°C.  
For SDS-PAGE analysis always 15 to 30 µl of flow-through (FT), wash (W), 
elution (E, prior dialysis) and dialysis (D) was saved. For those purifications where 
protein yield was expected to be low, protein concentration was further scaled up 
with Amicon Ultra-4 centrifugal filter units (10 kD molecular weight cut-off). For 
this, the filter unites containing the un-dialyzed protein elution, were centrifuged in 
a swinging bucket centrifuge (swinging-bucket centrifuge, Rotanta 460R, Hettich) 
at 4,000 x g for 5 to 10 minutes and 4°C. 
It is to be mentioned that due to the different downstream applications carried out, 
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for subsequent cryo-EM studies the CaMKII-α protein was dialyzed into 10% 
glycerol (in DB 1X), keeping the protein stable at 4°C for four weeks. If snap-
frozen in liquid nitrogen (for biochemical analysis) the protein could be stored at -
70°C for up to several months. 
For protein-specific buffers used during cell lysis, sample washing and sample 
elution, please refer to Table 17. 
 
 HMM-like  Myosin Va 
FL-Xenopus  
Myosin Va CaMKII-α 
Lysis LB-HMM-M5 LB-XM5 Brickey Buffer 
Wash WB-HMM-M5 WB-XM5 WB-CK 
Elution EB-HMM-M5 EB-XM5 EB-CK 
Dialysis DB-HMM-M5 DB-XM5 DB-CK 
 
 
4.3.4.2 Optimized protocol for FLAG-tag affinity purification of full-
length Xenopus l. Myosin Va 
For the purification of full-length Xenopus l. Myosin Va, in principle the general 
FLAG-tag affinity purification protocol was followed (for details, refer to Section 
4.3.4.1).  
Due to strong degradation of the full-length protein, any detergent in the lysis 
buffer was omitted and instead of Dounce-homogenization, cell lysis was 
performed via sonication for a total of three minutes (duty cycle: 40%, output 
control: 4). Cell lysate was cleared at 27,000 × g (Sorvall RC-5B and SS-34 rotor) 
for 30 minutes at 4°C. Because of its high molecular weight (larger than 215 kDa), 
the expression was expected to yield relatively low protein concentrations. Thus, 
immediately after the first incubation with anti-FLAG resin was completed the 
mixture was applied onto the column, and the flow-through of this first incubation 
round underwent a second round of incubation with anti-FLAG resin. 
Furthermore, two rounds of incubation with EB (1% total vol. of lysis solution 
volume) were performed while eluting the protein sequentially in-between. 
Before dialysis into 50% glycerol, protein concentration was typically scaled-up 
via Amicon Ultra-4 centrifugal filter units (as described in Section 4.3.4.1). 
Table 17. Listing of the different buffers used during FLAG-tag 
affinity purification of the different baculovirus-expressed 
proteins of interest. 
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4.3.5 Methods for functional protein analysis 
4.3.5.1 In vitro motility assays 
In vitro motility assays were utilized to test for the functionality of both, 
recombinant baculovirus-expressed proteins and whole organelles. Furthermore, 
by performing motility assays it is possible to characterize movement and 
transport of motor proteins and organelles on actin filaments as well as 
microtubules, biophysically. 
4.3.5.1.1 Flow cell preparation 
All in vitro (single-molecule, melanosome motility and gliding filament) motility 
assays were performed using 15-µl flow cells (area 18×5 mm), covered by a 
nitrocellulose coverslip. The cells were prepared by greasing a large coverslip (for 
TIRF microscopy) or microscope slide (for epi-fluorescence) on a flat surface with 
silicon vacuum grease along the length of the coverslip about 5 mm apart and 
placing a smaller coverslip on top of the grease. The second coverslip was gently 
pushed downward so that maximal capillary force for the reagents was achieved. 
The reagents were pipetted into the opening at one end of the channel created by 
the grease and the coverslip (Figure 20).  
Figure 20. Schematic of the flow cell setup used during in vitro motility assays. 
For in vitro gliding filament or single-molecule motility assays 15 µl-flow cells (approx. area 18 
× 5 mm) were prepared by applying a small coverslip on top of a larger one, with two stripes of 
silicon grease in between to create a flow channel. 
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4.3.5.1.2 Fluorescent labeling of motor proteins 
For visualizing individual motor molecules in motility assays on F-actin and 
microtubules, FLAG-purified myosins to be probed for fluorescence microscopy 
were conjugated to a monoclonal anti-FLAG Cy3 antibody. For this, the antibody 
was diluted 20-fold to 0.05 mg/ml in TBS 1X, while being kept on ice. The FLAG-
specific labeling was achieved by incubating 40 µl of 500 nM FLAG-tagged 
purified protein with 10 µl of the pre-diluted antibody at room temperature for 5 
minutes in AB 1X and subsequent storage on ice. Before use, the mixture was 
further diluted to the desired motor concentration in AB 1X (containing oxygen-
scavenging system). 
4.3.5.1.3 Single-molecule motility assays on microtubules and F-actin 
For assays with microtubules as the cytoskeletal track, an appropriate dilution of 
fluorescent microtubules was perfused into the flow cell, followed by a wash with 
BRB80-Tx (1X), containing 0.7 mg/ml casein to block the flow cell surface. 100 
nM of fluorescent-labeled Myosin protein in AB 1X (containing an oxygen-
scavenging system) was added to the flow cell. For experiments in which different 
ionic strength-conditions were applied to the flow cell, the required volume of KCl 
(1 M) was added, yielding a final assay concentration of 50, 100 or 200 mM KCl 
(Table 18).  
 
Step Reagent Incubation time (minutes) 
1 15 µl dilution of Atto488-labeled microtubules in BRB-Tx (1X) 3 
2 50 µl wash with BRB80-Tx (1X) plus 0.7 mg/ml casein 3 
3 100 nM Cy3-labeled Myosin in AB (1X) plus Oxygen Scavenging system 1 
or   
4 Step 3 plus: 
25, 75, 175 mM KCl (1M) 1 
 
 
 
For assays in which actin filaments served as cytoskeletal tracks, flow cells were 
pre-incubated with 0.1 mg/ml N-ethyl maleimide (NEM)-modified Heavy 
Meromyosin (HMM)154 (kind gift of Prof. T. Bausch, Technical University, Munich, 
Table 18. Pipetting scheme for in vitro single-molecule motility 
assays with Myosin V on microtubules. 
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Germany), rinsed with AB 1X, incubated with an appropriate dilution of TRITC-
labeled actin filaments, rinsed with AB 1X and then blocked with BSA (5 mg/ml). 
100 nM fluorescently labeled Myosin was applied and incubated for 1 minute, 
followed by a wash step with AB 1X containing 1 mM ATP (Table 19). 
 
Step Reagent Incubation time (minutes) 
1 15 µl NEM-HMM (0.1 mg/ml) in NHB (1X) 3  
2 50 µl wash with AB (1X) - 
3 15 µl TRITC-labeled F-actin dilution in AB (1X) 3 
4 50 µl wash with AB (1X) - 
5 50 µl wash with AB (1X) plus 5 mg/ml BSA 5  
6 100 nM Cy3-labeled Myosin in AB (1X) plus Oxygen Scavenging system 1  
7 50 µl wash with AB (1X) plus Oxygen Sc. system, 1 mM ATP 1  
 
 
 
The oxygen-scavenging system was included to keep photo-bleaching low. In this 
system, glucose-oxidase catalyzes the oxidation of D-glucose to form D-glucono-
1, 5-lactone and hydrogen peroxide. Hydrogen peroxide would severely damage 
the motor proteins, so that catalase is used to decompose the hydrogen peroxide 
to water and oxygen (Figure 21). 
 
 
 
 
Figure 21. Reaction of the oxygen-scavenging system used in in vitro 
motility assays. 
To avoid photo-bleaching of the sample during acquisition, an oxygen-
scavenging system containing glucose, glucose-oxidase and catalase was 
used. 
Table 19. Pipetting scheme for in vitro single-molecule motility 
assays with Myosin V on F-actin. 
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4.3.5.1.4 Gliding filament assays 
For gliding filament assays with the full-length Xenopus l. Myosin Va, the motor 
was surface-adhered non-specifically by infusing 50 to 650 nM protein into the 
flow cell. To prevent unspecific filament binding to the glass-surface, an additional 
wash step with BSA (5 mg/ml) in AB 1X was included. Then, an appropriate 
dilution of Atto488-labeled F-actin was perfused into the flow cell, followed by a 
wash step with BSA (5 mg/ml) in AB 1X. At last motility buffer, containing ATP 
and oxygen-scavenging system, was applied to the flow cell (Table 20). 
 
Step Reagent Incubation time (minutes) 
1 15 µl of 50- 650 nM Myosin in AB (1X) 3  
2 50 µl wash with AB (1X) plus 5 mg/ml BSA 5  
3 15 µl Atto488-labeled F-actin dilution in AB (1X) 3  
4 50 µl wash with AB (1X) 
plus 5 mg/ml BSA 
- 
5 50 µl wash with AB (1X) plus Oxygen Sc. system, 2 mM ATP 3  
 
 
 
4.3.5.2 TIRF and epi-fluorescence microscopy 
In vitro motility (Section 4.3.5.1) of HMM-Myosin Va loop 2 mutans, as well as 
Wildtype full-length Xenopus l. Myosin Va was studied by applying fluorescence-
microscopy techniques. For assays, where primarily the filament-gliding behavior 
was studied, both an epifluorescence microscope (Axiovert 200M) equipped with 
a apochromatic objective lens (100×, N.A. 1.4 Oil) and linked to a CCD camera 
(AxioCaM MRm, Zeiss) as well as the below described TIRF microscope were 
used (as indicated in the respective figures). For microscopy via epi-fluorescence, 
a mercury lamp (FluoArc 01.26D, Jena GmbH) along with band-pass filters 
allowing for fluorophore excitation at 488 and 532 nm was used, while the optical 
resolution was 10 px/µm, and dependent on the duration of image acquisition, 
integration times varied. In most cases, image acquisition took place for 1 to 3 
minutes. 
All the single-molecule motility assays where the behavior of HMM-Myosin Va 
constructs on microtubules and F-actin was examined, were studied with a total 
Table 20. Pipetting scheme for in vitro gliding filament assays with 
F-actin and Myosin V. 
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internal reflection fluorescence (TIRF) microscope (IX71), equipped with a Plan 
objective lens (100×, N.A. 1.65 Oil) and linked to a front-illuminated CCD camera 
(C-9100, Olympus). Fluorophores were excited with a solid-state laser at 
wavelengths of 532 or 488 nm. The optical resolution was 160 nm per 2×2 -
binned pixel, with integration time 200 ms. Typically, 350 images were recorded 
for a total of 70 s. 
4.3.5.3 ATPase activity assays 
ATPase activity was determined in a coupled enzymatic assay 35,155 (Figure 22). In 
this assay, ATP hydrolysis is linked to the oxidation of NADH, which is measured 
spectroscopically at 340 nm by its decrease in concentration. The coupling takes 
place via phosphoenol pyruvic acid (PEP), pyruvic acid kinase (PK) and lactate 
dehydrogenase (LDH), which is referred to as ATP regenerating system. 
To study the filament-stimulated ATPase activity of the assayed motor proteins, 
! 
A" = #" $d $c
#NADH at 340 nm = 6.22 Mol%1 $cm%1
d = 0.3125 cm
!
Figure 22. Schematic of the coupled enzymatic steady-state ATPase 
assay. 
Myosin Va hydrolyzes ATP to ADP and inorganic phosphate, while 
simultaneously the regenerating system recycles the generated ADP back 
into ATP. Therefore, the system maintains a steady state ATPase of Myosin 
Va. Via the enzymatic action of pyruvate kinase (PK), for each ATP molecule 
generated, one NADH molecule is oxidized by lactate-dehydrogenase (LDH) 
to NAD+. The resulting decrease in absorption can be measured at 340 nm. 
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measurements at different F-actin or microtubule concentrations were carried out. 
With the output value of absorption (A) in OD per second, the molar absorptivity 
(ε) of NADH at 340 nm and the diameter of the well, the NADH concentration in 
the activated ATPase assay can be determined by applying the law of Lambert-
Beer (see Equation 5). 
 
The amount of NADH that is oxidized per second corresponds to the amount of 
hydrolyzed ATP per second, which in turn reflects the maximal rate of ATP 
hydrolysis (Vmax). Km expresses the motor concentration that yields the half-
maximal reaction rate. kcat or the catalytic constant expresses the number of 
hydrolyzed ATP molecules per motor head (or motor dimer) per second, and was 
calculated according to Equation 6. 
The ATP regenerating system was prepared by mixing gently all reagents (Table 
21) on ice. 2.3 µl ATP regenerating system per well was applied to the reaction. 
 
Components for ATP 
Regenerating System 
(concentration) 
Final concentration 
(139.3 µl) 
Final Concentration 
per 96-Well (50 µl) 
NADH (solid)  
in Hepes Buffer (1X) 32.3 mM 1.5 mM 
PEP (solid) 
in KMg50 Buffer (1X) 189.5 mM 3 mM 
PK (700 U/ml) 34.2 U/ml 1.6 U/ml 
LDH (1000 U/ml) 48.8 U/ml 2.2 U/ml 
H2O (∆ 139.3 µl) - 
 
 
 
! 
kcat =
cATP " s#1
cmyosin
!
Equation 5 (Haid et al., 1975)1       
 
Equation 6 
Table 21. Final concentrations of ATPase regenerating system 
components. 
 
! 
A" = #" $d $c
#NADH at 340 nm = 6.22 Mol%1 $cm%1
d = 0.3125 cm
!
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It was crucial that ATP was added to the reaction immediately before the plate-
reading was started. All components were pipetted into the wells by following a 
strict order, which is outlined in Table 22. 
 
Order for the application 
of assay-components 
(volume) 
Applied volume/concentration 
100 nM HMM-Myosin Va 
2.3 µl ATP regenerating system Step 1 (10 µl) 
Δ 10 µl KMg50 Buffer (1X) 
F-actin or microtubules 
at desired concentrations Step 2 (37 µl) 
Δ 37 µl KMg50 Buffer (1X) 
Step 3 (3.3 µl) 3.3 µl MgATP at desired 
concentration 
Total reaction volume 50 µl 
 
 
 
 
 
ATPase activity assays were carried out in 96-well plates using a 
spectrophotometer at an excitation wavelength of 340 nm and 23°C. The data 
were analyzed with Kaleidagraph software (Synergy, Pittsburgh, U.S.A.) and fitted 
to the Michaelis-Menten function156 as is described in more detail in Section 4.4.5. 
4.3.5.4 Microtubule-affinity co-sedimentation assays 
Microtubules were polymerized from porcine tubulin overnight and their 
concentration was determined as described in Section 4.3.1.4. Typically, 0.5 to 1 
ml purified tubulin was diluted 3-fold in BRB80 1X so that after polymerization a 
microtubule concentration of 200 µM was yielded. 375 µg of the microtubule stock 
solution was treated with Subtilisin A (for experimental details see Section 
4.3.2.4). After E-hook digestion was completed, the mixture was cleared by 
centrifugation at 27,000 × g for 25 minutes and 25°C (Optima-TL ultra-centrifuge 
and TLA120 Rotor, Beckman-Coulter). The pellet was resuspended in 135 µl 
BRB80-Tx 1X (containing 1 mM GTP), yielding a final microtubule concentration 
of 50 µM. Likewise the untreated microtubule stock solution was diluted to 50 µM 
in BRB80-Tx 1X. 
Table 22. Reaction setup for actin- or microtubule-stimulated 
ATPase activity assays with Myosin V. 
Volumes and concentrations refer to one well. 
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Co-sedimentation assays were carried out at constant microtubule (1 µM) and 
motor protein (850 nM) concentrations, while the ionic strength of the assay milieu 
differed (25 to 200 mM KCl final concentration) (for details see Table 23). To 
ensure that all reactions took place under zero ATP, the non-hydrolyzable ATP 
analogue AMP-PNP as well as the phosphatase Apyrase (hydrolyzes all residual 
ATP to AMP and Pi) were included. 
The reactions were incubated for 20 minutes at 30°C before centrifugation 
through a sucrose cushion (40% in BRB80 1X) at 280,000 × g for 10 minutes at 
25°C (Optima-TL ultra-centrifuge and TLA120 Rotor, Beckman-Coulter) was 
carried out. For further SDS-PAGE analysis, a sample aliquot of the supernatant 
from each of the reactions was saved. Before aspirating the sucrose cushion, it 
was washed once with AB 1X. The pellet, now containing the microtubule-bound 
Myosin Va fraction, was washed twice with AB 1X and for the subsequent SDS-
PAGE analysis was resuspended in 20 µl AB1X. 
 
Component (concentration) Final concentration Applied  volume (µl) 
Microtubules, treated/untreated  
(50 µM) 5 µM variable 
Myosin Va (850 nM) 5 µM 2.5 
Apyrase (1000 U ml-1) 5 U ml-1 1 
AMP-PNP (0.1 M) 1 mM 2 
25 mM or - 
50 mM or 5 
100 mM or 15 
125 mM or 20 
KCl (1 M), if applicable 
200 mM 35 
AB (10X) 1X  (includes 25 mM KCl) 20 
H2O - Δ 200 
Total reaction volume  200 
 
 
 
 
 
 
 
 
Table 23. Reaction setup for ionic strength-dependent microtubule-
affinity co-sedimentation assays with Myosin V. 
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4.3.5.5  CaMKII-α autophosphorylation assays 
The autophosphorylation reaction was set-up by mixing calmodulin and the so-
called Ca2+ reaction mixes (2.5X), each of which contained a different 
concentration of free Ca2+. The mixture was incubated with 0.1 mM ATP and 
temperature-equilibrated on a shaking heat-block for 2 minutes at 25°C before 
purified C’ or N’ FLAG-tagged CaMKII-α (0.15 mg/ml) was added. Reactions were 
stopped after 0 (immediate stop), 2 or 3 minutes by adding Stop Solution, 
containing 9% SDS and 3% β-mercaptoethanol.  
The analysis was carried out by resolving the individual reactions via 10% SDS-
PAGE (Section 4.3.1.1) with subsequent targeting of the resolved samples for 
immunoblotting against total CaMKII-α protein and phospho-Thr286 of CaMKII-α 
(for details on immunoblotting, refer to Section 4.3.1.5).  
For detailed information on the applied volumes and final concentrations for the 
various assay ingredients, please refer to Table 24 and Table 25. 
 
 
Ca2+ Reaction 
Mix 
2.5X 
BSA 
(2 mg/l) 
Calmodulin 
(1 mg/ml) 
KCl 
(3M) in 
50 mM 
TrisCl 
H2O 
ATP 
(2 mM) 
 
CaMKII 
Mix 
(0.15 
mg/ml) 
 (µl) (µl) (µl) (µl) (µl) (µl) (µl) 
Sample Final Ca
2+ 
conc. (mM)       
 0 1.73 300       
Zero 80 - - 40 4 10 36 10 20 
Low - 80 - 40 4 10 36 10 20 
High - - 80 40 4 10 36 10 20 
 
 
 
 
 
 
 
 
 
Table 24. Reaction setup for autophosphorylation assays with CaMKII-α  at different 
calcium concentrations. 
The ability of CaMKII-α to undergo autophsophorylation was assessed at zero, low (1.73 µM) 
and high (300 µM) concentrations of free Ca2+. Concentrations of all other components were 
kept constant. Prior the addition of CaMKII-α, reactions were equilibrated at 25°C for 2 minutes 
(including 0.1 mM ATP). 
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Sample Total Ca2+ 
Free 
Ca2+ Mg
+ EGTA ATP KCl Calmodulin CaMKII 
 (µM) (µM) (mM) (mM) (mM) (mM) (mg/ml) (µM) (mg/ml) (µM) 
Zero 0 0 1 0.4 0.1 150 0.02 1.18 0.015 0.27 
Low 379 1.73 1 0.4 0.1 150 0.02 1.18 0.015 0.27 
High 700 300 1 0.4 0.1 150 0.02 1.18 0.015 0.27 
 
 
4.3.5.6 Assays to monitor CaMKII-α-mediated Myosin V release from 
melanosomes 
At first, melanosomes from eight to ten confluent flasks of cultured Xenopus l.  
melanophores were isolated according to the procedure outlined in Section 4.1.4. 
However, for this assay serum-deprived cells were rinsed once with PBS 0.7X 
and then again with AB 1X before being scraped into 2 ml of AB 1X (containing 
protease inhibitor). Subsequent lysis by Balch-homogenization and all the 
centrifugation steps were performed as described above. Before proceeding to 
the release-assay, isolated melanosomes were kept suspended in 800 µl AB 1X 
(containing protease inhibitor) on ice. Just before the assay, the granules were 
pelleted at 2,500 × g for 5 minutes and 4°C (Hettich, Rotina 420R) and 
resuspended in 100 µl PBS 0.7X (containing protease inhibitor).  
The fact that Myosin V release via CaMKII-α is possible only if the kinase is in its 
active form required a set-up where the CaMKII-α autophosphorylation assay 
(outlined in 4.3.5.5) is combined with the isolated melanosomes. The different 
Ca2+ reaction mixes (2.5X), calmodulin and 0.1 mM ATP were equilibrated on a 
shaking heat-block for 2 minutes at 25°C before activation of the kinase was 
induced in high Ca2+ (300 µM free Ca2+) for 30 seconds at 25°C. Lastly, 
melanosomes were added to the mixture for zero (immediately stopped with AB 
10X), 2, 4 or 5 minutes shaking at 25°C (Table 26). Reactions were stopped by 
mixing AB 10X with the sample in a 1:10 ratio. To separate melanosomes from 
supernatant, samples were centrifuged at 5,000 × g for 10 minutes and 4°C 
(Biofuge 15R, Heraeus). Both, supernatant and pelleted melanosomes were 
mixed with SDS 6X sample buffer, and resolved by SDS-PAGE. Subsequently, 
samples were analyzed by immunoblotting against the antigen of interest.  
Table 25. Final concentrations of CaMKII-α  autophosphorylation assay components. 
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The final concentrations of the assay components were identical to those of the 
auto-phosphorylation assays (Table 25). 
 
 
Ca2+ 
Reaction 
Mix 
2.5X 
BSA 
(4 mg/l) 
Calmodulin 
(1 mg/ml) 
KCl 
(3M) in 
50 mM 
TrisCl 
H2O 
ATP 
(4 mM) 
 
CaMKII 
Mix 
(0.28 
mg/ml) 
Mel. 
 (µl) (µl) (µl) (µl) (µl) (µl) (µl) (µl) 
Sample 
Final Ca2+ 
conc. 
(mM) 
       
 0 300        
Zero 40 - 5 2 5 20 2.5 5 20 
High - 40 5 2 5 20 2.5 5 20 
 
 
 
 
 
 
 
4.4 Data Analysis 
Unless mentioned otherwise in the detailed description of the respective method, 
data was analyzed as described below. 
4.4.1 Fluorescence microscopy data analysis: Single-molecule motility 
measurements 
Diffusion events were defined as follows: Those events in which the Myosin V 
molecule moves on microtubules in both directions (for > 300 nm) were classified 
as diffusive events. 
For the characterization of Myosin V diffusion on microtubules, the following 
parameters were determined: i) maximum speed of diffusion for a given 
encounter was defined as the maximum displacement along the microtubule 
during one frame interval (i.e., 5 frames per s); ii) scan distance for a given 
encounter was calculated as the distance between the two extreme positions of 
the microtubule, on which the respective Myosin V molecule has diffused along; 
iii) association time (tA) was defined as the total time an individual Myosin V 
Table 26. Reaction setup for the CaMKII-α-mediated Myosin V-release from 
melanosomes. 
The ability of CaMKII-α to trigger the release of Myosin V from melanosomes (from Xenopus 
melanophores) was assayed at zero and high (300 µM) concentrations of free Ca2+, while 
having 0.01 mM ATP present. All reactions were carried out at 25°C. The final concentrations 
of the applied assay components are identical to those used in the CaMKII-α-
autophosphorylation assays (Table 25). 
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molecule spent on the microtubule during recording. The individual values for tA of 
the respective Myosin V constructs were obtained from an exponential fit as 
described 116. 
The mean square displacement (MSD) for all diffusion events was calculated as 
described in 157, plotted as a function of time and fitted to linear function. 
Single displacements of individual diffusion events for a given Myosin V construct 
were plotted as a displacement histogram. A single Gaussian was fitted to the 
data according to Equation 7. 
Based on the Gaussian fit curve for the respective displacement histogram, the 
variance σ = b2 was calculated. From these data, the diffusion coefficient (D) was 
determined according to the 1st law of diffusion-derived equation, D = σ/2t, where 
t is the time interval between successive images. 
Quantification of microtubule association and diffusion was carried out with the 
data obtained from the single-molecule experiments on microtubules. For each 
microtubule, the numbers of diffusing and stationary particles during a 70-second 
period were counted. The numbers of diffusing and stationary particles on 
microtubule lengths of 1000 to 3000 µm were added and divided by the 
corresponding microtubule lengths and time of measurement. By this procedure, 
the number of associated and diffusing Myosin V particles per microtubule unit 
length and time at the respective salt concentration (25, 50, 100 and 200 mM KCl) 
was obtained. Quantification on S-microtubules is based on data obtained from 
experiments in 25 mM KCl. 
On actin, only events of individual Myosin V molecules (n ≥ 25) walking along the 
filaments with an interaction time ≥ 2 s were classified as processive. The length 
of a processive run was determined manually with CellR software (Olympus 
Biosystems, Germany). Runlength and velocity distributions were obtained from 
the single exponential and Gaussian fit as described by Helenius et al. 116 and 
Equation 7, respectively. 
! 
y = a " exp " # x # x0( ) b( )
2$ 
% & 
' 
( ) 
Equation 7 
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4.4.2 Fluorescence microscopy data analysis: Gliding-filament motility 
measurements 
Only those filament-gliding events (n ≥ 30) where the transport of an individual 
filament lasted for longer than 5 s and remained uninterrupted during that time 
period were taken into consideration. As for the single-molecule motility analysis 
of Myosin V on F-actin described above, the gliding velocity of individual actin 
filaments was determined using CellR software and IMAGEJ (NIH, Bethesda, 
U.S.A.). The mean-values for gliding velocity were obtained from the single 
Gaussian fit according to Equation 7.  
4.4.3 Fluorophore measurement and statistical analysis 
Distances and single displacements were measured by brightest centroid 
tracking, using MTrackJ for IMAGEJ. Single-displacement boxplots as well as all 
other data plotting and fitting, but also the statistical analysis was performed with 
IgorPro software (WaveMetrics, Inc., Portland, U.S.A.). 
Kymographs of representative video sequences from the performed single-
molecule TIRFM assays on actin and microtubules were generated with the 
MultipleKymograph macro for IMAGEJ. 
4.4.4 Quantitation of data obtained from microtubule-affinity co-
sedimentation 
Band intensities of the respective supernatant and pellet fractions were 
determined with the digital gel-analysis software ImageQuant (Version TL 7.0, GE 
Healthcare). By determining the average pixel value adjacent to the measured 
band of interest, background subtraction was carried out. The obtained 
background-corrected values of the reactions were subtracted by the median of 
the calculated ratio of the values determined for the control reactions (i.e., 
microtubules and Myosin V only). This way, all band intensities were not only 
background-corrected but also correction of potential assay-derived probe 
leakage into the supernatant and/or pellet fraction was included. As a last step, 
the obtained value of the respective sample (e.g., supernatant of reaction x) was 
related to the determined value of the respective control reaction (e.g., 
supernatant Myosin V only). This way the percentage of microtubule-bound 
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Myosin V relative to the situation where no microtubules are present at all could 
be calculated. Finally, the obtained values of all reactions from one assay were 
compared to the value of the 25 mM salt condition (set to 100%). 
4.4.5 Analysis of data obtained from ATPase assays on actin and 
microtubules 
Microtubule- and actin-activated ATPase activity of Myosin V was determined in a 
coupled enzymatic assay (4.3.5.3) with a final MgATP concentration of 1 mM and 
concentrations of Myosin V and F-actin or microtubules described above. 
Measurements were carried out in 96-well plates (Greiner, Frickenhausen, 
Germany) using a spectrophotometer (Biotek-Greiner, Frickenhausen, Germany) 
at an excitation wavelength of 340 nm and 23°C. The data were analyzed with 
Kaleidagraph 3.6 (Synergy Software, Reading, U.S.A.) software and fitted to the 
Michaelis-Menten function156 to determine the maximum ATPase rate (kcat) and 
the actin concentration at which Myosin V is activated half-maximally (Km). 
4.4.6 Sequence alignment 
Sequence alignment of the herein determined full-length Myosin Va sequence 
from Xenopus l. and full-length sequences from other species was performed 
using Megalign (DNAStar, Madison, WI, U.S.A.) and the blosum62 amino acid 
table. The full-length Myosin Va sequence from Xenopus l. was aligned from N’-to 
C’-terminus to Myosin Va from chicken (Gallus gallus, accession number: 
NP_990631), mouse (Mus musculus, accession number: CAX15576.1) and 
human (Homo sapiens, accession number: NP_000250.3) using a progressive 
pairwise methods. Sequence data were obtained from the NCBI database. 
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5 Results 
5.1 One-dimensional diffusion of Myosin Va on microtubules 
5.1.1 Strategy 
5.1.1.1 Generating HMM-like Myosin Va loop 2 mutants 
All Myosin Va constructs assayed in this work were cloned from the previously 
described pFastBac-dhM5-CaM plasmid 158. The myosin encoded by this plasmid 
corresponds to the Wildtype form of chicken Myosin Va, which is truncated at the 
position D1098, and is thus lacking the Carboxy (C’)-terminal globular tail domain 
(GTD). In the literature, this truncated version of Myosin Va is also referred to as 
the heavy meromyosin (HMM)-like fragment of Myosin V. To ensure dimerization, 
a leucine zipper motif was fused in-frame to the native coiled-coil. In this thesis 
the term mutant refers exclusively to changes of the amino acid composition 
within the actin binding-loop (loop 2) of Wildtype Myosin Va. The complete amino 
acid sequence of Wildtype HMM-like Myosin Va can be found in Section 7. 
5.1.1.2 Designing and cloning of HMM-like Myosin Va loop 2 mutants 
The plasmid encoding for the double-headed Wildtype HMM-like Myosin Va used 
in this thesis was a kind gift of Purcell, T. J. and colleagues (Stanford University, 
Stanford, U.S.A.)138. It served as a template to design the loop 2 mutants. To 
facilitate purification, double-headed Myosin Va contains an amino (N')-terminal 
FLAG-tag. As for other HMM-like Myosins that have been studied previously, the 
constructs described in this work contain all six IQ motifs of the lever arm region 
(Figure 23).  
The actin-binding loop commonly referred to as loop 2 is a well-defined region of 
~ 44 amino acids near the so-called 50/20 kDa junction of the head domain. It has 
been implicated in binding the motor domain to actin 35,111 and recently has been 
suggested to also mediate the interaction of Myosin V with microtubules 107. It is 
surface-exposed and exhibits a net positive charge of +5. 
To dissect the contribution of the Myosin V loop 2 to the interaction with 
microtubules, we have generated two HMM-like Myosin V mutants with surplus 
net negative charge (referred to as Minus4 and Minus13). For Myosin Va Minus4, 
all lysines and arginines within loop 2 were changed to alanines (K607A, R619A, 
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R624A, K628A, K631A, R633A, K639A, K642A, K643A). For Myosin Va Minus13, 
all lysines and arginines were substituted with glutamic or aspartic acid (K607E, 
R619D, R624E, K628E, K631D, R633E, K639E, K642E, K643E) (Figure 23). 
To directly assess the role of the negatively charged E-hook of tubulin 119 as a 
potential microtubule-binding site for Myosin Va, an additional mutant containing 
the surface loop sequence NKNKKKKKT 119 of kinesin KIF1A was designed. For 
this, the entire stretch of loop 2 amino acids S623 to R633 was replaced with the 
sequence encoding for the microtubule-interaction loop (K-loop) of kinesin KIF1A. 
Except for the helix breaker residues G623 and P624, all the amino acid residues 
Figure 23. Schematic representations of the Myosin Va loop 2 constructs.  
(A) Schematic domain model of the homodimeric truncated (HMM-like) Myosin V. The regions 
are color-coded for each structural motif. The same set of colors is used also in B. (B) 
Schematic diagram depicting the domain structure of Myosin V with its surface-exposed loop 2 
shown in yellow. The C-terminal GCN4 motif ensures dimerization. Lower part of B: 
comparison of the loop 2 sequences from Myosin Va Wildtype, K-loop, Minus4 and Minus13. 
Mutants Minus4 (blue) and Minus13 (green) were designed by altering positively charged 
amino acids (lysines and arginines) to alanine and glutamic/aspartic acid, respectively. For K-
loop a positively charged stretch within the loop 2 sequence (positions 625-633) was 
substituted with the K-loop sequence of kinesin KIF1A, flanked by GP as helix breaker. (+) and 
(-) indicate positively and negatively charged amino acids, respectively. The net charge of 
each construct is indicated in brackets next to the respective construct. 
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flanking the K-loop sequence correspond to those of the Minus4 mutant. In the 
following this mutant containing two positive net charges on its loop 2 is referred 
to as K-loop mutant. The complete protein sequence of Wildtype HMM-Myosin Va 
can be found in Section 7.  
The loop 2 sequences of the respective mutants were obtained by custom DNA 
synthesis (carried out by SloningBio-Technology, Puchheim, Germany). Details of 
the DNA sequence synthesis and cloning procedure are described in Section 
4.2.2.8. 
The baculovirus-compatible transfer vector plasmid was generated in such a way 
that the myosin gene itself was cloned downstream of the p10 promoter (PP10) of 
the dual p2bac/pfastbac transfer vector (Purcell et al., 2005)138, using the 
restriction sites NotI and SalI. In addition, via restriction enzyme-mediated cloning 
with NheI and KpnI the light chain calmodulin was cloned downstream of the poly 
H promoter (PPH)  (see vector maps in Section 7). 
Sections 4.3.3.6 and 4.3.4 outline the steps from the generation of baculovirus to 
protein purification. 
5.1.1.3 Actin- and microtubule-activated ATPase activity of HMM-like 
Myosin Va constructs 
Microtubule- and actin-activated ATPase activity of HMM-Myosin Va was 
determined with a final MgATP concentration of 1 mM. For this, the NADH-
coupled ATPase assay was carried out as described in Section 4.3.5.3. 
The ATP hydrolysis by Myosin Va was determined with 100 nM motor protein (in 
KMg50 Buffer) using 0 to 20 µM F-actin or 0 to 35 µM microtubules (in 12A25 
Buffer). The concentration of polymerized actin was not determined because 
statistically nearly all monomers will polymerize in the presence of phalloidin 159. 
In contrast, for assays where microtubules were used, the microtubule 
concentration was determined post-polymerization as described in 4.3.1.4. 
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5.1.1.4 Microtubule-affinity co-sedimentation assays with HMM-like 
Myosin Va constructs 
To test for the capability to interact with the filament, the four HMM-like Myosin Va 
constructs were assayed by the so-called microtubule-affinity co-sedimentation 
assay. A detailed protocol for this assay can be found in Section 4.3.5.4. In this 
assay, microtubules and the respective motor protein are mixed and subsequently 
ultra-centrifuged through a high-percentage sucrose cushion. Thereby, motor 
proteins that did not bind to the filaments remain in the supernatant on top of the 
cushion, while all filament-bound protein is present in the microtubule pellet. In 
addition to testing the affinity on untreated microtubules, the four Myosin Va 
constructs were tested as well in combination with subtilisin-treated microtubules 
lacking E-hooks (see also Section 4.3.2.4). Furthermore, all assays were carried 
out at different ionic strength conditions. 
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5.1.2 Results 
5.1.2.1 Purification of HMM-like Myosin Va loop 2 constructs 
The four different HMM-like Myosin Va loop 2 constructs were expressed and 
purified as described in Section 4.3.4.2. Figure 24 shows eluted and dialyzed 
fractions of the various constructs. Typically, when over-expressing the respective 
constructs in 300 to 350 ml of Sf9 cell suspensions, protein concentrations ranged 
between 5 and 10 µM in a total volume of 400 to 500 µl. The Myosin Va heavy 
chain corresponds to the 134 kDa-band, which is visible on the PAGE-photograph 
in Figure 24. The band that appears at roughly 100 kDa was identified by mass-
spectrometry as a degradation product of Myosin Va. The protein fractions were 
dialyzed into 50% glycerol and storage buffer AB 1X containing 25 mM KCl and 
were stored at -20°C to avoid any freeze-thaw cycles. They could be readily used 
for all subsequent experiments that were carried out in this study. 
 
5.1.2.2 Loop 2 is not the prime determinant of the interaction between 
Myosin V and microtubules 
To uncover the role of electrostatic interactions via loop 2 of Myosin Va with 
microtubules, I assessed the effects of increasing KCl-concentrations on the 
Wildtype and loop 2 mutants by quantifying the number of microtubule-interacting 
Myosin Va molecules. I discriminated between microtubule-colocalization events 
(defined as association events) and events where association was followed by 
subsequent diffusion (defined as diffusion events). The number of events per 
microtubule unit length and time period was determined at KCl concentrations of 
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Figure 24. FLAG-affinity protein 
purification of Myosin Va loop 2 
constructs. 
Protein was expressed in Sf9-insect 
cells via the baculovirus expression 
system, and was FLAG-affinity purified 
from suspension culture. Cropped 
images of Coomassie blue-stained 
polyacryl amide (10%) gels show the 
respective fractions of the purified and 
eluted protein of each Myosin Va loop 2 
construct (indicated on top). 
Approximate product size is indicated on 
the right. 
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25, 50, 100 and 200 mM. An increase in ionic strength decreased microtubule 
association of all four constructs (grey bars in Figure  25 and Table 27), though to 
different extents. 
  
 
 
Ionic strength 
condition 
(c(KCl) in mM) 
MT associations  
 (particles ⋅  (mm min)-1) 
Myo Va diffusions 
(particles ⋅  (mm min)-1) 
Fraction of  
Myo Va diffusion 
events  
(% of total MT 
associations) 
Wildtype 55.4 ± 5.0 17.6 ± 3.7 31.7 
K-loop 102.9 ± 10 28.4 ± 5.3 27.6 
Minus4 51.3 ± 8.6 7.0 ± 2.4 13.6 
Minus13 
25  
12.8 ± 2.5 2.1 ± 1.3 16.7 
Wildtype 45.9 ± 6.1 4.7 ± 1.7 10.3 
K-loop 86.5 ± 7.0 21.3 ± 4.4  8.9 
Minus4 33.4 ± 5.0 4.3 ± 1.8 12.9 
Minus13 
50  
13.0 ± 3.3 1.8 ± 1.1 13.9 
Wildtype 10.9 ± 2.5 0.4 ± 0.4 3.5 
K-loop 22.4 ± 4.3 4.6 ± 2.3 20.4 
Minus4 25.2 ± 5.2 0.0 ± 0.0 0.0 
Minus13 
100  
5.6 ± 2.0 0.8 ± 0.8 14.6 
Wildtype 6.4 ± 2.6 0.6 ± 0.6 9.7 
K-loop 10.9 ± 3.8 0.0 ± 0.0 0.0 
Minus4 11.2 ± 3.7 0.0 ± 0.0 0.0 
Minus13 
200 
0.0 ± 0.0 0.0 ± 0.0 n.a. 
 
 
 
 
 
 
 
The Minus13 mutant, in particular, showed the most dramatic reduction of 
microtubule association, even at moderate ionic strength (Figure 25). This behavior 
can be attributed to a pronounced repulsion between the highly negatively 
charged motor loop and the negatively charged surface of the microtubule 160.  
 
Table 27. Summary of microtubule association and diffusion of various constructs at 
increasing salt-concentrations.  
 
Values for microtubule association were calculated as mean ± S.E.M. from the total count of 
microtubule-associated (stationary and diffusing) molecules per unit length and time at the 
indicated salt-concentrations (left column). Among those, the diffusing fraction of motors was 
determined and calculated as mean ± S.E.M. of the total number of diffusing motors per unit 
length and time. The portion of diffusing molecules is expressed in % of the total number of 
microtubule-associated molecules (right column). For details of the conditions for counting refer 
to Section 4.4.1. n.a., not applicable. 
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Conversely the K-loop, a motif that specifically interacts with the E-hook of 
microtubules, boosts association with microtubules (Figure  25). Interestingly, even 
though more than twice as many K-loop mutant molecules interact with 
microtubules compared to the Wildtype construct, the strong ionic strength-
dependent association behaviors of the two constructs hardly differed from each 
other. Therefore, it is conceivable that for the K-loop mutant possessing an 
additional and specific microtubule-binding motif, an additional binding mode is 
triggered on microtubules. 
In an alternative approach, the potential of Myosin Va to bind to microtubules in 
an ionic strength-dependent manner was assayed in microtubule affinity co-
sedimentation assays. For this microtubules and the respective Myosin Va loop 2 
construct were mixed and ultra-centrifuged through a sucrose cushion (Section 
5.1.1.4). Here, microtubules alongside with bound Myosin V protein are found in 
the pellet fraction, whereas unbound myosin is present in the supernatant. The 
intensity-quantified data of the SDS-PAGE-resolved pellet and supernatant 
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Figure 25. Interaction of Myosin Va with microtubules under increasing ionic 
strength conditions. 
TIRFM movie sequences of single-molecule experiments with 100 nM Cy3-labeled 
Myosin Va Wildtype, K-loop, Minus4 and Minus13 on Atto488-labeled microtubules 
under increasing salt concentrations (i.e., 25, 50, 100 and 200 mM KCl), were 
analyzed for microtubule-association and subsequent diffusion. For this, the total 
number of microtubule-associated Myosin Va particles (shaded) and the number of 
diffusing particles (solid) per unit length of the microtubules are plotted as a 
function of KCl concentration. (*) indicates that in those cases only one event in 
total was counted. Error bars represent mean ± confidence interval (α= 0.95). 
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fractions imply that both constructs containing a net positively charged loop 2 bind 
to microtubules in a strongly salt-dependent manner. In contrast, for the Minus4 
and Minus13 mutant, microtubule binding remains relatively subtle under 
increasing ionic strength conditions (Figure 26). These findings are in concordance 
with the behavior observed at the single-molecule level, where for Wildtype and 
K-loop Myosin Va, a significant drop in microtubule-association was seen already 
at 50 mM salt. In contrast, for the Minus4 and Minus13 mutant a significant 
decrease in microtubule association was not observed below 200 mM added salt 
(Figure 25 and Figure 26). Even though in this assay it was not possible to 
distinguish association from diffusion events, the results clearly support the 
findings obtained by the microscopic assay (Figure 25).  
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7 Figure 26. Microtubule-affinity co-
sedimentation with Myosin Va loop 
2 constructs under increasing ionic 
strength conditions. 
Microtubules (1 µM) together with 
purified (850 nM) Myosin Va Wildtype, 
K-loop, Minus4 and Minus13 under 
increasing salt concentrations (i.e., 
25, 50, 100 and 200 mM KCl) were 
targeted for co-sedimentation at 
280,000 × g through a sucrose 
cushion (40%). The microtubule-
bound (i.e., the pellet) and unbound 
(i.e., supernatant) protein fractions 
were resolved on a polyacryl amide 
(12%) gel (A) and quantified as 
described in 4.4.4. To compare the 
association behavior under increasing 
ionic strength conditions, the obtained 
values for each condition and 
construct were related to the values 
determined at 25 mM salt condition, 
which for the illustration was set to 
100%. (B) Graph shows normalized 
relative content of microtubule-bound 
Myosin Va under increasing ionic 
strength. 
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Although these findings indicate that the surface-exposed loop 2 may indeed 
participate in Myosin Va’s affinity for microtubules, the observed attraction cannot 
be primarily attributed to simple charge-charge interactions between the 
negatively charged microtubule and the normally positively charged loop 2, for 
two obvious reasons: first, the positively and the negatively charged loop 2 
constructs display a similar salt-dependent decrease in microtubule association 
(grey bars in Figure 25); second, despite carrying opposite net charges on loop 2, 
Wildtype and Minus4 show comparable levels of association at 25 mM salt (Table 
27. 
Taken together, these results make testable predictions for Myosin V’s capability 
to diffuse on the microtubule. If, as previously proposed 107, the interaction 
between Myosin V and microtubules were exclusively dependent on electrostatic 
forces, only Wildtype Myosin Va with its positive loop 2 net charge (and most 
likely also the K-loop construct) would be expected to show diffusion on 
microtubules. However, if this interaction depends either on additional attraction 
forces or/and domain regions other than loop 2, the two negatively charged 
constructs, Minus4 and Minus13, should diffuse along the negatively charged 
microtubule lattice as well.  
Indeed, irrespective of their net charge, all four Myosin Va constructs showed 
diffusion along microtubules (Figure 25, black bars). Due to the clear salt-
dependent interactions shown here, charge-charge interactions are likely to 
dominate the binding of Myosin Va to microtubules. Notably, not only at low-salt 
conditions but also at 100 mM KCl (Wildtype, K-loop and Minus13) and 200 mM 
KCl (Wildtype) diffusion was observed (black bars in Figure 25, Table 27, Video 1). 
Hence it can be concluded that electrostatic attraction mediated by loop 2 cannot 
be considered the sole molecular determinant for microtubule association. 
Therefore, it cannot be ruled out that other attraction forces (e.g., non-ionic 
interactions) co-determine Myosin Va's affinity toward microtubules. 
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5.1.2.3 All Myosin Va loop 2 charge mutants show unperturbed 
diffusion on microtubules 
Next, the behavior of the diffusion events for Myosin V Wildtype and the loop 2 
mutants on microtubules was characterized (Figure 27, Figure 28, Figure 29, Figure 
30 and Figure 32, Videos 2 and 3). In Figure 27 A, a representative image section 
from the single-molecule assays acquired by TIRF microscopy for each of the 
Myosin V loop 2 constructs is provided. In addition, Figure 27 B shows an image 
sequence of Wildtype Myosin Va diffusing on microtubules.  
The kymographs in Figure 28 A show the traces for the diffusive motion that each 
of the loop 2 constructs generated during its interaction with microtubules. The 
Figure 27. Single-molecule TIRF microscopy of Myosin Va loop 2 constructs on 
microtubules. 
(A) 100 nM Cy3-labeled Myosin Va Wildtype, K-loop, Minus4 and Minus13 (bright particles) 
were infused into a flow cell containing surface-attached Atto 488-labeled microtubules (dim 
filaments in background). White arrowheads indicate representative single Myosin Va 
molecules that co-localized with microtubules and subsequently started to show diffusive 
motion on microtubules. Assay was performed in 25 mM KCl. Scale bar represents 10 µm. (B) 
Representative TIRF microscopy image sequence of a single Cy3-labeled Myosin Va Wildtype 
molecule (indicated by white arrowheads) on a microtubule. The position of the myosin at the 
beginning of each time row is indicated (white dotted line). Wave-like dispositions over time 
reflect characteristic unbiased one-dimensional diffusion behavior of Myosin Va on 
microtubules. Excitation wavelength in A and B was 532 nm and representative image 
sections were false-colored. In B the same image section (5 × 10 µm) was taken over time. 
Scale bar represents 2 µm. 
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subsequent biophysical and statistical analysis of the diffusive motion of Myosin 
Va on microtubules is based on such kymograph-derived traces. Diffusion of 
Wildtype yielded a diffusion constant (D= 0.113 µm2/s) which is in good 
agreement with previous work 110 (Figure 28 B ,Table 28 and Video 2). Strikingly, the 
analysis demonstrates that the diffusion coefficients of the loop 2 mutants were 
similar to those of Wildtype (Figure 28 B and Table 28). The diffusion-derived single 
displacements of all three constructs distributed as zero-centered Gaussians, as 
expected for one-dimensional Brownian motion (Figure 28 B) 161.  
 
 
Figure 28. One-dimensional diffusion of Myosin Va loop 2 constructs on microtubules. 
(A) Kymographs of sequential frames depicting diffusive movement of single Cy3-labeled 
Myosin Va Wildtype, K-loop, Minus4 and Minus13 molecules (top to bottom, pseudo-colored 
green) on Atto488-labeled microtubules in 25 mM KCl. Microtubules are not shown for this 
purpose. Control represents a stationary, non-diffusing motor molecule on the microtubule. (B) 
TIRF microscopy movie sequences of single Myosin Va molecules on microtubules in 25 mM 
KCl were analyzed and then plotted as a displacement histogram. A single Gaussian (solid 
color-coded lines) was fitted to the data using Equation 7 (Section 4.4.1). From the obtained 
fit, the variance was used to calculate the diffusion coefficient D according to the equation, 
variance= 2Dt, where t is the time interval between images, resulting in DWt= 0.113 µm2 s-1 (n= 
464), DK-loop= 0.097 µm2 s-1 (n= 1225), DMinus4= 0.089 µm2 s-1 (n= 801) and DMinus13= 0.081 µm2 
s-1 (n= 425). Black, blue and green color-coded fit-lines depict the Gaussian fit for the 
individual displacement distribution of Myosin Va Wildtype, K-loop, Minus4 and Minus13, 
respectivelya. 
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Diffusion 
coefficient (D) 
(µm2 s-1) 
Maximum 
speed (Vmax) 
(µm s-1) 
Scan 
distance 
(xscan) (µm) 
Association 
time (tA) (s) 
n Diffusions n Displacements 
Wildtype 0.113 ± 0.004* 1.04 ± 0.06 2.21 ± 0.27 14.1 ± 0.5* 31 464 
K-loop 0.097 ± 0.002 ** 0.86 ± 0.04 ** 2.05 ± 0.13 * 20.5 ± 1.0 *** 77 1225 
Minus4 0.089 ± 0.003 *** 0.99 ± 0.06 * 2.95 ± 0.28 * 23.8 ± 3.2 *** 35 801 
Minus13 0.081 ± 0.003 *** 0.84 ± 0.06 ** 2.07 ± 0.23 * 16.2 ± 0.8 ** 32 425 
on S-microtubules 
Wildtype 0.226 ± 0.006 *** 1.21 ± 0.09 * 3.02 ± 0.34 * 12.4 ± 2.7 * 20 327 
Figure 29. Mean-squared displacement 
analysis of diffusive motion of the four 
Myosin Va loop 2 constructs on 
microtubules. 
(A-D) The mean-squared displacement 
(MSD) data of Myosin Va Wildtype, K-loop, 
Minus4 and Minus13 are plotted versus 
time, with the individual slopes providing 
an estimate of the respective D-values. 
The following D-values were calculated: 
DWt= 0.11 µm2 s-1 (± 0.004 µm2 s-1 S.D.), 
DK-loop= 0.07 µm2 s-1 (± 0.001 µm2 s-1 S.D.), 
DMinus4= 0.06 µm2 s-1 (± 0.002 µm2 s-1 S.D.) 
and DMinus13= 0.07 µm2 s-1 (± 0.002 µm2 s-1 
S.D.). Data were obtained from single-
molecule TIRFM experiments with 100 nM 
Cy3-labeled Myosin Va on Atto488-labeled 
microtubules in 25 mM KCl. Error bars 
represent the S.E.M. of the squared 
displacement values. 
Table 28. Key parameters of diffusion of Myosin V (Wildtype) and three Myosin V loop 2 
mutants. 
 
Diffusion coefficients (D) were measured from the variance of the Gaussian fit function of the 
displacement histogram (Figure 28 B). Values for maximum speed (Vmax) reflect the maximum 
displacement along a microtubule during one frame interval and diffusion event. Scan distances 
(xscan) were calculated as the distance between the two extreme positions the motor has scanned 
on the microtubule during one diffusion event. Association times (tA) represent the total time a 
Myosin V molecule spent on the microtubule during one diffusion event. Mean values for tA were 
measured from the exponential fit of the plotted histogram of single tA-values (Figure 30). 
Diffusion events are defined as events during which the Myosin V molecule has bound to the 
filament and subsequently started diffusing. Diffusion was quantified by single displacement 
measurements. Parameters of Myosin V diffusion on subtilisin-treated microtubules (S-
microtubules) for Wildtype are shown in the bottom part. All parameters were obtained from 
experiments in 25 mM KCl. Values represent mean ± S.E.M. Statistical significance at *P > 0.05, 
**P < 0.05 and ***P < 0.005 vs. Wildtype was determined using Student’s t-Test. 
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Additional support came from the linear increase in mean square displacement 
(MSD) over time (Figure 29) 162,163,164. As expected, by calculating D from the 
slopes in the MSD-plots, the validity of the Gaussian-based D-value calculations 
could be confirmed. 
During diffusion, the time of association with the microtubule (tA) for all four 
constructs distributed exponentially (Figure 30). Individual mean values of tA (Table 
28) ranged from 14.1 s to 23.8 s, with tA of Wildtype being the shortest. Finally, the 
average distance scanned during diffusional events did not vary significantly 
amongst Wildtype and Minus13 and was only slightly larger for Minus4 (Table 28). 
Furthermore, in microtubule-stimulated ATPase assays it could be excluded that 
microtubules stimulate Myosin Va’s ATPase activity (Figure 32). 
!
!"
#
$
%
&%'%!% (%
)**+,-./-+012-3415*6
0+
71+
814
94
0/
*
"#$%&'
(
#
$
%
&%'%!%
)**+,-./-+02-3415*6
0+
71+
814
94
0/
*
"#$%&)*
"&
"%
!&
!%
&
%
&%'%!% (%
)**+,-./-+012-3415*6
0+
71+
814
94
0/
*
+,-../
01
#
$
%
&%'%!%
)**+,-./-+02-3415*6
0+
71+
814
94
0/
*
(%
2#-345/6
!"
Figure 30. Interaction lifetime of diffusing Myosin Va on microtubules.  
(A-D) The distribution of the association times (tA) for Myosin Va Wildtype, 
K-loop, Minus4 and Minus13 were plotted as histograms. Data were 
obtained from single-molecule TIRFM experiments with 100 nM Cy3-labeled 
Myosin V on Atto488-labeled microtubules in 25 mM KCl. Exponential 
curves fitted to the respective histograms (solid lines) yield mean tA-values 
of 14.1 s (n= 31), 20.5 s (n=77), 23.8 s (n= 35) and 16.2 s (n= 32) for Myosin 
Va Wildtype (A), K-loop (B), Minus4 (C) and Minus13 (D), respectively. 
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Control experiments confirmed that diffusion was not caused by the antibody that 
coupled the motor to the fluorophore, nor did the antibody display any specific 
association with microtubules. In line with the Myosin V-microtubule association 
analysis, the diffusion analysis strongly supports the notion that the interaction 
between the motor and the microtubule is not restricted to loop 2-conveyed 
electrostatic forces. Most notably, Minus13, a construct carrying 13 negative net 
charges on loop 2, shows a similar diffusion behavior as the positively charged 
Wildtype (Figure 28 B). 
In addition to the TIRF microscopy experiments, also electron microscopy of 
Myosin Va on microtubules was carried out. A representative negative stain 
image of the Wildtype Myosin Va construct is provided in Figure  31, illustrating 
Myosin Va’s ability to bind to microtubules. 
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Figure 32. ATPase activity of Myosin 
Va on microtubules. 
Microtubule-activated ATPase for 
Myosin Va Wildtype (black, open 
circles) and K-loop (orange, open 
squares) was measured with the 
NADH-coupled enzymatic assay and 
plotted as a function of microtubule 
concentration (Myosin Va 
concentration, 100 nM). The data were 
fitted to the Michaelis-Menten equation. 
As expected, Myosin V’s ATPase 
activity could not be stimulated by 
microtubules. 
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Figure 31. Electron micrographs of Myosin Va on 
microtubules. 
HMM-like Myosin Va Wildtype (160 nM) was mixed 
with microtubules (approx. 1 µM) and thereafter 
briefly centrifuged (low-speed) to remove unbound 
motor. As desired, different dilutions of the pellet 
fraction were used for the preparation of negative-
stains. Representative negative stain image shows 
an HMM-like Myosin Va molecule bound to the 
surface of a microtubule (as indicated). Scale bar 
represents 10 nm. 
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Next, the proposed role of the negatively charged E-hooks (Ali et al., 2007) in 
tethering Myosin V to the microtubule surface was assessed. 
5.1.2.4 Myosin Va diffusion takes place without the help of E-hooks 
To test if the negatively charged E-hooks play a substantial role in microtubule 
association and diffusion of the Myosin V constructs, we made use of limited 
proteolysis by subtilisin to generate S-microtubules that lack the E-hook 119,162. E-
hook removal was confirmed by SDS-PAGE and Western-blot analysis (Figure 33) 
113,119,145. 
In favor of the non-ionic attraction model, the absence of E-hooks does not 
interfere with the ability of Wildtype to associate with microtubules (Figure  34 and 
Table 29). Moreover, for all four loop 2 constructs the number of associated motors 
per microtubule unit length leveled off (grey bars in Figure 34, Table 29). 
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Figure 33. Removal of the Carboxy-terminal E-hook from microtubules.  
(Left panel) Coomassie-blue stained SDS polyacryl amide gel (12%) shows 
untreated microtubules (lane 1), and microtubules after subtilisin-treatment 
(lane 2). (Middle and right panel) Western-blots of both lanes with anti-α or 
anti-β tubulin antibodies. Subtilisin-treatment resulted in the complete loss of 
epitope reactivity, hence complete E-hook removal can be assumed. 
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 MT associations (particles ⋅  (mm min)-1) 
Myo V diffusions 
(particles ⋅  (mm min)-1) 
Fraction of 
Myo V diffusion events 
(% of total MT associations) 
Wildtype 58.2 ± 6.7 * 7.3 ± 2.4 ** 12.5 
K-loop 49.3 ± 6.5 * 3.1 ± 1.5 ** 6.3 
Minus4 65.0 ± 6.9 * 0.0 ± 0.0 *** 0.0 
Minus13 50.8 ± 6.5 *** 0.0 ± 0.0 * 0.0 
 
 
 
 
 
For the most negatively charged Minus13 construct, E-hook removal resulted in a 
significant increase in microtubule association by 75 % (Table 27 vs. Table 29). For 
the K-loop construct with its E-hook-specific motif, on the other hand, the 
association with S-microtubules decreased significantly by 50 % (p< 0.005) (Table 
27 vs. Table 29).  
Therefore, as already predicted and assumed from the findings in section 5.1.2.2, 
the observed boost in association with untreated microtubules ceases as soon as 
the K-loop-specific binding-motif on microtubules, the E-hook, is removed.  
Myosin Va’s attraction for microtubules lacking the E-hook was also assayed by 
means of microtubule-affinity co-sedimentation assays under increasing salt 
conditions (Figure 35, for experimental details, see Section 5.1.1.4). 
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Figure 34. Interaction of Myosin Va with S-
microtubules. 
TIRFM movie sequences of single-molecule 
experiments with 100 nM Cy3-labeled Myosin 
V Wildtype, K-loop, Minus4 and Minus13 on 
Atto488-labeled S-microtubules, in 25 mM KCl 
were analyzed for microtubule-association 
and subsequent diffusion. The total number of 
S-microtubule-associated and diffusing 
Myosin V particles per unit length of the 
microtubules is plotted as category plot for the 
respective Myosin V constructs. Error bars 
represent mean ± confidence interval (α= 
0.95). 
Table 29. Summary of association and diffusion of various constructs on S-
microtubules. 
 
Values for microtubule association and diffusion were calculated as described in Table 27. 
Data were obtained from single-molecule studies on subtilisin-treated microtubules (S-
microtubules) in 25 mM KCl. Significance levels in association and diffusion on S-
microtubules vs. untreated microtubules (*P > 0.05, **P < 0.05 and ***P < 0.005) (Table 
27) were determined using Student’s t-Test. For details of the counting conditions applied 
refer to Section 4.4.1. 
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In contrast to the behavior on untreated microtubules, neither positively nor 
negatively charged loop 2 mutants show a salt-dependent association with S-
microtubules (Figure  26). Here the lowest level of relative Myosin Va content was 
about 65% (Wildtype, at 50 mM salt), whereas on untreated microtubules at 200 
mM salt, microtubule-association of the Wildtype construct was reduced to 20%. 
Interestingly, for Minus4 and Minus13 the association at increasing ionic strength 
hardly differed from that on untreated microtubules (Figure 26). The fluctuations in 
values for relative Myosin V content are reflected in the standard deviations of the 
data of Figure  34 and Table 29 and are most likely due to experimental difficulties 
arising from dealing with S-microtubules. 
Most importantly, the removal of E-hooks did not interfere with the ability of 
Wildtype or K-loop Myosin V to diffuse along S-microtubules. The diffusion 
behavior of Wildtype on S-microtubules meets all the criteria of a one-dimensional 
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Figure 35. Affinity co-
sedimentation assays with various 
Myosin Va loop 2 constructs and 
S-microtubules under increasing 
ionic strength conditions. 
1 µM S-microtubules and 850 nM 
purified Myosin Va Wildtype, K-loop, 
Minus4 and Minus13 under 
increasing salt concentrations (i.e., 
25, 50, 100 and 200 mM KCl) were 
targeted for co-sedimentation and 
analyzed as described for Figure 26. 
To compare the association behavior 
under increasing ionic strength 
conditions, the obtained values for 
each condition and construct were 
related to the values determined at 
25 mM salt condition, which for the 
illustration was set to 100%. (B) 
Graph shows normalized relative 
content of microtubule-bound Myosin 
Va under increasing ionic strength. 
S-microtubules were generated as 
described (Section 4.3.2.4). 
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diffusion process (Figure 36) 107,161,162,163,164. 
The maximum speed of Myosin V diffusion on S-microtubules (1.21 ± 0.09 µm 
s-1) is higher than that on untreated microtubules and shows a trend towards 
prolonged scan distances (3.02 ± 0.34 µm). However, the average association 
time of 12.4 s remained essentially unchanged (Table 28 and Figure 36). 
Notably, the diffusion coefficient D= 0.226 µm2/s was twice as high as that of 
Wildtype on untreated microtubules (Table 28 and Figure 36). 
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Figure 36. One-dimensional diffusive motion of Myosin Va on microtubules lacking the 
E-hook.  
(A) Kymograph of sequential frames depicting the diffusive motion of a single Cy3-labeled 
Myosin Va Wildtype molecule (pseudo-colored green) on Atto488-labeled microtubules (for 
this purpose not visualized). Control represents a stationary, non-diffusing motor molecule on 
the microtubule. (B) The displacement between successive image frames of diffusive 
movements for Myosin Va Wildtype on S-microtubules was determined. TIRF microscopy 
movie sequences of 100 nM Cy3-labeled Myosin Va Wildtype on Atto488-labeled microtubules 
were analyzed and plotted as a displacement histogram. The diffusion coefficient D was 
calculated according to the equation, variance= 2Dt, where t represents the time interval 
between images. The variance was obtained from the Gaussian fit (solid line), resulting in D= 
0.226 µm2 s-1 (n= 327). (C) The distribution of the values for tA is plotted as histogram with an 
exponential curve fit (solid line), yielding a mean tA-value of 12.4 s (n= 20). (D) Here, the 
displacement distribution of Myosin Va Wildtype on S-microtubules is plotted as Box-Whisker 
Plot, where the top and bottom of the boxes indicate the 75 and 25 percentile, the whiskers 
indicate the 90 and 10 percentile, while the solid line within the box represents the median. As 
it was observed for Myosin Va Wildtype on untreated microtubules (Figure 28 B), also on S-
microtubules Myosin Va Wildtype exhibits no net displacement during diffusion and hence the 
median centers at zero. 
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5.1.2.5 Non-electrostatic attraction forces contribute to the interaction 
of Myosin Va with microtubules 
The striking observation that irrespective of the net charge of loop 2 all four 
constructs bind to S-microtubules, while only Wildtype and K-loop (Figure 34, 
Figure 36, Table 29 and Video 4) diffuse, raises the question whether additional 
attraction forces besides electrostatics contribute to the interaction between 
Myosin V and microtubules. I propose that due to the E-hook removal, the 
formerly homogeneously negatively charged microtubule is now marked by 
negative and also positive surface charges 160,165. Hence, formerly prevalent 
electrostatic repulsion forces (negative loop 2 vs. negative E-hooks) are now 
eliminated and electrostatic attraction forces (negative loop 2 vs. positive patches 
on the microtubule surface) are free to exert their effects. The absence of the 4 
nm E-hook spacers would enhance additional, non-ionic attraction forces that 
have strong effects over short distances, thereby preventing the individual 
molecule from advancing from an associative to a diffusive state (as is the case 
for Minus4 and Minus13) (Figure 34). Under such circumstances, only constructs 
bearing a residual ionic repulsive capacity (positive loop 2 vs. positive patches on 
the microtubule surface), such as Wildtype or K-loop, display diffusion (Figure 34).  
Taken together, the data presented here suggest that additional, non-electrostatic 
attraction forces contribute to Myosin V’s interaction with microtubules.  
5.1.2.6 A negative charge on loop 2 impairs the Myosin Va interaction 
with actin filaments whereas Myosin Va carrying a Kinesin-
loop is functional on F-actin 
To assess the intrinsic functionality of the four Myosin Va loop 2 constructs, single 
molecule motility as well as ATPase activity measurements on F-actin were 
carried out. In Figure 38 A, a representative image from the single-molecule 
assays acquired by TIRF microscopy for each of the respective Myosin V loop 2 
constructs on F-actin is provided. In addition, in Figure 38 B an image sequence of 
Wildtype Myosin Va showing directed walking along one or even two actin 
filaments (see also, Video 8). 
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As for the interaction with microtubules, in Figure 37 a representative negative 
stain image of the Wildtype Myosin Va construct, is shown. Both heads bound to 
the actin filament and also the motor’s stalk region is clearly visible. 
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Figure 37. Electron micrographs of Myosin Va on 
F-actin. 
HMM-like Myosin Va Wildtype (160 nM) was mixed 
with F-actin and 1 mM AMP-PNP. The unbound 
motor fraction was removed by brief (low-speed) 
centrifugation. As desired, different dilutions of the 
pellet fraction were used for the preparation of 
negative-stains. Representative negative stain image 
shows an HMM-like Myosin Va molecule that is 
bound to an actin filament (as indicated). Scale bar 
represents 10 nm. 
Figure 38. Single-molecule TIRF microscopy of Myosin Va loop 2 constructs on F-actin. 
(A) 100 nM Cy3-labeled Myosin Va Wildtype, K-loop, Minus4 and Minus13 (bright particles) 
was infused into a flow cell containing surface-attached Atto488-labeled F-actin (fuzzy 
filaments in background). White arrowheads indicate representative single Myosin Va 
molecules that co-localized with actin filaments and subsequently exhibited directed 
movements on F-actin. Assays were performed in 25 mM KCl and 1 mM ATP. Scale bar 
represents 10 µm. (B) Representative TIRF microscopy image sequence of a single Cy3-
labeled Myosin Va Wildtype molecule (indicated by white arrowheads) on F-actin. The position 
of the motor molecule at the beginning of each time row is indicated (white dotted line). The 
continuous edging up of displacements over time reflects the characteristic processive walking 
behavior of Myosin Va on actin filaments. Excitation wavelength in A and B was 532 nm and 
representative image sections were false-colored. In B the same image section (5 × 10 µm) 
was taken over time. Scale bar represents 2 µm. 
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 Velocity  (nm s-1) 
Runlength  
(µm) n  
Km 
(µM) 
kcat 
(mol of ATP s-1 ⋅  (mol of myosin)-1) 
Wildtype 230 ± 4 1.41 ± 0.04  62 2.6 4.3 
K-loop 140 ± 4 *** 1.51 ± 0.04 * 65 7.4 4.5 
Minus4 n.m. n.m. n.m. n.m. n.m. 
Minus13 n.m.  n.m. n.m. n.m. n.m. 
 
 
 
 
 
 
 
 
In line with previous studies where a decrease of the positive net charge on loop 
2 led to a diminished affinity for actin 35,111,166, in Myosin V constructs carrying a 
negative net charge on loop 2, actin-stimulated ATPase activity was nearly 
(Minus4) or completely (Minus13) abolished (Figure 39 and Table 30).  
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Figure 39. ATPase activity measurements of the four Myosin Va loop 2 constructs on F-
actin. 
Actin-activated ATPase for Myosin Va Wildtype (black, open circles), K-loop (orange, open 
squares), Minus4 (blue, open diamonds) and Minus13 (green, open triangles) were measured 
with the NADH-coupled enzymatic assay and plotted as a function of actin concentration 
(Myosin V concentration, 100 nM). The data were fitted to the Michaelis-Menten equation to 
determine the maximum ATPase rate (kcat) and the actin concentration at which Myosin Va is 
activated half-maximally (Km). Due to the negatively charged loop 2 motifs of Minus4 and 
Minus 13 hardly any and no stimulation by actin was observed, respectively. Data-set shown is 
representative and was reproducible. 
Table 30. Summary of behavior of Myosin Va loop 2 constructs on F-actin. 
 
Velocities and runlengths of the single-molecule measurements on F-actin were obtained 
at 1 mM ATP. Values for velocity and runlength are mean ± S.E.M. from Gaussian and 
exponential fits to the data (Figure 41), respectively. n is the number of processive runs. 
Km represents the actin concentration at which the ATPase rate is half the maximal rate, 
determined from the Michaelis-Menten curve fit (Figure 39). kcat shows the maximum rate 
of ATP turnover as determined from fitting the data to the Michaelis-Menten equation 
(Figure 39). n.m., not measurable. 
Results 
________________________________________________________ 
 133 
Accordingly, in in vitro motility studies only occasional brief attachments of single 
Minus4 and Minus13 molecules were recorded, but no single molecule runs 
(Figure 38 A, Video 5). Thus only a positively charged loop 2 promotes a 
productive interaction with actin. 
The kymographs in Figure 40 show the traces of directed movement of Wildtype 
and K-loop Myosin Va (see also, Videos 6, 7 and 8) constructs during their 
interaction with actin filaments. Biophysical and statistical analyses of these 
movements of Myosin Va were performed using such kymograph-derived traces. 
Strikingly, with its +2 net charge, the K-loop mutant was not only capable of 
binding to actin, it also displayed numerous walking events (Figure 40, Figure 41, 
Videos 6 and 7). However, its average velocity was decreased compared to 
Wildtype (140 vs. 230 nm s-1) (Figure 41 and Table 30), while the runlength 
distribution coefficient remained essentially unchanged (Figure 41 and Table 30).   
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Figure 40. Processive walking of Myosin V 
Wildtype and K-loop on F-actin. 
Kymographs of representative walking events of 
single Cy3-labeled Myosin Va Wildtype and K-
loop, on Atto488-labeled F-actin in buffer 
containing 25 mM KCl and 1mM ATP. On F-actin, 
no movement for Minus4 and Minus13 was 
observed and thus no kymographs are depicted. 
Figure 41. Biophysical analysis of 
processive walking behavior of 
Myosin V Wildtype and K-loop on F-
actin. 
Velocity (A) and runlength (B) 
distributions of Myosin Va Wildtype (left 
panels) and K-loop (right panels) were 
plotted as histograms. Data were 
obtained from single-molecule TIRFM 
experiments, where 100 nM Cy3-labeled 
Myosin Va was incubated with Atto488-
labeled F-actin in 25 mM KCl and 1 mM 
ATP. In (A) the data were fitted to a 
single Gaussian (according to Equation 
7), yielding a mean velocity of 0.23 µm2 
s-1 (n= 62) and 0.14 µm2 s-1 (n= 65) for 
Wildtype and K-loop, respectively. For 
the runlength distribution in (B) an 
exponential curve was fitted to the 
histograms (solid lines), resulting in 
mean values of 1.41 µm (n= 62) and 
1.51 µm (n= 65) for Wildtype and K-
loop, respectively. 
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The in vitro single-molecule velocity and runlength measurements (Table 30), as 
well as the ATPase activity values of HMM-like Wildtype Myosin Va were in good 
agreement with those reported previously (Figure 39 and Table 30) 38,44,45,111,167. 
When comparing the ATPase activity measurements of the Wildtype and K-loop 
construct, the Km-value of K-loop was decreased three-fold. This finding points to 
a decreased binding affinity of K-loop for actin, while yielding almost the same 
kcat-value as the Wildtype construct (Figure 39 and Table 30). 
In summary, only a positively charged loop 2 strongly promotes productive 
interaction with actin, even if it comes from the loop of a kinesin motor. 
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5.2 Studying the effects of Calcium-/Calmodulin-dependent 
Kinase II-α  on melanosome-associated Myosin V 
Karcher and colleagues (2001)121 showed that incubation of melanosomes with 
mitotic cell extract from Xenopus l. oocytes leads to the release of melanosome-
associated Myosin V. In addition, the authors provided evidence that the 
observed release was due to Calcium-/Calmodulin-dependent Kinase II-α 
(CaMKII-α)-mediated phosphorylation of a specific Serine residue within the tail 
domain of Myosin V. With this in mind, I decided to take a closer look at the role 
of CaMKII-α in melanosome transport.  
Therefore, my primary goal was to set up an assay where melanosomes that 
contain Myosin Va are targeted for CaMKII-α-mediated release in vitro. Such a 
method would for the first time allow for the specific manipulation of melanosome 
transport in vitro. Thus it would be finally possible to determine in vitro using a 
native cellular cargo, if and how Myosin V might assist the Kinesin-2-driven cargo 
transport on microtubules (for a detailed protocol, refer to Section 4.3.5.6). 
5.2.1 Results 
5.2.1.1 Cloning and purification of baculovirus-expressed CaMKII-α 
Most studies that in the past dealt with the characterization of CaMKII, used 
protein that had been purified from rat brain, simply because in the forebrain 
CaMKII composes up to 1% of the total protein 168. However because of two 
fundamentally important reasons, in this work I aimed on setting up a protocol for 
the purification of baculovirally expressed recombinant CaMKII-α: i) enhancing 
the yield of total kinase protein, while lowering the required labor time; and ii) not 
being relient on supply of rat brain as a natural source. This section provides a 
brief summary of the cloning, and purification procedure of baculovirus-expressed 
CaMKII-α. 
The coding sequence of CaMKII-α (kindly provided by Prof. Y. Hayashi, RIKEN 
institute, Saitama, Japan), was originally blunt-end cloned into the pBluescript SK 
(-) vector via EcoRI. Therefore, the coding sequence, which at this point still also 
contained a portion of non-coding region (approx. 200 bases), was retrieved via 
restriction enzyme-mediated digestion with EcoRI (Figure 42 A).  
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To amplify the coding region from the template sequence and to add the 
sequence encoding for the FLAG-tag (either to the 3’ or 5’ ends), PCR was 
carried out (for a complete list of primers as well as details on the specific PCR 
performed, see Sections 3.4 and 4.2.2.2.1). An N’, C’FLAG-tagged as well as an 
untagged version containing SpeI- (3’) and NotI-restriction sites (5’), were 
generated (Figure 42 B). The two FLAG-tagged constructs are 1470 bp long, the 
untagged version only 1437 bp. All three constructs were pre-digested with SpeI 
and NotI, and purified as described (4.2.3.1 and 4.2.2.5). Via their restriction sites 
Figure 42. Cloning of FLAG-tagged CaMKII-α  for baculovirus expression. 
(A) The CDS (and approx. 200 bases non-coding region) encoding for CaMKII-α was retrieved 
from the pBluescript SK (-) vector by restriction enzyme-mediated digest with EcoRI. The 
purified fragment of size 1673 bp subsequently was sequenced and used as template during 
further cloning. (B) The sequence encoding for the FLAG-tag motif was fused 5’ and 3’ of the 
CaMKII-α gene, by using forward and reverse primers containing respectively SpeI- and NotI- 
restriction sites along with the FLAG-encoding sequence. The amplified product (approx. size 
1500 bp) was used for the subsequent cloning into the pFastBac 1 vector. (C) Successful 
cloning of the FLAG-tagged as well as untagged CaMKII-α gene into pFastBac 1 was 
confirmed via restriction enzyme-mediated test digestion with SpeI and NotI (left part). A 
schematic of the insert and vector along with the respective product sizes is provided on the 
right. 
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NotI and SpeI, each of the three insert sequences was cloned under the control of 
the polyhedrin promoter of the baculovirus-specific transfer vector pFastBac 1  
(Figure 42 C, see Section 7 for vector maps). 
FLAG-affinity purification of the CaMKII-α protein was carried out from 300 to 350 
ml of Sf9 cell suspension culture (for details of the purification protocol, refer to 
Section 4.3.4). Typically concentrations of approx. 20 µM CaMKII-α (corresponds 
to approx. 1.1 mg/ml protein) in a final volume of 300 to 400 µl were yielded 
(Figure 43).  
5.2.1.2 Autophosphorylation of CaMKII-α 
For CaMKII-α to become an active enzyme, it requires auto-phosphorylation of 
Thr286 (T286)169,170. Therefore, it was important to pinpoint under which 
conditions CaMKII-α autophosphorylation was strong or weak when compared to 
the inactive state. For this study, via Western-blot analysis against 
phosphorylated Thr286 (pT286) of CaMKII-α the kinase’s ability to undergo 
autophosphorylation was tested (a detailed protocol can be found in Section 
4.3.5.5). 
To this end, the kinase was incubated with 300 µM free Ca2+ and ATP (0.1 mM) 
for different time periods, and auto-phosphorylation was assayed via Western-blot 
analysis using an antibody against the phosphorylated T286 (pT286) of CaMKII-α 
(Figure 44). 
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Figure 43. FLAG-affinity protein 
purification of N’ and C’FLAG-
tagged CaMKII-α . 
Protein was expressed in Sf9-insect 
cells via the baculovirus expression 
system, and was FLAG-affinity 
purified from suspension culture. 
Cropped images of Coomassie 
blue-stained SDS polyacryl amide 
(10%) gels show the eluted fraction 
of purified N’ and C’FLAG-tagged 
CaMKII-α. Both products were 
confirmed by mass-spectrometry 
analysis. Approximate product size 
is indicated on the right. 
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As expected, at 300 µM free Ca2+ and 0.01 mM ATP CaMKII-α showed high 
levels of pT286. However, while for the C’FLAG-tagged version the size of the 
auto-phosphorylated product corresponded to the molecular weight of monomeric 
CaMKII-α (approx. 55 kDa), for the N’FLAG-tagged construct strong pT286 auto-
phoshorylation was detected in a product of approximately 40 kDa. It should be 
noted that at the longest reaction time (i.e., three minutes) also at 55 kDa a faint 
duplex band was detected. In addition, with increasing reaction time (i.e., one to 
three minutes) the degree of auto-phosphorylation was increased (Figure 44). 
Perhaps due to a calcium-SDS gel artifact, the detection levels of total CaMKII-α 
protein were higher when Ca2+ was included in the reaction. Judging from the 
Coomasie-stain (Figure 44), it is unlikely that unequal sample loading accounted 
for the higher intensities in the blots. Under zero-Ca2+ conditions, no activation 
was observed. Thus the C’FLAG-tagged CaMKII-α construct is fully functional 
under the conditions used here. 
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Figure 44. Autophosphorylation of N’ and C’FLAG-tagged CaMKII-α . 
Both, N’FLAG- (left panel) and C’FLAG-tagged (right panel) CaMKII-α, were tested for their 
ability to undergo autophosphorylation at T286. For this 270 nM purified kinase protein was 
stimulated for one to three minutes with 0.1 mM ATP and 0.3 mM free Ca2+ (conditions labeled 
at the top). Top and middle part: Semi-quantitative Western-blot analysis against total kinase 
protein and phosphorylated T286 (pT286). Bottom part: Coomassie blue-stained SDS 
polyacryl amide gels (10%) sections showing the kinase bands at 55 kDa. The 66 kDa-product 
comprises BSA, which was included in the assay. Control (left-most lane): Here, no Ca2+ was 
included, thus stimulation of the kinase cannot occur. Product sizes (in kDa) are indicated on 
the right. 
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5.2.1.3 Initial structural analysis of CaMKII-α by cryo-electron 
tomography 
Besides providing the biochemical evidence for the kinase’s functionality, in 
collaboration with the laboratory of Prof. W. Baumeister and Dr. V. Lucic (Max-
Planck-Institute for Biochemistry, Martinsried, Germany), cryo-electron 
tomography (cryo-EM) studies have been initiated and are still ongoing. For these 
experiments, exclusively the C’FLAG-tagged CaMKII-α was used.  In Figure 45 A 
and B, representative negative stain electron micrographs of the dialyzed kinase 
are shown. At a 10-fold dilution of the protein solution several thousands of (non-
aggregated) holoenzyme-assembled particle images could be acquired. An 
excellent sample quality was crucial for the cryo-EM work and the following three-
dimensional (3D) reconstruction (Figure 45 C and D). In Figure 45 A, an overview 
image of the sample is shown, whereas Figure 45 B shows one optimally plane-
oriented holoenzyme kinase particle (black square box). Already on the level of 
conventional electron microscopy (EM), the reported hexagonally shaped 
holoenzyme structure becomes vislible. Furthermore, a pore-like structure in the 
middle of the holoenzyme was observed (Figure 45 A), confirming earlier reports of 
EM structures of the CaMKII-α holoenzyme 171. Preliminary 3D reconstructions, 
obtained from approx. 80,000 single particles, impressively show the unstimulated 
(non-autophosphorylated) as well as the stimulated (autophosphorylated) state of 
C’FLAG-tagged CaMKII-α (Figure 45 C and D, resolution of approx. 30 Å). The 
quality of the kinase preparation even allowed for reconstructions where the 
kinase can be looked at from different perspectives (top- and side-view). From 
these reconstruction images, it seems as if upon stimulation, the holoenzyme 
swivels out the N-terminal portion of each of the six duplex-arranged kinase 
molecules (Figure 45 C and D). 
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Taken together, I could provide evidence that the purified C’FLAG-tagged 
CaMKII-α exhibits full autophosphorylation activity (Figure 44, Section 5.2.1.2). 
Furthermore, cryo-EM (performed by Z. Kochovski, Baumeister-Lab, MPI for 
Biochemistry, Martinsried, Germany), demonstrated that the kinase assembles 
into a functional, but more importantly dynamic holoenzyme (Figure 45). 
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Figure 45. Structural analysis of CaMKII-α  by cryo-electron tomography. 
(A and B): Representative negative stain electron micrographs of purified C’FLAG-tagged 
CaMKII-α; scale bars provided in the lower right. The overview-image section in (A) shows that 
with the applied dilution (0.5 to 2 µM) of the kinase sample an even distribution of fully 
assembled holoenzyme-particles without any signs of protein aggregation was achieved. 
Under the applied conditions, purified C’FLAG-tagged kinase assembles into the characteristic 
petal-like hexagonal holoenzyme structure (B). (C and D) Three-dimensional (3D) 
reconstructions of unstimulated (no Ca2+, C) and stimulated (plus Ca2+, D) CaMKII-α. For this, 
approx. 80,000 particles from cryo-tomograms of both the conditions were aligned in three 
dimensions followed by 3D-averaging. Depicted are reconstructions showing the 
holoenzymatic structure from three different orientations (top and side views) with an approx. 
resolution of 30 Å. Images provided by Z. Kochovski, Baumeister-laboratory, MPI for 
Biochemistry, Germany. 
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5.2.1.4 Assaying the interaction of CaMKII-α and melanosomes 
With the fully functional protein I set out to establish a release assay to better 
understand the effect on melanosome-bound Myosin V (for experimental details, 
refer to Section 4.3.5.6). For this assay, a high-Calcium concentration (300 µM 
free Ca2+) was applied to ensure that the kinase is active and able to 
phosphorylate Myosin Va as the potential substrate. Once stopped, the samples 
were briefly centrifuged to separate the melanosome fraction from potentially 
released Myosin Va molecules. Subsequently both the supernatant and the pellet 
fraction were subjected to Western-blot analysis. 
As expected, high autophosphorylation (i.e., active state turned on) was observed 
in the supernatant fractions, under conditions where free Ca2+ was present and 
Figure 46. CaMKII-α-mediated Myosin V release from melanosomes.  
Melanosomes, isolated from Xenopus l. melanophores, were targeted for the herein introduced 
release-assay (outlined in Section 4.3.5.6) to investigate the potential of (endogeneous as well 
as exogenous) CaMKII-α to trigger Myosin Va-release from the melanosome. Left and right 
panels: after completion of the respective reaction, by brief sample centrifugation the 
supernatant and pellet fraction was obtained. This way, Myosin Va-release from and also any 
potential kinase-recruitment onto the melanosome could be assessed by immunoblotting 
against Myosin Va, total kinase protein and autophosphorylated kinase at T286 (indicated to 
the left of each row). Bottom row: Coomassie blue-stained SDS polyacrylamide gel (10%) 
image sections; the respective conditions applied are labeled on top of the image sections; 
product sizes (in kDa) are indicated in-between both panels. The relative intensities of the 
herein presented semi-quantitative Western-blot analysis is provided in Figure 47. 
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where purified kinase was added. The different reaction times of kinase activation 
did not yield significant differences in the level of autophosphorylation (anti-pT286 
CaMKII-α of Figure 46). As shown in lane 1 of the SN-fraction, purified kinase does 
not undergo autophosphorylation under Ca2+-free conditions (anti-pT286 CaMKII-
α of Figure 46). Furthermore, according to the band intensity quantification, it made 
no significant difference whether melanosomes were present in the reaction or not 
(Figure 47). 
Figure 47. Semi-quantitative analysis of CaMKII-α-mediated Myosin V release. 
Left and right panels: Intensities were determined for each protein product at the given 
condition (#1 through 8, for details refer to Figure 46 from both the supernatant (left panel) and 
pellet fractions (right panel). Barcharts display the relative intensities, normalized to the 
intensity values of condition #5 (i.e., melanosomes only). For the purpose of correct 
visualization, intensities of condition #5 were set to 100% when significantly higher than the 
background value, while they were set to 0% when below the background value. x-axis: 
reaction conditions of the pellet (P) and supernatant (S) fractions are labeled #1 through 8 ; y-
axis: relative intensity are given in %; the respective protein product analyzed and quantified is 
indicated on top of each diagram. 
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It should be mentioned that the added kinase does not pellet as such (anti-total 
CaMKII-α and pT286 CaMKII-α of Figure 46). However, under conditions where 
melanosomes are present, total and even active CaMKII-α protein is found in the 
pellet fraction (Figure 46 and Figure 47). Another rather surprising finding was that 
under Ca2+-free conditions highly active CaMKII-α was detected in the pellet even 
though in the bulk of the supernatant no activated kinase could be detected (anti-
total CaMKII-α and pT286 CaMKII-α of Figure 46 and Figure 47). The level of 
activity was identical to the autophosphorylation level determined for the pelleted 
kinase fraction under high-Ca2+ conditions at the longest activation period (anti-
pT286 CaMKII-α of Figure 46 and Figure 47). Furthermore, high 
autophosphorylation in the presence of melanosomes but not in their absence 
was observed when no exogenous pre-activated kinase was included to the 
assay (compare SN and P lanes 5 of anti-pT286 CaMKII-α of Figure 46). It made 
no difference whether non-pre-activated or pre-activated (2 minutes) purified 
kinase was added (Figure 46 and Figure 47). Under conditions where no 
exogeneous kinase was added, CaMKII-α is largely confined to the supernatant 
fraction (anti-total CaMKII-α of Figure 46 and Figure 47). Taken together, the kinase 
is found in the pellet only when melanosomes are present. Moreover, active 
endogeneous kinase is very likely capable of binding to melanosomes. 
The fact that active endogenous CaMKII-α might associate with melanosomes 
strengthens the hypothesis of CaMKII-α-mediated regulation of melanosome-
associated components. As shown in Figure 46 and Figure 47 along with the band 
intensity quantifications, significant amounts of full-length Myosin Va were 
detected in the supernatant. This strongly suggests that Myosin V-specific release 
from the melanosome surface takes place even under conditions where no 
exogenous kinase was added. Strikingly, the relative amount of released Myosin 
Va and melanosome-associated active kinase show strong correlation (compare 
lanes of SN and P for anti-Myosin Va and anti-pT286 CaMKII-α, respectively).  
These data provide evidence that endogenous active melanosome-bound 
CaMKII-α has a role in releasing Myosin Va from the melanosome. However, 
under the conditions used, a complete release of Myosin Va from the 
melanosome was not achieved by either the endogeneously expressed or 
exogenously added and melanosome-bound kinase. 
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5.3 Purification of isolated melanosomes via MACS technology 
The novel technique described here deals with the further purification of 
melanosomes that had been isolated the conventional way and therefore still 
contain contaminating cytoplasmic proteins. 
Motivated by the problem that for very sensitive analytical methods, like mass-
spectrometry, the conventional method for the isolation of melanosomes is hardly 
suitable, I combined the established gentle two-step centrifugation method with a 
magnetic bead-based enrichment technology (MACS).  So far MACS has been 
used primarily in immunobiological research, where cells rather than organelles 
are sorted and enriched.  
In brief, magnetic beads bind specifically via bead-conjugated secondary 
antibodies to the target (i.e., melanosomes), which in turn is marked with surface-
marker-specific primary antibodies. This way, no additional centrifugation step is 
Figure 48. Schematic of MACS bead-assisted melanosome purification. 
(a) Melanophores from Xenopus l. were harvested and lyzed via Balch-homogenization. (b) To 
separate cell debris (e.g., membranes) from cytoplasmic proteins, the lysate was centrifuged 
at 750 × g. (c) The melanosome fraction was separated from low molecular weight proteins 
and other small cytoplasmic molecules by centrifugation at 3,000 × g. The pellet fraction from c 
is here referred to as “crudely” isolated melanosome fraction. (d) For further purification by 
MACS, the pelleted melanosome fraction from c was incubated with surface marker-specific 
primary (1°) antibodies. Here, Tyrosine-related protein 1 (Trp1) was chosen as marker, as it 
represents a transmembrane and thus is an integral part of the protein melanosome 
membrane. Antibody-labeled melanosomes were subjected to incubation with paramagnetic 
MACS® microbeads, which are conjugated to secondary (2°) antibodies that are reactive 
against the earlier applied 1° antibodies. By using a strong magnet, almost like using a fishing-
rod, the magnetically labeled organelles are attracted toward the magnet and can eventually 
be eluted. Sizes of cells, organelles and other components here depicted are schematics and 
are not drawn to scale. 
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required, and only those organelles that contain the marker against which the 
beads are reactive are purified. For details on the protocol for MACS bead-
assisted purification of isolated melanosomes, refer to Section 4.1.4 and the 
schematic in Figure 48. 
5.3.1 Results 
5.3.1.1 Comparative analysis of the different purification methods 
The main goal of this work was to establish a protocol that yields highly pure but 
intact melanosomes. In brief, melanosome isolation from melanophores was 
carried out according to the established isolation protocol 65,93, yielding a crudely 
isolated melanosome (Melcrude) fraction. This was followed by density gradient 
ultra-centrifugation purification (DC). Using SDS-PAGE and mass-spectrometry, 
melanosome fractions purified by the standard crude method or by DC were 
compared (Figure 49). 
The appearance of the Coomassie-stained bands from the cell lysate, cytosolic 
(SN 3000) and crude melanosome (Melcrude) fractions hardly differed from each 
other (Figure 49). In contrast, in both the tested purification methods (DC and 
MACS) in principle all the protein bands that were obtained at the Melcrude 
isolation stage became absent in the process of further purification (Figure 49). In 
collaboration with the Zentrum für Proteinanalytik (ZfP, LMU Munich, Germany) 
the DC-purified and crude melanosome fractions were subjected to tandem mass-
spectrometry (the list of protein hits obtained, is provided in Section 7). 
Figure 49. Comparison of the different 
melanosome purification procedures. 
Image sections of Coomassie blue-stained 
SDS polyacrylamide gels (12%), showing 
lanes of the cell lysate, cytosolic (SN 3000) 
and melanosome (Melcrude) fractions after 
centrifugation of the lysate at 3,000 × g (first 
three lanes); in lanes 4 through 6 the purified 
melanosome fractions after density gradient 
ultra-centrifugation (MelPost DC) or magnetic-
bead assisted sorting (MelPost MACS) are 
provided. Virtually all proteins detected by 
Coomassie-staining are depleted upon 
purification via DC and MACS. Sizes of 
proteins (in kDa) are indicated on the left. 
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For the Melcrude fraction, mass-spectrometry provides a long list of proteins, of 
which only very few could be matched to proteins or protein families that are 
known to be associated with the (still poorly) characterized melanosome 
proteome. This is consistent with the many Coomassie-stained protein bands 
detected by SDS-PAGE (Figure 49, the list of protein hits is provided in Section 7).   
For the MelPost DC probe, mass spectrometry gave improved spectra along with 
several significant peptide matches (the complete list of protein hits is provided in 
Section 7). In addition, a reasonable portion of the MelPost DC results matched 
previous reports of mass-spectrometric analyses of melanosomes from mouse 
melanocytes (see complete list of protein hits is provided in Section 7). More 
importantly, the reliability of the analysis was underlined by the fact that 
tyrosinase-related protein 1 (Trp1), a melanosome-specific surface marker 
protein, was identified with the highest protein score among the proteins 
identified. However, despite the improved quality in the mass-spectra, none of the 
known melanosome-associated motor proteins could be detected. 
For melanosomes isolated via MACS, at this point only preliminary mass-
spectrometry results could be obtained (data not shown). However, the fact that 
for the first time also motor proteins (myosins, kinesins and dynein) as well as 
melanosome-specific adaptor-molecules (dynactin) could be identified is 
encouraging. This and the fact that the MACS-purification was carried out via the 
melanosome surface marker Trp1, makes this novel purification technique 
superior to the other two procedures used here. 
5.3.1.2 Qualitative analysis of the purity of MACS-purified 
melanosomes 
To determine the degree of contamination of melanosomes purified by MACS, 
Western-blot analysis against ubiquitous cellular proteins was performed. β-
tubulin was chosen because it is an abundant cytoskeletal protein. The glycolytic 
enzyme GAPDH is a housekeeping enzyme that is present in almost all cell types 
172, and is representative of the cytosolic protein fraction. And Myosin Va was 
chosen because it is a melanosome-specific marker that is expected to remain on 
the melanosome during the purification procedure. 
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In Figure 50, a Western-blot of a representative preparation of MACS-purified 
melanosomes is shown, from which three important conclusions could be drawn: 
i) GAPDH is present in the lysate and SN3000 fraction, but is nearly absent (only 
a faint band remained) in the melanosome fraction after the second centrifugation 
step; ii) even though clearly reduced, the melanosome probe from this second 
centrifugation step still contained β-tubulin. Importantly however, after the MACS 
bead-purification, the contaminating β-tubulin fraction vanished; and iii) even 
though each step in the purification procedure was accompanied by a slight 
reduction in the content of Myosin Va, a significant portion of this melanosome 
surface marker stayed associated with the organelles. Therefore, the two 
contaminating cytoplasmic proteins, GAPDH and β-tubulin, could be successfully 
depleted from the melanosome fraction by the MACS protocol (Figure 50). 
5.3.1.3 Analysis of the MACS-purification protocol by FACS 
To quantitatively determine the specificity of this novel melanosome purification 
technique, Fluorescent Activated Cell Sorting (FACS) analysis with the crudely 
isolated but not yet MACS-purified melanosomes was carried out. By applying the 
same primary and secondary antibodies at dilutions identical to those used for 
MACS-purification, via FACS the antibody-specific binding of the melanosomes 
can be monitored and quantified. 
In Figure 51 representative plots for melanosomes stained with anti-Trp1 and 
Kinesin-2 antibody are presented. As controls, unstained melanosomes as well as 
melanosomes stained with secondary antibody only were included. Approximately 
11,000 melanosomes per antigen and condition were analyzed in one run.  
Figure 50. Qualitative analysis of MACS-
purified melanosomes. 
Via Western-blot analysis, the amounts of 
Myosin Va, β-tubulin and GAPDH, representing 
proteins from the melanosome-bound transport 
machinery, cytoskleton and cytosol, 
respectively, in the cell lysate and cytosolic 
fraction, as well as crudely purified melanosome 
fraction were compared with equal amounts 
from the MACS-purified melanosome fraction 
(from left to right). Protein product sizes (in kDa) 
are indicated on the right. 
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Comparing the respective peaks of the green curve (melanosomes plus primary 
and secondary antibody) to the red and blue curves of the control measurements, 
in both sets (anti-Trp1 and anti-Kinesin-2) an obvious shift toward higher mean 
intensity for the green curves is observed (Figure 51). 
This finding clearly demonstrates the specific binding of the Trp1 antibody to the 
crudely isolated melanosomes, and thereby encourages further use of the current 
protocol of the MACS-purification technique. 
 
 
 
 
Figure 51. Surface marker-specific FACS analysis on isolated melanosomes. 
Depicted are two representative histogram overlays for the surface marker-specific staining of 
crudely isolated melanosomes (green lines) of Tyrosinase-related protein 1 (Trp1, upper 
panel) and Kinesin-2 (lower panel). As Controls unstained melanosomes (red lines) as well as 
melanosomes stained with the respective secondary antibody only (blue lines) were subjected 
for FACS analysis. Histogram overlays are plotted as fluorescent intensity of phycoerythrin (x-
axis) versus % of maximum fluorescence (y-axis). The latter is calculated by setting the 
highest count of one fluorescent intensity unit to 100%. Thereby, it is possible to compare the 
two controls to the specific staining. 
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5.4 Determining the full-length sequence of Xenopus l. Myosin Va 
One of the goals of this work was to obtain the complete full-length sequence of 
Xenopus l. Myosin Va and to subsequently clone the complete gene into a 
baculovirus-specific transfer vector for the expression in insect cells. Lots of 
biologically relevant applications could be tackled if it was possible to produce this 
important organelle transporter as recombinantly over-expressed protein. In 
addition, once successfully cloned the Wildtype full-length version can easily be 
mutated and then studied both, in vivo and in vitro. 
5.4.1 Strategy 
To obtain the full-length sequence of Xenopus l. Mysoin Va the following five 
steps were performed: First, mRNA was isolated from cultured Xenopus l. 
melanophores followed by reverse transcription into cDNA (Sections 4.2.1.1 and 
4.2.1.2); second, with the cDNA at hand PCR with gene-specific forward and 
reverse primers as well as RACE-PCR was performed (Sections 4.2.2.2.2 and 
4.2.1.3). Via this gradual retrieval of new sequence fragments, the stepwise 
proceeding toward the end of the coding sequence was achieved; and third, 
before restriction-mediated cloning of the obtained gene into a baculovirus 
transfer vector, the sequence was confirmed by DNA sequencing (Section 
4.2.2.6). 
5.4.1.1 Step-by-step PCR on cDNA from Xenopus l. melanophores 
Based on the known approximate molecular weight of 215 kDa, the coding 
sequence for the full-length Myosin Va from Xenopus l. would be expected to be 
almost 6000 base pairs (bp) long. However, the sequence that has been 
published as coding sequence for Xenopus l. Myosin Va (accession number: 
NM_001087248), with 1760 bp hardly covers one third of the expected full-length 
sequence.  
To provide the entire sequence, reverse transcribed cDNA from Xenopus 
melanophores served as template for as series of PCR reactions, which for 
reasons of clarity are sub-divided into the three distinct but overlapping phases A, 
B and C (Figure 52). 
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5.4.1.1.1 Overview on Phases A, B and C 
Phase A primarily served the purpose of validating and correcting the published 
but yet incomplete sequence, hence primers used during Phase A were designed 
on the basis of this incomplete Myosin Va coding sequence. 
The fact that 3’ of the sequence that had been obtained during Phase A, no 
further sequence information was available, made a Xenopus l. Myosin Va gene-
specific primer design impossible. Therefore, as an alternative approach for 
Phase B reverse primers were designed on the basis of the published and 
complete full-length Myosin Va gene from chicken.  
PCR reactions of Phase A and B were carried out with overlapping primer 
combinations, so that the newly retrieved sequence fragments could be easily 
aligned and compared to each other. This way, new preliminary template 
sequences could be obtained. For primer design it was important to not consider 
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Figure 52. Obtaining the full-length Myosin Va sequence from Xenopus l. melanophore 
cDNA −  Overview. 
In the three overlapping Phases A, B and C the full-length Xenopus l. Myosin Va sequence from 
melanophore cDNA was obtained. Phase A: By using forward and reverse primers that were 
specific for the published but incomplete Myosin Va gene (solid black portion of the cDNA), a 
product of 3.15 kb was retrieved. Phase B: PCR on the not known sequence (grey portion of the 
cDNA) was performed by using a combination of forward and reverse primers annealing at the 3’-
end of the Phase A product and the related full-length Myosin Va gene from chicken, respectively 
(1.6 kb-product yielded). Phase C: The remaining 1.8 kb of the coding sequence (solid grey) were 
obtained by RACE PCR, using a Phase B gene product-specific forward primer along with a 
reverse primer that was specific for the poly A+ tail of the cDNA. Products yielded by PCR are 
depicted as blue portions for the respective phases (indicated on the left). A schematic of the cDNA 
containing the coding sequence of the full-length Myosin Va gene is provided at the very top. 
Arrows along with primer numbers indicate the carried out sequencing reactions in Phases A 
through C (yellow) and prior to the subsequent cloning of the full-length product (orange). 
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the very end of the sequences for primer annealing because errors are more 
likely to occur towards the ends of the sequencing reaction, which would 
ultimately result in erroneous design of new primers. Therefore, primers were 
designed such that annealing could occur close (i.e., 20 to 50 nucleotides inward) 
but not at the very 3’-end of the respective sequence template. 
The third and final phase aimed at the retrieval of the remaining approx. 2 kb of 
the full-length Myosin Va coding sequence. For this, the more specialized PCR 
technique of Rapid Amplification of cDNA Ends (RACE-PCR) was used, as it is 
ideally suited for amplifying a certain portion of a given gene sequence encoded 
by the isolated poly A+ mRNA. 
For details on the PCR reactions of phases A, B and C and a summary list of the 
primers used, please refer to Section 4.2.2.2.2 and 4.2.1.3. A list of all primers 
that were used to step-by-step sequence the respective PCR products is provided 
in Section 3.4.2.11. 
5.4.1.2 Cloning of full-length Xenopus l. Myosin Va for baculovirus 
expression in Sf9 cells 
To express the full-length protein in insect cells, the coding sequence coding for 
the full-length protein was cloned into the pFastBac Dual transfer vector under the 
control of the p10 promoter. By using forward and reverse primers that contained 
both, the sequences for the restriction enzyme-specific recognition sites (NheI 
and SphI) as well as the FLAG-coding sequence motif, the full-length Myosin Va 
coding sequence was N’ or C’FLAG-tagged and prepared for restriction enzyme-
mediated cloning via NheI and SphI. This way expression of the full-length protein 
in insect cells with the subsequent purification via FLAG-affinity chromatography 
became possible. For more detailed information about the preparation of the full-
length Myosin Va gene for vector cloning, please refer to Section 4.2.2.2.3. 
Both versions, N’ and C’FLAG-tagged full-length Xenopus l. Myosin Va, were 
expressed in insect cells via the baculovirus expression system and subsequently 
FLAG-tag affinity-purified (for more details, refer to Sections 4.3.3.6 and 4.3.4.2). 
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5.4.2 Results 
5.4.2.1 Sequence retrieval of full-length Xenopus l. Myosin Va 
The goal of the Phase A work was to check the already published but incomplete 
sequence for errors and/or point mutations. A product constituting the first 3146 
bases of the gene (Figure 53 A) revealed five point mutations and six base 
insertions within the published sequence, including a 5 bp insertion at position 
1754 (GTAAG). The base shift generated by the absence of this quintet 
generates a STOP-codon, ending the published coding sequence at position 
1760. In addition, at position 2708 a Thymidine was inserted.  
Figure 53. Obtaining the full-length Myosin Va sequence from Xenopus l. melanophore 
cDNA 
(A) Phase A: By PCR on cDNA from Xenopus l. melanophores with Xenopus l. sequence-specific 
primers, a product of 3146 bp was obtained. Forward primers of Phase B derived from the 
assembled sequence obtained in Phase A. (B) Phase B: PCR on cDNA with a Phase A-
sequence-derived forward primer and a chicken Myosin Va-specific reverse primer, yielded a 
product of 1633 bp. The forward primer used in Phase C derived from the assembled sequence 
obtained in Phases A and B. (C) Phase C: RACE PCR on RACE-ready cDNA, using a Phase B-
derived forward primer and an universal primer (kit-provided) as reverse primer. The product 
obtained (approx. 2500 bp) contained the missing last 1784 bp along with approx. 700 bp of 
untranslated region. (D) By using the in-silico assembled full-length coding sequence, forward and 
reverse primers containing restriction site-specific sequences for NheI and SphI, were used to 
amplify the full-length product (5576 bp) from Xenopus l. melanophore cDNA. For primers used 
along with sequences, refer to Sections 3.4.1 and 4.2.2.2.2. 
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By combining a forward primer annealing close to the 3’-end of the newly 
obtained sequence and a reverse primer specific for a portion of the published 
full-length chicken Myosin V, in Phase B additional 1633 bases were retrieved 
(Figure 53 B). The remaining portion of the coding sequence (approx. 2 kb) was 
retrieved via RACE PCR (Phase C). 
The obtained product of approx. 2.5 kb, contained the remaining 1.8 kilobases of 
the coding region, along with about 700 bases of untranslated region (Figure 53 C). 
Via conventional gene-specific PCR, the final full-length product (total length, 
5559 bp) including the restriction sites specific for NheI (5’) and SphI (3’) could be 
obtained and prepared for the cloning into the pFastBac Dual transfer vector 
(Figure 53 D and Figure 54, for details refer to Section 5.4.1.2). 
Figure 54. Cloning of the full-length Xenopus l. Myosin Va gene 
for baculovirus expression. 
Test digest of the pFastBac Dual vector containing the full-length 
Myosin Va sequence from Xenopus l. with restriction enzymes NheI 
and SphI. Right: A schematic of the insert and vector along with the 
respective product sizes is provided. 
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In Figure 55 the plasmid was digested with restriction enzymes AgeI/SphI, to show 
more clearly that the insert is of the right size and was inserted correctly. 
Representing a gene-internal restriction site (near the 3’-end/C’-terminus of the 
insert), AgeI was used to confirm the correct insertion direction into the vector. 
Additional PCR was carried out to generate N’ (5’-end) and C’ (3’-end) FLAG-
tagged full-length constructs. As for the untagged version, both FLAG-tagged 
constructs were provided with NheI and SphI restriction sites at the 5’- and 3’-end, 
respectively (Figure 56; a list of primers sequences is provided in Section 3.4.1).  
Figure 55. Confirming the correct insertion of full-length Xenopus l. Myosin Va 
into the pFastBac Dual vector. 
Test digest of the pFastBac Dual vector containing the full-length sequence of Myosin 
Va from Xenopus l. with restriction enzymes AgeI and SphI or AgeI only to confirm 
the correct insertion into the vector. AgeI was used as it represents a unique 
restriction site within the insert. A schematic of the insert and vector along with the 
respective product sizes is provided on the right. 
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5.4.2.2 Domain analysis and comparative alignment 
To identify both the conserved and rather divergent regions, the deduced amino 
acid sequence of the full-length Xenopus l. Myosin Va was compared to published 
Myosin Va sequences from chicken (Gallus gallus), mouse (Mus musculus) and 
human (Homo sapiens) (for the complete sequence alignment, refer to Section 7). 
The protein sequence comparison focused on the head, neck, stalk and tail 
domains and is summarized in the following. Figure 1 in Section 1.3.1 shows the 
individual domains of Myosin V. 
As was reported previously for Myosin Va from other species 173,174,175, the head 
domain (aa1-775) represents a highly conserved region (see also complete 
sequence alignment in Section 7). For instance the ATP-binding (aa167-177) as 
well as loop 1 regions (aa193-203) are identical among the four Myosin Va 
species (Figure 57).  
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Figure 57. Comparative sequence alignment of full-length Xenopus l. Myosin Va with 
other class V myosins −  ATP binding site and loop 1. 
The sequence of the full-length Myosin Va from Xenopus l. was aligned with class V myosins 
from chicken, mouse and human. The depicted section shows the ATP binding site and loop 1 
within the highly conserved head domain. The regions and motifs of interest are labeled and 
color-coded. For more details on the alignment, refer to the complete alignment in Section 7. 
Figure 56. Cloning of FLAG-tagged full-length 
Xenopus l. Myosin Va for baculovirus 
expression. 
The sequence encoding for the FLAG motif was 
fused to the 5’- and 3’-ends of the full-length 
Myosin Va gene, by using forward and reverse 
primers containing respectively NheI- and SphI-
restriction sites along with the FLAG-encoding 
sequence. The amplified product (approx. size 
5600 bp) was used for the subsequent cloning into 
the pFastBac Dual vector. 
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The actin-binding region (aa505-532) is similar (four differences out of 28 amino 
acids) to the actin-binding regions from the other three Myosin Va species (Figure 
58).   
 
By contrast, in the loop 2-sequence (aa594-639) representing a region of the 
head domain crucial for the actin-binding-mediated phosphate release, almost 
half of the residues (21 out of 46 amino acids) are divergent (Figure 59). 
Interestingly, more than half of those divergences come from the Xenopus l. 
Myosin Va alone. The remaining (C-terminal) approx. 140 aa of the head domain 
(including the loop 3 region) are highly conserved among the four species. 
However, from the eight divergences in this region, six are found in Xenopus l. 
Myosin Va alone. 
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Figure 59. Comparative sequence alignment of full-length Xenopus l. Myosin Va with 
other class V myosins −  Loop 2 region. 
The sequence of the full-length Myosin Va from Xenopus l. was aligned with class V myosins 
from chicken, mouse and human. The depicted section shows the loop 2 region within the 
otherwise highly conserved head domain. Loop 2 in the Xenopus Myosin Va shows high 
divergence in comparison to Myosin V from the other species. The regions and motifs of 
interest are labeled and color-coded. For more details on the alignment, refer to the complete 
alignment in Section 7. 
Figure 58. Comparative sequence alignment of full-length Xenopus l. Myosin Va with 
other class V myosins −  Actin-binding region. 
The sequence of the full-length Myosin Va from Xenopus l. was aligned with class V myosins 
from chicken, mouse and human. The depicted section shows the actin-binding region within 
the highly conserved head domain. The regions and motifs of interest are labeled and color-
coded. For more details on the alignment, refer to the complete alignment in Section 7. 
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The neck domain (aa776-908) shows obvious differences compared to the other 
three Myosin Va species. While the consensus sequence IQxxxRGxxxRxxY of 
the IQ repeats is conserved, in particular the repeats IQ3, IQ4 and IQ5 diverged 
more than the other three IQ-motifs (Figure 60). 
 
The proximal tail or rod domain (aa 915 through approx. aa 1320) is marked by 
two extensive coiled-coil regions (CC#1 and CC#2), which are separated by a 
calpain-sensitive PEST site. The four sequences diverge in 79 of the 202 amino 
acids that comprise CC#1. Nearly half of these, i.e., 35 residues, are found in 
Xenopus l. Myosin Va (see also complete sequence alignment in Section 7). 
While the PEST site shows high similarity among the species (Figure 61), with 22 
out of 81 residues diverging, CC#2 again shows high sequence-variability. Again, 
most of these divergences were found only in the Xenopus l. sequence. 
Just before the beginning of CC#3, a stretch of 27 amino acids (consensus 
sequence, aa1324-1351) is present in mouse and human Myosin Va but missing 
in Xenopus l. as well as chicken Myosin Va (Figure 62). 
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Figure 60. Comparative sequence alignment of full-length Xenopus l. Myosin Va with other 
class V myosins −  IQ motifs. 
The sequence of the full-length Myosin Va from Xenopus l. was aligned with class V myosins 
from chicken, mouse and human. The depicted section shows the six IQ motifs of the lever arm 
domain. While the IQ repeat consensus sequence is kept, some minor divergences for the 
Xenopus Myosin Va exist. The regions and motifs of interest are labeled and color-coded. For 
more details on the alignment, refer to the complete alignment in Section 7. 
 
Figure 61. Comparative sequence alignment of full-
length Xenopus l. Myosin Va with other class V 
myosins −  PEST site. 
The sequence of the full-length Myosin Va from 
Xenopus l. was aligned with class V myosins from 
chicken, mouse and human. The depicted section 
shows the calpain-sensitive PEST site of the rod 
(proximal tail) region. While this region in general 
shows high sequence variability (see complete 
alignment in Section 7), the PEST motif is highly 
conserved. The regions and motifs of interest are 
labeled and color-coded. 
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In contrast, the distal rod region (aa1321-1430), marked by a third coiled-coil 
(CC#3), shows high sequence similarity and conservation among the four 
species. However, the second half of CC#3 has an insertion of 25 amino acid 
residues in Xenopus l. Myosin Va, (Figure 63). 
 
 
To summarize, while a large portion of the head and distal tail domains are highly 
conserved, parts of the neck and most of the proximal stalk/tail are highly divergent in 
Xenopus l. Myosin Va.  
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Figure 62. Comparative sequence alignment of full-length Xenopus l. Myosin Va with 
other class V myosins −  Sequence deletion in the distal rod region. 
The sequence of the full-length Myosin Va from Xenopus l. was aligned with class V myosins 
from chicken, mouse and human. The depicted section shows a stretch just before the third 
coiled-coil of the distal rod region, where for Xenopus and chicken Myosin V a sequence 
deletion (27 residues) was detected. The regions and motifs of interest are labeled and color-
coded. For more details on the alignment, refer to the complete alignment in Section 7. 
Figure 63. Comparative sequence alignment of full-length Xenopus l. Myosin Va with 
other class V myosins −  Unique sequence insertion in the distal rod region. 
The sequence of the full-length Myosin Va from Xenopus l. was aligned with class V myosins 
from chicken, mouse and human. The depicted section shows the second half of the third 
coiled-coil region. Normally this portion of the tail domain shows high sequence similarity, but 
for Xenopus Myosin Va a unique insertion of 25 amino acids was detected. The regions and 
motifs of interest are labeled and color-coded. For more details on the alignment, refer to the 
complete alignment in Section 7. 
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5.4.2.3 FLAG-affinity purification of full-length Xenopus l. Myosin Va 
The initial purification of both the N’ and C’FLAG-tagged construct was carried out 
from as few as 200 ml of Sf9-cell suspension (Figure 64). 
Via mass-spectrometry, both full-length protein products were confirmed as 
Myosin Va (Table 31). The prominent degradation bands at approx. 110 and 125 
kDa (only for the C’FLAG version) that along with the full-length protein product 
were co-eluted (Figure 64), via mass-spectrometry were clearly identified as 
Myosin Va derivates (Table 31). 
 
 
Sample # Match to (Protein/Species) Score Sequence coverage (%) 
1 MyoVA/Gallus g. 3247 30 
2 MyoVA/Gallus g. 5428 19 
3 MyoVA/Gallus g. 1307 22 
4 MyoVA/Gallus g. 5336 30 
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Figure 64. Initial FLAG-tag affinity 
purification of N’ and C’FLAG-tagged 
full-length Xenopus l. Myosin Va. 
Proteins were expressed in Sf9-insect cells 
via the baculovirus expression system, and 
FLAG-affinity purified from suspension 
culture (200 ml). Cropped images of 
Coomassie blue-stained SDS polyacryl 
amide (12%) gels show the eluted fraction 
of purified N’ and C’FLAG-tagged full-length 
Xenopus l. Myosin Va. Bands of the full-
length (bands #1 and #2), but also of three 
lower-running protein products (bands #3, 
#4 and #5) were confirmed by mass-
spectrometry as Myosin Va. Approximate 
size of the full-length protein is indicated on 
the right. 
Table 31. Mass-spectrometry analysis of FLAG-tag affinity-purified 
full-length Xenopus l. Myosin Va. 
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For optimized full-length Myosin Va purification (Figure 65), protein expression and 
purification had to be fine-tuned. It was most important to scale up the virus titer 
as well as to increase the number of cells to be infected. Also, two cycles of 
FLAG-resin incubation were required, and twice the amount of FLAG-peptides 
was included during the elution process.  
5.4.2.4 In vitro gliding motility of full-length Xenopus l. Myosin Va on 
F-actin 
Both, the N’ and C’FLAG-tagged version of the full-length protein were assayed 
for their capabilities to bind to, and move, actin filaments. Intuitively, one might 
expect the C’FLAG-tagged version to be better suited for gliding assays because 
a tag at the head domain might interfere with motor function. Under zero-ATP 
conditions both full-length protein constructs perfectly bind to actin filaments 
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Figure 65. Optimized and large-scale FLAG-tag affinity purification of N’ and C’FLAG-
tagged full-length Xenopus l. Myosin Va. 
Left and right panel: N’ and C’FLAG-tagged proteins were expressed in Sf9-insect cells via the 
baculovirus expression system, and FLAG-affinity purified from suspension culture (800 ml). 
After elution of the purified protein (left lanes), one fraction was further dialyzed in buffer 
containing 50% glycerol (middle lanes), followed by an additional concentration via Amicon-
Ultra device (right lanes). Cropped images of Coomassie blue-stained SDS polyacryl amide 
(12%) gels show the respective fractions of the purified N’ and C’FLAG-tagged full-length 
Xenopus l. Myosin Va. Approximate size of the full-length protein is indicated on the right. 
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(Figure 66 A and Figure 67 A). However, upon the addition of 2 mM ATP, the 
observed gliding motion of the C’FLAG-tagged version was clearly impaired 
(Figure 66 B and Video 9) when comparing it to the N’FLAG-tagged full-length 
construct (presented in the next paragraph). In other words, only the mechanical 
force generation and/or catalytic activity of the C’FLAG-tagged molecule are 
disturbed, while its ability to bind to F-actin seems not to be affected. 
In contrast, with ATP (2 mM) present, the N’FLAG-tagged full-length Myosin Va 
practically moves all of the bound actin filaments (Figure 67 B and C, Videos 10 
and 11). The fact that without ATP no gliding motility was observed (Video 12) 
indicates that the post-purification dialysis of the protein solution effectively 
removes any ATP that had been present during the purification procedure. 
Figure 66. Filament gliding assay with the C’FLAG-tagged version of full-length Xenopus 
l. Myosin Va 
(A and B) Atto488-labeled F-actin (green filaments) was infused into a flow cell containing 
surface-attached C’FLAG-tagged full-length Xenopus l. Myosin Va. (A) Directly after infusion, 
filaments were tightly bound to the surface by myosin. Assay was performed in 25 mM KCl, 
without ATP, thus no movement could be observed. White frame box indicates the region from 
where a close-up is provided in B. Scale bar represents 10 µm. (B) Representative TIRF 
microscopy image sequence of an Atto488-labeled actin filament (indicated by white 
arrowheads), which is bound to the coverslip by surface-adhered full-length Xenopus l. Myosin 
Va (at 25 mM KCl and 2 mM ATP). The position of the filament at the beginning of each time 
row is indicated (white dotted line). Also, the position of the filament at the end of one row is 
marked in the first frame of the row below (dotted white line on the left). Despite the presence of 
ATP, hardly any filament gliding was observed. Excitation wavelength in A and B was 488 nm. 
In B same image section (5 × 10 µm) was taken over time with scale bar representing 2 µm. 
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Furthermore, the results imply that the initial binding to F-actin happens also in 
the absence of ATP. The rapid tearing-apart of the transported filaments 
(compare Figure 67 A and B), most likely is due to the high density of surface-
attached motor molecules and the resulting intense pulling force on the filaments. 
The gliding events lasted on average for 31.4 s with an average gliding 
distance of 3.8 µm (Table 32). A gliding velocity histogram yielded a single-
Gaussian fit (Figure 68) with a deduced mean value for the gliding velocity of 
131.2 nm s-1. This corresponds to velocities that have been reported for the 
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Figure 67. Filament gliding assay with the N’FLAG-tagged version of full-length 
Xenopus l. Myosin Va 
(A) Atto488-labeled F-actin (green filaments) was infused into a flow cell containing 
unspecifically surface-attached N’FLAG-tagged full-length Xenopus l. Myosin Va. As for the 
C’FLAG-tagged version, directly after infusion filaments were tightly bound to the surface. 
Assay was performed in 25 mM KCl and zero ATP, thus no movement could be observed. (B) 
To the experiment from A, 2 mM ATP was added and directly thereafter filament gliding of the 
before tightly bound actin filaments was observed. White frame box indicates the region, from 
where in C a close-up is provided; Scale bars in A and B represent 10 µm. (C) Representative 
TIRF microscopy image sequence of an Atto488-labeled actin filament (indicated by white 
arrowheads), which is bound to the coverslip by surface-adhered full-length Xenopus l. Myosin 
Va. The position of the filament at the beginning of each time row is indicated (white dotted 
line). Also, the position of the filament at the end of one row is marked in the first frame of the 
next row (dotted white line on the left). An obvious downward movement over time was 
measured (compare positions at the beginning and end). Excitation wavelength in A through C 
was 488 nm. In C same image section (5 × 10 µm) was taken over time with scale bar 
representing 2 µm. 
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Myosin V-driven melanosome transport on F-actin in vivo 176 and in vitro (D. 
Zimmermann & A. Oberhofer, unpublished data). 
 
 
 
 
 Velocity (nm s-1) 
Distance 
(µm) 
Duration 
(s) n 
FL Myo Va 131.2 ± 6.5 3.8 ± 0.2 31.4 ± 1.7 70 
 
 
 
 
 
 
To test for single-point attachments indicative of processive movement (Figure 69 
and Video 13), the motor concentration was reduced to 200 nM while keeping the 
F-actin concentration constant. Expectedly, this led to a decrease in filament 
binding events. However, those filaments that were bound to the surface of the 
flow cell mostly were bound through the action of only one or a few motors 
(indicated by white arrowheads in Figure 69). Even though this decreased the 
likelihood of smooth filament gliding, the typical filament threading where one 
processive motor molecule takes multiple consecutive power-strokes, could be 
observed.  
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Figure 68. Analysis of filament gliding behavior of 
N’FLAG-tagged full-length Xenopus l. Myosin Va. 
Filament gliding velocity distribution was plotted as 
histogram. Data were obtained from filament gliding 
experiments, where 500 nM full-length Xenopus l. 
Myosin Va (N’FLAG-tagged version) was adhered to 
the surface of a coverslip and incubated with Atto488-
labeled F-actin in 25 mM KCl and 2 mM ATP. The data 
were fitted to a single Gaussian (according to Equation 
7), yielding a mean velocity of 0.13 µm s-1 (n= 70). 
Table 32. Summary of the filament gliding behavior of 
N’FLAG-tagged full-length Xenopus l. Myosin Va. 
 
Mean filament gliding velocities, distances and durations for the 
full-length Xenopus l. Myosin Va (N’FLAG-tagged version, 500 
nM) were obtained from gliding filament assays at 2 mM ATP 
and 25 mM KCl. Mean gliding velocity was determined from the 
Gaussian fit to the histogram data provided in Figure 68. All 
values represent the mean ± S.E.M with n as the number 
sampled for this summary. 
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With this finding, evidence was provided that single full-length Myosin Va 
molecules exhibit ATP-dependent, but most importantly, processive movement. 
5.4.2.5 In vitro single-molecule motility of full-length Xenopus l. 
Myosin Va on F-actin  
The motile behavior of full-length Xenopus l. Myosin Va was studied in single-
molecule motility assays. To this end, motors were labeled at their head domain 
with a FLAG-tag reactive Cy3-labeled antibody (for experimental details, see 
Section 4.3.5.1.2). In the presence of 2 mM ATP, single fluorescently labeled 
motor molecules landing on surface-adhered F-actin were observed (Figure 70 A, 
Video 14). However, only infrequently an actin-bound Myosin Va molecule was 
also observed to move (Figure 70 B, Video 15). This finding shows that in principle 
the tracking of single full-length Xenopus l. Myosin Va motor molecules is 
possible. 
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Figure 69. Filament gliding assay with the N’FLAG-
tagged full-length Xenopus l. Myosin Va showing 
single-point attachments. 
Atto488-labeled F-actin (green filaments) was infused into 
a flow cell containing 200 nM unspecifically surface-
attached N’FLAG-tagged full-length Xenopus l. Myosin Va. 
Immediately after infusion, filaments were bound to the 
surface and started to show movements. Due to the low 
number of filament-bound motor molecules, the filament 
gliding was hardly as smooth as observed in Figure 67. 
However, the filament threading by single motor molecules 
implies processive movement of the assayed motor 
protein. White arrowheads indicate said single-point 
attachments by (in this case) three Myosin V molecules. 
Assay was performed in 25 mM KCl and 2 mM ATP; 
excitation wavelength was 488 nm; scale bar represents 
10 µm. 
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As is known from previous studies on full-length Myosin Va from other species 
54,177,178,179, under low-salt and low Ca2+ conditions the globular tail domain almost 
always folds back onto the two heads, causing auto-inhibition. Thus, though the 
mechano-catalytic function is inhibited, the capability to bind to F-actin is not 
affected 55. 
One possibility to overcome this problem is to test the single-molecule behavior of 
the full-length protein under high-salt conditions (150 mM). Compared to the low-
salt condition, the overall specific binding of Myosin Va to F-actin was decreased, 
however, still only infrequently directed movements along F-actin were observed 
(Figure 71 A and B, Video 16). 
 
 
 
 
Figure 70. Single-molecule motility of N’FLAG-tagged full-length Xenopus l. Myosin Va on 
F-actin. 
(A and B) 100 nM Cy3-labeled N’FLAG-tagged full-length Xenopus l. Myosin Va (bright 
particles) were infused into a flow cell containing surface-attached Atto 488-labeled F-actin 
(fuzzy green filaments in background). (A) White arrowheads indicate representative single 
Myosin Va molecules that co-localized with actin filaments. Assay was performed in 25 mM KCl 
and 2 mM ATP. Myosin was excited at 532 nm and F-actin at 488 nm; scale bar represents 10 
µm; white frame box indicates the region from where a close-up is provided in B;  (B) Image 
sequence of a single Cy3-labeled full-length Xenopus l. Myosin Va molecule (indicated by white 
arrowheads) on F-actin. The vertical as well as horizontal position of the motor molecule at the 
beginning of each time row is indicated (white dotted lines). The continuous edging up of 
displacements over time reflects the characteristic processive but slow walking behavior of the 
full-length motor molecule on F-actin. The same image section (5 × 10 µm) was taken over time. 
Scale bar represents 2 µm. 
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Unfolding the auto-inhibited molecule by the binding of an artificial cargo to the C-
terminal domain was a second approach to revoke auto-inhibition. Analogous to 
the fluorescent labeling with anti-FLAG-Cy3 antibody, the C’FLAG-tagged full-
length version was conjugated to an anti-FLAG-Biotin antibody and thereby 
biotinylated. This way, quantum dots (Qdots) coupled to streptavidin can bind to 
the tail domain, imitating motor-bound cargo. The fact that control experiments 
(i.e., same Qdot concentration but no motor protein) showed only very few 
unspecific surface-attached Qdots, indicates that the Qdot-coupling works well 
Figure 72).  
Figure 71. Single-molecule motility of N’FLAG-tagged full-length Xenopus l. Myosin Va on 
F-actin −  High salt. 
(A and B) Setup of this experiment was the same as described for Figure 70, except that 150 
mM salt instead of 25 mM salt was included. (A) White arrowheads indicate representative 
single Myosin Va molecules that co-localized with actin filaments. Myosin was excited at 532 
nm and F-actin at 488 nm; scale bar represents 10 µm; white frame box indicates the region 
from where a close-up is provided in B;  (B) Image sequence of a single Cy3-labeled full-length 
Xenopus l. Myosin Va molecule (indicated by white arrowheads) on F-actin. The vertical as well 
as horizontal position of the motor molecule at the beginning of each time row is indicated 
(white dotted lines). In this sequence the molecule of interest shows strong rightward movement 
at the beginning but then also starts to move vertically. The same image section (5 × 10 µm) 
was taken over time. Scale bar represents 2 µm. 
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However, no directed motion could be observed. Whether this is because 
unfolding via the Qdot-tail conjugation simply does not work or because the 
C’FLAG-tagged version’s walking ability in general is impaired, remains to be 
shown. 
Future experiments will show whether under optimized high ionic-strength 
conditions and with sufficient amounts of applied motor protein, movement of 
single Myosin Va molecules can be visualized or whether certain modifications 
have to be made to turn the full-length protein constitutively active. 
!"#$%&'()*+ Figure 72. Single-molecule TIRFM measurement of 
Quantum dot-labeled full-length Myosin Va on F-
actin. 
A final concentration of 10 nM full-length Xenopus l. 
Myosin Va (C’FLAG-tagged version) conjugated to 
Qdots (bright particles; 2.5 motor molecules per Qdot) 
were infused into a flow cell containing surface-attached 
Atto488-labeled F-actin (not visible in this setup). In the 
here presented and representative image section (60 × 
60 µm, false-colored) only static non-motile particles 
were observed. Assay was performed in 25 mM KCl and 
2 mM ATP at 532 nm excitation wavelength. Scale bar 
represents 10 µm. 
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6 Discussion 
6.1 Movement of Myosin Va loop 2 mutants on F-actin and 
microtubules 
In all myosins the loop 2-motif represents a crucial surface structure that lies 
between the upper and lower 50 kDa sub-domain of the head domain. While the 
conventional class II myosins contain a relatively short loop 2 (18 to 24 amino 
acids), in Myosin Va it is 45 amino acids in length and highly positively charged 
(net charge +5) 35,112,180. Loop 2 lies at the actin-binding site of Myosin V 24 and is 
most widely believed to be responsible for the initial weak binding to actin via 
electrostatic interactions between the positively charged amino acids of loop 2 
and negatively charged residues in the subdomain-1 of actin 181. Upon binding to 
actin, the initial stereospecific actin-binding interface is created eventually 
culminating in rapid phosphate release 24,111,182,183,184. In recent years, the 
functional role of the Myosin V loop 2 has been studied with mutants, where 
single lysine residues at the C- or N-terminal Myosin V-specific amino acids have 
been substituted with neutral or negative residues 35,111. By substituting all nine 
positively charged amino acids with either neutral or negative residues, in this 
study two novel mutants with a negative net charge on loop 2 were created. In 
addition, by inserting a microtubule E-hook-binding loop motif from a class 3 
kinesin into the central part of loop 2, a third mutant was generated here. The 
behavior of the three Myosin Va loop 2 mutants along with the Wildtype Myosin V 
was studied on F-actin as well as on microtubules. 
6.1.1 Myosin Va loop 2 mutant behavior on F-actin 
It has been suggested that loop 2 is pivotal for the coupling of ATP hydrolysis to 
the actual mechanical work. Therefore the behavior of the four Myosin Va loop 2 
constructs on F-actin was assayed for actin-stimulated ATPase activity and in 
single-molecule motility assays yielding unexpected results. 
For the Wildtype construct, the ATPase activity values were in good agreement 
with those reported previously (Figure 39 and Table 30) 35,44. This confirmed the 
integrity and functionality of the motor proteins. In contrast, in mutants containing 
a negative loop 2 net charge (Minus4 and Minus13), ATPase activity was 
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abolished completely (Figure 39). This is consistent with findings of previous 
studies where a so-called AAA-mutant with a decreased positive loop 2 net 
charge showed a decrease in ATPase activity 35,111,166. In contrast to the Minus4 
and Minus13 mutants, the AAA-mutant ATPase activity was not abolished 
completely, most likely because its loop 2 still contained an overall positive net 
charge (+2) and thus the Km was decreased by only a factor of 5 35. At the 
molecular level this is explained by the fact that for Myosin Va to trigger 
phosphate and ADP-release it is a prerequisite to weakly bind to actin, for which 
electrostatic attraction of loop 2 towards F-actin is crucial 24,111,183,184. If however 
electrostatic attraction is changed into electrostatic repulsion (i.e., negative 
charge on loop 2 and on sub-domain1 of F-actin), then actin-stimulation of the 
ATPase cycle cannot occur. Along this line, if the initial weak binding does not 
function properly, then essential intramolecular rearrangements within the upper 
and lower sub-domains of the head domain cannot occur, culminating in impaired 
mechanical force generation 24,111,183,184,185. Therefore, no persistent walking 
events were observed in the single molecule assays of Minus4 and Minus13 
mutants (Figure 38 A and Video 5). 
Strikingly however, the loop 2 mutant carrying the microtubule E-hook-binding 
motif from kinesin KIF1A (kinesin-3), exhibited proper ATPase activity as well as 
single-molecule motility on F-actin (Figure 38 A, Figure 39, Figure 40, Table 30, Videos 
6 and 7). While both, Myosin Va Wildtype and K-loop, showed highly similar 
values for kcat (i.e., actual hydrolysis rate of ATP mol-1 s-1), in comparison to 
Wildtype, the Km of the K-loop mutant was increased almost three-fold (Table 30). 
This finding indicates that K-loop can hydrolyze ATP at the same rate as 
Wildtype, but to achieve the same performance it however must be stimulated 
with three times higher actin concentrations. In other words, ATP hydrolysis was 
not impaired or harmed but the affinity by which the weakly-bound actin state is 
achieved was significantly lower. A similar observation was made by Yengo, CM 
and colleagues (2004)35, who reported that compared to Wildtype Myosin Va the 
Km of the AAA-mutant (2 instead of 5 positive net charges) was decreased five-
fold. 
Across all the myosins classes, actual ATP-hydrolysis takes place in the absence 
of actin. Hence, for this the lower affinity of K-loop for F-actin would be irrelevant. 
However, a myosin molecule can only re-bind a new ATP molecule for the next 
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round of ATP-hydrolysis, if the hydrolysis products inorganic phosphate (Pi) and 
ADP were released. This in turn is only possible, if the initial binding to actin is 
properly achieved, which according to the ATPase data for K-loop is three times 
less likely or can be assumed to take place at three times slower pace. 
Therefore, if it took the K-loop mutant longer to re-bind to actin and initiate 
product release, then how does it catch-up to re-bind fresh ATP within the same 
cycle time as the Wildtype construct? The single-molecule motility analyses 
revealed that the mean velocity of K-loop was half as fast as Wildtype Myosin Va 
(Table 30). Slower speed means that less distance within the same time frame was 
covered. Thus per given time interval fewer steps (i.e., power-strokes) were taken 
along the filament. According to recent models, the power-stroke of the lever-arm 
does not happen before Pi release but rather directly before or during release of 
ADP 24,33,185,186,187,188. As mentioned, Pi release happens only after the binding to 
F-actin was successfully initiated by loop 2. It has been shown that for the 
electrostatic weak binding, only the net charge and not the size of loop 2 matters 
111. Thus for K-loop with its lower positive net charge on loop 2, fewer power-
strokes are triggered, resulting in slower walking.  
In processive myosins like Myosin V, the rate-limiting step is ADP release from 
the binding pocket of the head domain. Compared to the rapid phosphate release, 
the release of ADP is very slow (12-16 s-1) 32. Thereby processive motors such as 
Myosin Va ensure to stay attached long enough attached with one (the leading) 
head, while the second, detached (trailing) head hydrolyzes the bound ATP (> 
250 s-1) 32, and via diffusive search finds the next actin-binding site 45,46. This 
leads to the fact that in the presence of ATP, Myosin V spends more than 70% of 
its kinetic cycle strongly bound to actin 32. Interestingly, even though the K-loop 
mutant showed slower walking speed (i.e., decreased mean velocity), the same 
average runlength as for Wildytpe was obtained (Figure 41 and Table 30). With 
runlength being a measure of processivity, this suggests that the rate-limiting 
ADP release step remained unaltered. Given that processivity must not change 
and that ADP release succeeds phosphate release and that the weak- to strong-
binding transition occurs after the initial loop 2-contact has been made 189, then it 
seems plausible that phosphate release entails the automatic delay in ADP 
release. Thus slower cycle rates (i.e., kcat) would be expected. For the K-loop 
mutant, however, this discrepancy between the predicted outcome and the actual 
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findings might be explained as follows: Once weakly bound to actin (i.e., during Pi 
release and subsequent power stroke), the cluster of positively charged lysines in 
the central part of loop 2 enforces the faster transition to the strong binding state, 
which in turn would cause ADP to be released faster. This way, the slower 
phosphate release would be caught up by the accelerated ADP release. This 
would imply that unlike for the initial weak binding to actin, for Myosin Va to 
successfully complete multiple ATPase cycles, the distribution of charged 
residues and not only the total net charge, could play a role. This is in line with a 
previous study, where it was shown that the specific distribution of charged amino 
acid residues on their binding partners was more important than the net charge in 
the vicinity of the binding site 190. My work here shows that a Myosin V that 
contains a microtubule-binding motif from kinesin within its conserved loop 2 
region is still functional, despite exhibiting lower velocities 191.  
Furthermore, it is not unlikely that besides loop 2 also additional structural motifs 
ensure and maintain the correct initial binding to the actin filament. To obtain a 
better view of all the potential factors that play important roles at the myosin-actin 
interface, over the past decade a number of structural simulation and modeling 
studies have been undertaken. However, the nature of the actin-myosin interface 
is still a matter of speculation and details are lacking 189,192, which is mainly 
because to date there is no structure of an actin filament available 193. Therefore, 
studying of the actual binding interface is hard and thus relies on models that are 
based on results from cross-linking studies and the docking of high-resolution 
structures of myosin into more or less well-resolved cryo-EM density maps 
194,195,196,197,198. In those models it was suggested that besides the electrostatic 
binding by loop 2 also hydrophobic attraction from loop 2 and other loops (e.g., 
cardiomyopathy-loop) takes place at the interface 112. Mutations within those 
regions caused partial or complete ATPase activity abrogation 184. Furthermore, 
besides the binding to the major actin monomer (i.e., AC3), more recent 
simulations showed that most likely by using surface loops 3 and 4, the myosin 
also binds to the first (i.e., AC1) of the five involved actin monomers 112,194. 
Therefore, in the future it will be worth investigating, if for the K-loop mutant the 
hypothesis that the distribution of positive charges rather than the total net 
charge, holds true and whether additional motifs of the Myosin V head contribute 
to this intriguing and novel finding. 
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6.1.2 Role of the loop 2 net charge for its interaction behavior with 
microtubules 
The observation that not only positively but also negatively charged loop 2 
constructs displayed a salt-dependent decrease in microtubule association (Figure 
25) allows the following two conclusions. First, electrostatic interaction is indeed 
the prevailing force mediating the association of Myosin Va with microtubules. 
Second, loop 2 is not the site responsible for such attraction because the 
oppositely charged loop 2 constructs Wildtype and Minus4 (+5 vs. -4) display 
equivalent salt-sensitive binding behavior. Along with the observation that the 
Wildtype and Minus4 mutants associate at equivalent levels with microtubules 
further supports the notion that loop 2 neither mediates nor maintains the 
interaction between Myosin Va and microtubules (Figure 25). Thus another charged 
patch (or even multiple patches) on the Myosin Va surface, mediating the 
observed salt-dependent interaction with the microtubule, need to be considered. 
If, as hypothesized here, the electrostatic interaction between Myosin Va and 
microtubules is not mediated by the previously proposed myosin loop 2-
microtubule E-hook interaction, then the K-loop construct with its E-hook-specific 
binding motif would be expected to yield higher association rates than the 
Wildtype construct. Notably, as was shown in Figure  25 the K-loop mutant indeed 
showed the most efficient association with microtubules. This implies that the 
previously proposed interaction between loop 2 of Myosin Va and the microtubule 
E-hooks can take place, but only if the E-hook-specific binding motif K-loop is 
present on the loop 2 of Myosin Va. This is in line with a previous study, where 
the K-loop motif induced diffusional motility when introduced into the head domain 
of the normally non-diffusive but processive class 1 kinesin Kif5 146. Similarly, the 
diffusive behavior of MCAK (class 13 kinesin) that had lost the ability to diffuse 
was restored when introducing the K-loop motif into the motor/microtubule-binding 
domain of this prototypical diffusional kinesin 199. 
Conversely, as soon as enough negative charges were introduced into loop 2 of 
Myosin Va (e.g., Minus13), microtubule “affinity” for Myosin Va was significantly 
reduced (Figure 25). Those two findings suggest that for the Minus13 mutant strong 
repulsion forces arise from the evenly distributed negative charges, while for the 
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K-loop construct the additional E-hook binding motif and not net charge itself 
accounts for the observed additional microtubule binding events.  
Taken together, the results suggest that the dominating force that tethers Myosin 
Va to the microtubule is due to charge-charge interactions. However, those 
interactions are by no means mediated by loop 2. In addition to electrostatic 
forces, non-electrostatic forces may exert a significant influence at the Myosin Va-
microtubule interface. 
Most strikingly, and contrary to the predictions inferred from the electrostatic 
model, the charge of loop 2 neither determines nor limits the diffusion behavior of 
Myosin Va. The similarity of the diffusion constants (0.113 µm2 s-1 of Wildtype to 
0.089 µm2 s-1 of Minus13) (Figure 28 and Table 28) argues against a loop 2-biased 
charge-dependence in diffusion. The diffusion constants not only are comparable 
to each other, but also are in fine agreement with diffusion constants obtained for 
other microtubule-binding proteins and even proteins diffusing along DNA 
107,116,164,200. 
6.1.3 Role of the microtubule E-hooks for the interaction of Myosin Va 
with microtubules 
The fact that on the side of the interactor (i.e., Myosin Va) loop 2 as the potential 
electrostatic tether structure is neither required for the binding to nor for the 
diffusion along microtubules, prompted us to dissect the potential contributions of 
the substrate (i.e., microtubule) to Myosin Va association and diffusion. If indeed 
attraction forces other than electrostatic tethering contribute to the interaction 
between Myosin Va and microtubules, then microtubule E-hooks representing the 
proposed electrostatic tethering structures should be dispensable. 
Indeed, on S-microtubules lacking E-hooks, association levels for Wildtype and 
Minus4 remained unchanged compared to untreated microtubules (Figure  34 vs. 
Figure  25), demonstrating that E-hook-mediated tethering is not involved in 
microtubule association of Myosin Va. In fact, these effects were readily revoked 
after the repulsive microtubule element (i.e., E-hooks) was removed (compare 
Figure  34 with Figure  25). This leads to the proposal that E-hooks impact the 
association behavior of K-loop (with its E-hook-specific motif) and Minus13 (with 
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its extensive negative charge) only if the interacting molecule (here Myosin Va) 
carries the specific E-hook binding motif or provides an abnormally high repulsion. 
As mentioned earlier, the K-loop represents only an additional and KIF1-specific 
E-hook binding loop 146. Being intrinsically monomeric, KIF1A cannot move along 
the microtubule in a hand-over-hand fashion and thus relies on the ability to 
exhibit diffusional displacements. Therefore, for KIF1A a K-loop comes handy 
because it ensures weak binding and thus provides the basis for one-dimensional 
diffusion along the microtubule 119. However, other kinesins such as MCAK 
almost exclusively exhibit diffusional motility on microtubules but at the same time 
lack the K-loop structure 116,146. In that respect, it has been shown for a number of 
kinesins that for weak binding (required for one-dimensional diffusion along the 
lattice) to the microtubule surface, the electrostatic interaction with E-hooks is not 
essential. For instance, via its surface loop L7 class 3 kinesins bind to the β-
tubulin subunit of the protofilament directly 201,202,203. Also, such highly conserved 
structures like the α-helical segments 4, 5 and 6 together with loop L8 (all part of 
the motor head-domain) were shown to mediate the weak binding to the 
microtubule surface via electrostatic interaction 146. In addition, from structural 
studies on the MCAK kinesin it is known that not always a specific binding motif, 
such as the K-loop or the myosin loop 2 is required to initiate weak binding, but 
rather unspecific binding via unstructured and flexible regions would be sufficient 
116,199,204. Taken together, even kinesins show diverse ways and structural motifs 
(mostly within the motor’s head domain) to weakly interact with microtubules. With 
this in mind, it is just logical that Myosin Va, which so far has not been conceived 
as a classical microtubule-associated protein, uses different ways and structures 
than those used for the initial binding to actin filaments. 
While the capacity to interact with S-microtubules did not differ significantly, 
diffusion was observed only with the Wildtype and K-loop construct (Figure 34 and 
Table 29). In other words, on microtubules lacking E-hooks, the fraction of 
associated motors remains high, though fewer of the attached Myosin Va 
molecules advance to the diffusive state and thus remain stationary. As soon as 
the nearly homogeneous mantle of negatively charged E-hooks is removed, non-
ionic forces (e.g., van-der-Waals interactions) that show strong effects over short 
distances 205,206 become a substantial attraction force. This is well reflected again 
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by the fact that on S-microtubules salt-sensitivity for all four Myosin Va constructs 
is decreased (compare Figure 26 and Figure 35). 
This suggests that non-ionic attraction forces account for the observed decrease 
in diffusion for all four Myosin Va constructs, while the overall affinity remains 
comparable to that of Wildtype Myosin Va on untreated microtubules. In addition, 
when E-hooks are present, they may act as negatively charged 4 nm spacers 
160,161 that via repulsion facilitate transitions from the stationary to the diffusion 
phase. Hence on microtubules that lack E-hooks, constructs containing a 
pronounced negatively charged loop 2 region (Minus4 and Minus13) are now free 
to productively interact with the unshielded positive patches on the "naked" 
microtubule surface 160,165 (Figure 34). In contrast, the Wildtype and K-loop 
constructs with their net positive loop 2 charge, retain some residual ionic 
repulsive capacity (positive loop 2 vs. positive patches on the microtubule 
surface) and thereby on S-microtubules still manage to advance into the diffusive 
state (Figure 34, Figure 36, Video 4). 
This suggests that only these two constructs are capable of balancing the 
interplay between ionic and non-ionic effects, making them almost “immune” to 
harsh changes on the microtubule. A closer look at the diffusion behavior of 
Wildtype Myosin Va reveals that compared to untreated microtubules, its diffusion 
along S-microtubules in fact is smoother (larger single displacements), yielding an 
increased diffusion constant (Figure 36 and Table 28).  
6.1.4 Conclusion and Outlook 
To gain detailed mechanistic insights into the unbiased diffusion of Myosin Va, in 
this study association of Myosin Va with microtubules (i.e., binding without 
additional quantification of subsequent diffusion events) was distinguished from 
diffusion per se. Also, by assaying monomeric and dimeric Myosin Va mutants 
(Wildtype loop 2) that contained the head-domain only, microtubule interaction 
and one-dimensional diffusion by Myosin Va can be assumed to be limited to the 
head domain (preliminary data not included in this work). Even though only 
preliminary, these results now provide a robust basis to perform further studies, 
aiming on revealing the definite site(s) within the head domain responsible for the 
interaction between Myosin Va and microtubules. 
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In analogy to recent findings by Minoura et al. 161, the here presented findings 
suggest the following two-phase model for diffusion of Myosin Va on 
microtubules. Phase One is the initial association with the filament. This step 
represents a prerequisite for diffusion and is accomplished as long as 
electrostatic surface effects exerted from both, the interactor and the substrate, 
cause attraction rather than repulsion. Phase Two is the advancement to the 
diffusive state. This phase heavily depends on a balanced interplay between 
attractive and repulsive forces of Myosin Va and microtubules. Here, it is crucial 
that the strength of attraction is limited to such an extent that the motor is free to 
move laterally. Simply put, strong attraction forces may bind a high number of 
motor molecules to the surface but they also prevent those motors from moving 
(Minus4 and Minus13 on S-microtubules); conversely, weak attraction favors the 
diffusion along filaments, but at the same time gives the molecule a hard time to 
initially bind (Minus13 on untreated microtubules). Since the dosage makes the 
difference, in this specific case the dosage of electrostatic vs. non-ionic attraction 
Figure 73. The balance between attraction forces determines the diffusive state of Myosin 
V on microtubules.  
(Left part) Strong attraction forces prevent microtubule-bound Myosin V molecules from 
advancing to the diffusive state. This Trapped State is achieved, if in addition to electrostatic also 
non-ionic attraction forces become increasingly dominant (Minus4 and Minus13 on S-
microtubules). (Middle part) Diffusion takes place if for Myosin V the attraction toward the 
microtubule is of moderate strength. This Diffusive State in general is achieved when attraction 
and repulsion outweigh each other. Two different possibilities might account for that behavior. 
First, electrostatic and non-electrostatic interaction forces at the Myosin V binding-interface are 
well-balanced (Wildtype on untreated and S-microtubules); second, strong loop 2-derived ionic 
attraction is dominated by ionic repulsion elements (E-hooks) on the microtubule binding-
interface (Minus4 on untreated microtubules). (Right part) Weak attraction toward microtubules 
prevents Myosin V from binding effectively to the filament, and hence diffusion becomes unlikely. 
This Dissociative State is given, if electrostatic repulsion via hydrophilic surface structures (E-
hooks) becomes predominant (Minus13 on untreated microtubules). Red and blue colors indicate 
strong and weak attraction forces toward the microtubule surface, respectively. 
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on the surface determines the strength of binding and the likelihood of moving 
(Figure 73). 
Compared to motor-driven directed movement, unbiased one-dimensional 
diffusion is faster over short distances and does not consume energy, thus 
representing a supportive mechanism for intracellular transport processes 
25,108,147,164,207. In addition to Myosin Va, in most recent years a number of kinesins 
and other microtubule-binding proteins (e.g., MCAK, Dam1 complex, Ncd80 
complex, tau and XMAP215) have been shown to exhibit unbiased (non-
directional) one-dimensional diffusion 116,200,208,209,210. Despite all those candidates 
so far identified, to date most of the hypotheses brought forward base on 
knowledge that has been acquired from the well-studied phenomenon of one-
dimensional unbiased diffusion of DNA-binding proteins along DNA strands 
211,212,213,214. Interestingly, the diffusion constants for proteins exhibiting diffusional 
motility along microtubules (0.1 - 0.4 µm2 s-1) are in the same range as those of 
diffusion along DNA 107,116,164,200. However, the mechanism of protein diffusion on 
microtubules is still unclear. However, based on the previous and now here 
presented findings, it becomes evident that an even more complex and 
multilayered picture of the interaction modes between Myosin Va (and perhaps 
further microtubule- and non-microtubule binding proteins) and microtubules 
emerges. 
Furthermore, as long as atomic structures of the microtubule are missing, it will be 
difficult to predict the exact binding events on the microtubule lattice. Another 
important aspect that so far has not been paid attention to is that posttranslational 
modifications of the track might affect the diffusion of interacting proteins. From a 
previous study of DNA-DNA methyl-transferase interaction, it is known that the 
enzyme’s diffusional motility was enhanced drastically when it encountered hemi-
methylated DNA. Since in a cell tubulin is known to be heavily modified both post-
translationally as well as post-polymerisationally 215,216,217, this aspect will need to 
be investigated in more detail. 
In this respect unbiased diffusion of Myosin Va contrasts with biased diffusion of 
certain kinesins such as MCAK along microtubules, which is E-hook-dependent 
116,218. A different kinesin motor, kip3 from yeast, which belongs to the kinesin-8 
class, also diffuses on microtubules, but does so without the help of E-hooks 219. 
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Thus different types of motors can diffuse on microtubules, but the underlying 
mode of interaction differs.  
However, the E-hook-independent mode of interaction displayed by Myosin Va 
offers an attractive explanation for the recent in vitro observation that Myosin Va 
might increase kinesin’s run length on microtubules 110. The here presented 
results point to a possible synergism between E-hook-independent tethering by 
Myosin Va to microtubules that might enhance the E-hook-dependent processive 
movement of kinesin. However, Myosin V-mediated runlength-enhancement of 
Kinesin-2 has been assayed in a rather artificial in vitro-system, where purified 
Kinesin-2 and truncated Myosin Va were attached to Qdots to mimic cargo 110.  
To better study the proposed role of Myosin Va, in future studies it would be 
appealing to use a more biologically relevant system. For this, it would be ideal to 
use a cellular cargo, which contains the necessary motor make-up, in an in vitro 
assay similar to what Ali et al. were using. Melanosomes would be ideally suited 
for this because if isolated carefully, melanosomes retain all three motor protein 
classes (cytoplasmic dynein, Myosin Va and Kinesin-2) and transport on 
microtubules 65,74 as well as actin filaments can be reconstituted in vitro (D. 
Zimmermann & A. Oberhofer, manuscript in preparation). To test whether Myosin 
V’s ability to interact with microtubules indeed assists the kinesin-driven transport 
on microtubules, the transport of normal and Myosin V-deficient melanosomes 
would have to be assayed and compared. If indeed Myosin V enhances 
runlength, then the Myosin V-containing melanosomes would be expected to yield 
longer transport ranges on microtubules than melanosomes lacking Myosin V. It 
will by no means be trivial to obtain melanosomes that lack Myosin V on their 
surface. However, Karcher et al. showed that the Calcium-/Calmodulin-dependent 
kinase II (CaMKII) in mitotic Xenopus egg-cell-extract is capable of releasing 
Myosin V from melanosomes 121.  
Therefore, it would be highly valuable to investigate whether purified CaMKII can 
indeed specifically remove Myosin Va from melanosomes, while leaving the other 
melanosome-associated motor proteins (especially kinesin) untouched. Such a 
study would also provide further insights about the interplay between the CaMKII 
and melanosomes. 
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6.2 Studying the effects of Calcium-/Calmodulin-dependent 
Kinase II-α  on melanosome-associated Myosin Va 
6.2.1 Expression and purification of functional recombinant CaMKII-α 
CaMKII-α is one of the most abundant proteins in the brain and thus has been 
thoroughly studied over the past two to three decades, in the majority of cases the 
full-length native-form CaMKII-α has been purified from rat brain 220,221. Even 
though, isolating the kinase from rat brain is a tedious procedure that requires 
high amounts of brain material (about 20 rat brains), with at the end relatively low 
yields in protein concentration (Z. Kochovski, personal communication). In cases, 
where only a kinase fragment (e.g., the active N-terminal portion) is needed, it 
has become a standard procedure to express such constructs in E.coli 222. 
However, due to high cytotoxicity of the constitutively active kinase fragment, 
protein yields are very low when using this procedure 223. By contrast, high yields 
of the fragment can be expected when over-expressed in insect cells via the 
baculovirus system 222. The initial attempt to express recombinant full-length 
CaMKII-α via the baculovirus system was made by Brickey and colleagues two 
decades ago 224. However, most likely due to the laborious additional purification 
via calmodulin-sepharose (which is rather expensive, if purchased commercially) 
and FPLC, which is required when purifying untagged recombinantly over-
expressed proteins, only very rarely the full-length protein has been retrieved this 
way 122,225.  
One goal of this work was to set up a protocol that allows for FLAG-tag affinity 
purification of the baculoviral-expressed full-length protein. Therefore a FLAG-tag 
was fused to either the later N- or C-terminus of the full-length CaMKII-α-
encoding cDNA from rat brain (Figure 42 and Figure 43, Section 5.2.1.1). This way, 
the time-consuming and expensive additional purification steps, which at the 
same time also entail further protein loss, could be omitted from the procedure. 
The expression and purification protocol used here yielded high (> 20 µM) protein 
concentrations for both the C’ and N’FLAG-tagged kinase version (Figure 43). 
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6.2.2 Functional analyses of FLAG-tag affinity-purified CaMKII-α 
6.2.2.1 Biochemical analysis 
In contrast to the constitutively active chymotryptic N-terminal kinase fragment, 
the full-length kinase has been shown to be capable of phosphorylating 
substrates only if it first underwent autophosphorylation at Threonine 286 (T286) 
169,170. Therefore, to test whether the FLAG-tag affinity purified CaMKII-α shows 
the ability to activate itself, autophosphorylation assays with both, the purified N’ 
and C’FLAG-tagged kinase versions, were performed (for experimental details, 
see Section 4.3.5.5). 
While for the C’FLAG-tagged CaMKII-α the expected autophosphorylation at 
T286 took place, for the N’FLAG-tagged version strong autophosphorylation of a 
40 kDa-fragment was detected (Figure 44). The fact that the 40 kDa-fragment 
exhibited autophosphorylation implies that the T286 autophosphorylation site of 
the regulatory domain R1 was not affected 226,227,228. Also, the often used 
constitutively active chymotryptic N-terminal fragment is not capable of triggering 
autophosphorylation 170,229,230,231,232. This indicates that 40 kDa-fragment must be 
different. Furthermore, it is important to keep in mind that in vivo and in solution 
the monomeric kinase assembles into a dodecameric holoenzyme 122,123,124,171, 
only when the C-terminal hub domain is present 123,124. Therefore, the functional 
kinase fragment contains the C-terminal hub domain (approx. 150 amino acids) 
for certain. On the other hand, autophosphorylation has been shown only to take 
place, if upon Ca2+/CaM binding onto the regulatory subunit R3 the inhibitory bond 
between T286 of R1 and the N-terminal kinase domain is released 124,233. 
Therefore, the N-terminal FLAG-tag of the non-shortened kinase protein is very 
likely to be involved in the formation of this inhibitory bond and thus might keep 
the kinase locked in the non-autophosphorylable state.  
It is worth noting, that the shortened but autophosphorylable product was 
detected only in Western-blots, indicating that low concentrations of the 40 kDa-
kinase fragment yield pT286-levels nearly as high as those detected of the 
C’FLAG-tagged CaMKII-α construct. 
Due to the unusual and yet not fully understood autophophorylation behavior of 
the N’FLAG-tagged kinase version, in all subsequent experiments the C’FLAG-
tagged version of CaMKII-α was used. 
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6.2.2.2 Structural analysis by cryo-electron tomography 
CaMKII-α with its highly conserved dodecameric holoenzyme structure 122,123,124 
has the most complex and unique structure among all protein kinases identified 
so far. Therefore, the FLAG-tagged CaMKII-α was studied also by cryo-electron 
tomography (carried out by Z. Kochovski, from the Baumeister-Lab, MPI for 
Biochemistry, Martinsried, Germany). For cryo-EM, only samples of high purity 
can be processed. The uniform distribution of holoenzyme-like particles in 
negative-stain images (Figure 45 A and B) offered two important insights for the 
continuation of this project: i) neither any protein precipitation nor aggregation 
takes place using the FLAG-tag affinity purification protocol; and ii) by assaying 
multiple independent protein preparations of C’FLAG-tagged CaMKII-α, the 
assembly into the proposed hexagonal holoenzymatic structure was observed 
repeatedly (Figure 45 B). 
One of the advantages of cryo-EM is that images of assembled structures in their 
native state can be obtained 234,235. Also, “snapshots” of differently oriented 
particles can be acquired, which then allows for high-resolution 3D-
reconstructions. With the recent progress in cryo-EM, it has become possible to 
determine 3D structures to near atomic resolution, allowing the reconstruction of 
full atom models of multi-subunit proteins 234,236,237. The quality of recombinantly 
expressed CaMKII-α was confirmed by our preliminary 3D reconstructions (Figure 
45 C and D). Up to this point, the reconstructions are based on approx. 80,000 
particles, providing an approximate resolution of 30 Å.  
The reconstructions presented in this work provide clear evidence that the 
stimulated and unstimulated holoenzymes have structurally distinct 
conformations. This is an important observation, as over the past years there has 
been intense debate on what the real holoenzyme structure of CaMKII-α looks 
like and whether dynamic conformational changes between the unstimulated and 
stimulated state exist at all. Based on computational simulation models from 
crystal structures of kinase subunit fragments, a number of different structures 
describing the autoinhibited as well as non-inhibited state have been put forward 
122,171,238,239,240. Based on the most recent structural information that mainly has 
been obtained from small-angle X-ray scattering (SAXS) studies 122,123,240,241, 
Chao and colleagues have now presented a crystal structure of the full-length 
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autoinhibited CaMKII-α (4.0/3.6 Å)124. This structure shows a very compact 
arrangement of the kinase domains around the hub domain (core). The kinase 
domains of the twelve individual holoenzyme subunits are arranged as two 
hexameric rings, which are stacked in a petal-like structure above and below the 
core. This general concept in principle accords with the initial EM-studies, which 
had proposed a similar structure a decade ago 171. However, still contrasting is 
the fact, that in EM the kinase domains of the individual subunits of the 
autoinhibited holoenzyme were shown to extend outward, while in the most recent 
crystal structure by Chao et al. all twelve kinase domains are tightly packed and 
thus are not accessible for Ca2+/CaM 124,171. In addition Chao and colleagues 
added that according to computational kinetic simulation analyses it is very likely 
that parallel to the compact holoenzyme structure, also a semi-extended though 
still autoinhibited state exists. This semi-extended conformation is proposed to 
facilitate the otherwise impossible binding of Ca2+/CaM to the regulatory domains, 
thereby allowing for the initial autophosphorylation at T286, which concomitantly 
leads to a complete pop-out of the kinase domain (extended non-autoinhibited 
state) 124. 
With the current means in crystallography it will be highly unlikely to confirm the 
true existence of the recently proposed (auto-inhibited) semi-extended model 
structure. And to solve the fully extended (auto-activated) structure of the 
holoenzyme will be almost impossible when using crystallography. The 
preliminary cryo-EM results nicely show that under non-stimulating conditions 
(i.e., no Ca2+/CaM), the kinase adopts a rather compact structure without showing 
any domains extending outward (Figure 45 C). This contrasts with the previously 
proposed auto-inhibited EM structure by Kolodzeij, S. et al. (2000)171, but is in 
agreement with the recently presented crystal structure of the autoinhibited full-
length CaMKII-α 124. The 3D-reconstructed cryo-EM structure of the stimulated 
CaMKII-α presented here clearly shows six presumably N’-terminal kinase 
domains extending outward (Figure 45 D). This underlines that upon stimulation 
obvious conformational rearrangements within the holoenzyme take place.  
At the current resolution of 30 Å, the structures here presented are still subject to 
interpretation and speculation. Critically speaking, the here observed extended 
structure in Figure 45 D could as well represent the semi-extended and still 
autoinhibited state that has been documented by Chao et al. 124. This assumption 
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is however unlikely, as in Figure 44 it was shown that at stimulating conditions, 
CaMKII-α clearly becomes autophosphorylated and thus exists as a stimulated 
molecule. The fact that in this study only the subunits from the upper ring show 
the characteristic outward extending, is simply due to the tilt-angle used during 
the herein applied 3D-reconstuction modeling. By taking a closer look at the side-
view of the 3D-reconstruction of stimulated CaMKII-α, in the lower part indicated 
structures in-between the extended subunits of the upper ring become apparent. 
Therefore, at this point the structure of the stimulated CaMKII-α most certainly 
represents the extended and fully active state of the holoenzyme. 
To date, crystallography studies have only predicted but they could never directly 
show holoenzymatic dynamics of the full-length CaMKII-α. Even though still 
preliminary, the cyro-EM structures of the stimulated and unstimulated CaMKII-α 
presented here for the first time provide direct evidence that in solution the 
CaMKII-α holoenzyme undergoes drastic conformational changes. To further 
improve the resolution and thereby obtain further proof, 3D-reconstructions from 
over 160,000 single cryo-EM particles will be carried out. 
6.2.3 Studying the interaction between CaMKII-α and melanosomes 
First and foremost, this project was motivated by the fact that Rogers et al. 
(1999)103 reported on the specific release of Myosin Va from melanosomes when 
incubated with mitotic Xenopus egg-cell extract. Shortly thereafter, Karcher and 
colleagues (2001)121 could provide evidence that the observed release was 
mediated by CaMKII-α-specific phosphorylation of Serine 1650 within the distal 
tail domain of Myosin Va.  Based on those findings, my goal was to establish an 
in vitro assay by which the following questions could be easily addressable: First, 
does endogenous CaMKII-α from Xenopus l. melanophores interact with 
melanosomes? Second, if indeed such an interaction between melanosomes and 
endogenous CaMKII-α exists, then to which extend does Myosin V release take 
place? And third, via the in vitro release-assay system introduced here, would a 
complete Myosin Va-release from the melanosome be enforced when using the 
recombinant purified CaMKII-α? 
Indeed, autophosphorylated CaMKII-α was detected, even though no exogenous 
recombinant CaMKII-α was included (condition 5, Figure 46). This implies that 
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endogenous CaMKII-α from Xenopus l. melanophores interacts with 
melanosomes, while being active (i.e., autophosphorylated). Importantly, for the 
respective supernatant of this condition no autophosphorylation was detected at 
all, suggesting that (i) only activated autophosphorylated CaMKII-α interacts with 
the melanosome fraction; or (ii) endogenous CaMKII-α is turned active only when 
bound to melanosomes. As was shown in the autophosphorylation tests (Figure 
44), the recombinant and purified CaMKII-α does not undergo any 
autophosphorylation at condition 1. Also, the supernatant of this condition did not 
show any autophosphorylation, while at those conditions where Ca2+/CaM was 
added together with recombinant purified CaMKII-α only (conditions 2 through 4) 
high activity for the supernatant fraction was observed. This underlines that even 
though in condition 1 exogenous kinase was present, the detected 
autophosphorylation must be attributed to the endogenous melanosome-bound 
CaMKII-α.  
Also, the endogenous kinase was turned active most likely before or during the 
isolation procedure because it was detected as activated kinase at condition 1, 
where neither Ca2+ nor calmodulin had been added (Figure 46). 
It should be mentioned that only very low levels of total endogenous kinase 
protein in the pellet were detected (condition 5), while clearly under those 
conditions active kinase was present in the pellet fraction. This is most likely 
attributed to the fact that compared to the exogenously added purified kinase the 
amount of total kinase protein bound to the melanosome was below the 
antibody’s sensitivity.  
Importantly, the Myosin Va release (supernatant fractions of conditions 1 and 5 
through 8) seems to correlate with the amount of melanosome-bound active (i.e., 
autophosphorylated) kinase (compare Myosin V supernatant with pT286 pellet 
fractions). The fact that under zero Ca2+/CaM conditions exogenously added 
kinase was believed to be inactive, while endogenous melanosome-associated 
CaMKII-α showed clear signs of activation, leads to the assumption that Myosin 
Va release is due to the active endogenous and not the exogenously added 
purified kinase.  
Previous studies showed that once activated, the CaMKII-α exhibits its kinase 
activity in a completely Ca2+-independent manner 242,243,244. This fits the notion 
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that the release takes place even though no Ca2+/CaM was added, implying that 
for the kinase to phosphorylate its substrate (e.g., Myosin V) it is sufficient to 
being autophosphorylated rather than requiring additional supplies of Ca2+/CaM.  
Importantly, even though the amount of total kinase protein on the melanosome 
was significantly higher under conditions where exogenous CaMKII-α was added 
(conditions 6 through 8), Myosin Va release was hardly increased. This implies 
that the exogenously added purified kinase most likely did not contribute to 
Myosin Va release. This in turn might be explained by the fact that the 
melanosome-bound purified CaMKII-α seems to reside in the inactivate state. 
This is underlined by the finding that the association of exogenous purified kinase 
takes place only if Ca2+/CaM was present (compare pellet fraction of conditions 1 
and 6 through 8), while showing unperturbed autophosphorylation when in 
solution. Therefore, it seems as if the exogenously added kinase is clearly 
capable of binding to the melanosome, it however does not undergo 
autophosphorylation in this state even though sufficient amounts of Ca2+/CaM are 
present.  
In conclusion, only the endogenous CaMKII-α is turned active when bound to the 
melanosome, while in solution it seems to reside in the auto-inhibited state. 
Myosin Va-specific release doubtlessly takes place, although it was not as 
complete as suggested by the previous study of Karcher et al. (2001)121. 
It is important to mention that the release in Karcher’s work was triggered 
primarily upon the addition of mitotic frog egg-cell extract. By contrast, here the 
Myosin Va-specific release was mediated solely by the endogenous activated 
melanophore-borne CaMKII-α. In this context, it is worth mentioning that due to 
the actions of CaMKII-α, during mitosis, motor-activity is preferentially down-
regulated 245. Furthermore egg-cells can be assumed to show higher rates in 
proliferation than dermal pigment cells, thus more mitosis events would be 
expected to occur. Therefore it is very likely that frog egg-cells contain higher 
amounts of CaMKII-α than melanophores. It has been shown that in HeLa cells 
moderate levels of active CaMKII-α are required for proper cell cycle progression 
246. Therefore, due to moderate expression levels of CaMKII-α, significant but 
incomplete motor release from the melanosome would indeed be a logical 
consequence. Additionally, in contrast to an egg-cell the primary task of 
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melanophores is pigment distribution, which would be largely abrogated if 
important parts (e.g., Myosin V) of the transport machinery were deleted. 
6.2.4 Conclusion and Outlook 
In further studies one of the major goals will be to find optimal conditions under 
which the enforced release of Myosin Va from the melanosome via specific 
activation of melanosome-hooked CaMKII-α becomes possible. Furthermore, to 
find out why for the endogenous CaMKII-α only the activated state was found on 
melanosomes will be a major question in future studies. Lastly, it will be important 
to determine why the purified kinase stimulated without having melanosomes 
around while being recruited to the melanosome exclusively as inactive kinase. 
Costa et al. provided evidence that on vesicles from nerve terminals, CaMKII-α 
binds to the medial tail of Myosin Va, activating Myosin V in a Ca2+-dependent 
manner, most likely with Myosin V acting as a Ca2+-transferring unit 247. Those 
findings support the notion that only the active form of endogenous CaMKII-α was 
detected on the melanosome, which was accompanied by the release of Myosin 
Va. 
The fact that exogenous CaMKII-α was capable of binding to melanosomes but 
remained attached in an inactive state, could indicate that the exogenous kinase 
does not bind properly to Myosin Va and thus is not activated properly. In that 
sense, Myosin Va would act as a melanosome-specific co-factor that regulates 
the activation of the kinase and thus its own release from its cargo. 
In that respect, one option to further explore the melanosome-specific activation 
of CaMKII-α, would be to perform pull-down assays with purified full-length 
Xenopus l. Myosin Va and melanophore cell extract. This might reveal if any 
endogenous non-melanosome-associated CaMKII-α is capable of binding to 
Xenopus l. Myosin Va. 
If CaMKII-α binds Myosin Va directly, then both the kinase and the full-length 
Xenopus l. Myosin Va can be studied under varying conditions by cyro-EM. In 
addition, one could assess the complex interaction between Myosin Va and the 
CaMKII-α on intact isolated melanosomes.  
Both approaches would ask similar questions. Are accessory proteins involved in 
the interaction between Myosin Va and CaMKII-α? If yes, can those accessory 
Discussion 
________________________________________________________ 
 187 
proteins be confirmed also biochemically? Finally, with further co-factors identified 
and visualized, would it be possible to reconstitute protein CaMKII-α:Myosin Va 
complex in vitro? 
In addition, it would be highly interesting to reveal whether in melanophores 
CaMKII-α functions differently in anterogarde or retrograde melanosome 
transport. If indeed the release of Myosin V from the melanosome surface takes 
place in vivo, what factors would be involved in the regulation of this 
phenomenon. 
 
6.3 Purification of isolated melanosomes via MACS technology 
For the past three decades, the majority of studies on melanosome transport 
focused on characterizing the components by fluorescence microscopy and 
biochemistry, or by making use of reconstituted motility experiments. However, 
with the rapid progress in proteomic tools, the analysis of whole proteomes of 
certain organelles via mass-spectrometry adds an additional facet. Over the past 
years a number of pivotal factors involved in melanosome transport could be 
elucidated 63,68,73,75,104,131,132,248,249 (for reviews, see also 70,72,94,250,251,252,253,254). As 
a next step, it would be important to unravel the regulation of those factors on the 
melanosome, for which a proteomic “bottom-up” approach might bear a great 
potential.  
To date only two studies from the same laboratory used the bottom-up approach 
to analyze the melanosome and its associated proteome via (conventional) mass-
spectrometry 125,126. Those studies were performed on human melanoma (MNT-1) 
cells, but as yet a similar approach has not been applied to the otherwise very 
well studied pigment cells from Xenopus l.  
Due to its high sensitivity 255, mass-spectrometry allows to identify many proteins 
while requiring only very small amounts of protein. However, the sensitivity of 
proteomics goes along with the demand for pure protein samples. In the two 
studies mentioned, sample purity was achieved by applying sucrose density 
gradient centrifugation (DC)125,126, which primarily has found usage for the 
purification of other organelles (e.g., mitochondria)127,128,129,130. An often-
encountered problem with DC-based organelle purification is, however, that the 
organelle’s functionality is harmed or that only incomplete proteome fractions are 
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retained and purified 256, thus making the subsequent analysis prone to 
misinterpretation. 
In this part of the work I focused on establishing a novel method by which 
functionally intact but at the same time also pure organelle fractions are obtained. 
To reach this ultimate goal, two rather unrelated techniques were combined here. 
The first is the conventional and established melanosome isolation protocol 65,249, 
which in the past has been successfully utilized for numerous in vitro 
melanosome motility studies 65,74. Due to two low-speed centrifugation steps, this 
method results in gently handled (important for functionality) but quite crudely 
isolated melanosome fractions with many cellular contaminants. Therefore, as an 
additional purification step the likewise gentle and highly specific MACS® 
(magnetic activated cell sorting)-technology was applied. MACS is based on the 
magnetic sorting of surface-marked particles and most commonly is used to sort a 
certain cell type or population depending on its specific surface-marker 
composition 257. By combining both these techniques, neither harsh centrifugation 
steps nor contaminating additives (e.g., sucrose, percoll etc.) are being used. 
6.3.1 Efficiency of MACS-based melanosome isolation 
To assess the efficiency of this novel melanosome purification technique, the 
post-MACS fraction was compared to melanosome probes that had been purified 
either by DC or crude isolation (no additional purification). As illustrated in Figure 
49 all three techniques resulted in the removal of virtually all protein bands 
detected via Coomassie-stained SDS-PAGE. 
The analysis by tandem mass-spectrometry revealed that for fractions that had 
not been further purified (i.e., Melcrude, Figure 49), a relatively long list of proteins 
with significant hit -scores was identified. However, the great majority of those 
proteins belonged to the family of elongation factors, ribosomal proteins, and 
cytoskeletal proteins (actin, tubulin and members of the intermediate filament 
proteins). Mitochondrial proteins as well as mitochondrial precursors were among 
those proteins identified with the highest score (for a complete list of protein hits, 
refer to Section 7). The presence of mitochondria-derived proteins is most likely 
due to the fact that mitochondria are highly similar to melanosomes in terms of 
size and density and thus hard to separate from melanosomes by the two-step 
centrifugation procedure. Taken together, this particular purification procedure 
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fails to eliminate the cytosolic factors, which seem to overwhelm the 
melanosome-derived peptide signals (personal communication with mass-
spectrometry core facility). 
When melanosomes were further purified by DC, a larger fraction matched those 
proteins that were proposed to belong to the melanosome proteome 125,126 (color-
coded in the listing of mass-spectrometry results, Section 7). This result implies 
that, even though the majority of cytoplasmic contaminants remain present in the 
probe, the proportion of contaminants was reduced, enabling the detection of the 
less abundant melanosome-associated components (color-coded in respective 
list of protein hits, Section 7). However, a fair number of proteins that do not 
belong to the melanosome-associated group of proteins (e.g., elongation factors, 
ribosomal and mitochondrial proteins), are also listed in the studies by Basrur et 
al. and Chi et al 125,126. 
Compared to the crude isolation procedure, in DC a 50 times higher centrifugation 
force is applied to the probe, leading to the detachment or disruption of parts of 
the melanosome-associated transport machinery most likely due to the high 
shear-forces applied on the organelle 256. In fact, DC-purified melanosomes never 
displayed any movement in in vitro reconstitution motility assays. To conclude, 
even though DC yields improved results in terms of eliminating cytosolic 
contaminants, the method is not well suited to identify motility-related factors on 
melanosomes. 
Although in the past DC has been used for the purification of blood or immune 
cells, specific membrane fractions, or organelles such as mitochondria 
128,129,130,258,259, two major disadvantages come along with this method: i) it is a 
time-consuming method for which access to an ultra-centrifuge is required; and ii) 
contaminations of the sample by sucrose are not unlikely and may interfere with 
subsequent mass-spectrometric analysis. Even though by additional purification 
steps such contaminations could be removed further losses of the limited sample 
material might ensue. 
By contrast, MACS purification is less time-consuming and omits any harsh 
centrifugation steps. The MACS method takes advantage of the fact that the 
antibody-antigen bond is among the strongest non-covalent bonds in biology 
260,261. With Trp1 a melanosome-specific surface marker was chosen to further 
enhance binding specificity. Removal of unspecifically bound material was 
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ensured by multiple washes in large volumes of buffer, so that aggregation 
became less likely. 
Western-blot analysis of each step during the isolation/purification procedure 
showed that the three target proteins herein assayed (β-tubulin, GAPDH and 
Myosin V) turned up in high and comparable amounts in both, the lysate 
(membranes, cytoplasmic and nuclear proteins, melanosomes) as well as in the 
SN 3000 (cytoplasmic proteins only) fraction (Figure 50). This finding was not 
surprising because for GAPDH and β-tubulin, as abundant cytoplasmic proteins 
172, the cell extract as well as the cytoplasmic fraction are expected to contain 
both of these marker proteins. Myosin Va, constituting the prototypical actin-
based cargo transporter protein, is detected in high amounts in both, the lysate 
and the SN 3000 fraction. In the crude fraction (i.e., no additional purification by 
MACS), clearly less Myosin Va is present, implying that in the second 
centrifugation step (3,000 × g) most of the cytoplasmic (non-melanosome-
associated) Myosin Va was successfully depleted (Figure 50). However, with β-
tubulin, as the second marker protein and representing the cytsokeletal protein 
fraction in the cell, in Figure 50 evidence is provided that without further purification 
still contaminations by this protein (and most likely other abundant proteins) takes 
place. The more striking is the fact that for those samples that underwent 
additional purification by MACS, the usually omnipresent β-tubulin fraction was 
removed, while the Myosin Va fraction remained associated with the probe. The 
fact that only about 20% (quantification not included) of the detected Myosin Va in 
the crude fraction got lost during the purification by MACS while the abundant β-
tubulin could be removed (Figure 50), demonstrates the specificity and efficiency of 
the here introduced technique. It furthermore shows that in addition to the 
commonly used GAPDH, other likewise abundant protein markers should be 
included to show the purity of an organelle preparation by immunoblotting. These 
include Golgin97, KDEL, Rab4, lamins A and C or β-actin, representing markers 
of the Golgi apparatus, endoplasmic reticulum, endosomes, nucleus and 
cytoskeleton, respectively. 
The efficiency in immuno-labeling melanosomes by using the melanosome-
specific surface marker Trp1 was determined by FACS (fluorescent activation cell 
sorting) analysis, a commonly used tool in the field of immunology. To my 
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knowledge, FACS has never before been performed on melanosomes before, so 
that in addition to testing the melanosome-specific transmembrane protein Trp1, 
Kinesin-2 as a known surface-bound (but not membrane-integrated) protein was 
selected as a test-candidate (Figure 51 A and B). Regardless of the surface marker 
tested (Trp1 or Kinesin-2), the FACS analysis showed clear detection-specificity 
for melanosomes containing either one of those markers (Figure 51). First and 
foremost, this underlines the functionality and integrity of the here presented 
MACS bead-assisted melanosome purification via the surface marker protein 
Trp1. And secondly, with the performed FACS analysis clear evidence is provided 
that even Kinesin-2 would be a highly sensitive marker and thus could be used for 
melanosome purification via MACS.  
6.3.2 Summary and Outlook 
The herein presented MACS-bead-assisted melanosome purification not only 
fulfills all the required needs for a functional but still pure isolation, it also 
represents a technique that is very flexible and can be adapted to any specific 
needs. For instance, besides targeting exclusively those antigens/surface 
markers that are known to be stably associated with the melanosome, marker 
proteins known to be associated with melanosomes only under certain conditions 
or at specific cellular stages, could be used. This additional aspect of condition-
specific melanosome sorting would significantly add to the initially intended goal 
of simply purifying the otherwise crudely isolated melanosomes. It also holds the 
promise of answering yet unaddressed questions, whether during melanosome 
aggregation and dispersion certain proteins are transiently recruited or released 
to and from the melanosome surface. Furthermore, cell state-specific markers 
could easily be used to select for only those organelles that actually derive from 
the one or the other state. 
Though final in vitro motility experiments will be required for proving full 
functionality of MACS-purified melanosomes, the here presented biochemical 
analysis demonstrates, that this methodology marks a significant progress in 
obtaining purer melanosome fractions while remaining functional, as suggested 
by the retained presence of motor proteins. 
By using FACS in combination with the MACS-based melanosome purification, it 
becomes possible to analyze and compare individual purifications from 
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consecutive stages. The fact that per FACS-analysis typically 10,000 to 12,000 
particles (in this context, organelles) are analyzed, allows for robust quantitative 
statistical analyses. By searching for additional and new surface markers, 
perhaps an even better antigen-antibody combination can be identified, by which 
even higher amounts of MACS-purified melanosomes will be yielded. 
The major advantages of the here presented MACS-based melanosome 
purification are: i) no additional centrifugation steps are required; ii) the technique 
is less time-consuming and easier to perform than the conventional purification by 
DC; and iii) it omits further application of shear-forces on the applied probe. Most 
importantly, the quality of the purified melanosome probe can be monitored by 
FACS analysis. 
 
6.4 Determining the full-length sequence of Xenopus l. Myosin Va 
6.4.1 Comparative sequence-analysis 
The deduced amino acid sequence of the here determined coding sequence of 
the full-length Xenopus l. Myosin Va altogether shows strong homology to the 
three Myosin Va sequences (chicken, mouse and human). However, certain parts 
such as the loop 2 region (head domain), neck domain and portions of the 
proximal tail displayed more divergence than others (for the complete alignment, 
refer to Section 7). The homology of the functionally and structurally important 
regions infers that the secondary structure of the protein is most likely conserved, 
while the amino acid usage in the Xenopus l. version is different, as has been 
described previously for other proteins 173. 
Interestingly, with four instead of five net positive charges, loop 2 of Xenopus l. 
Myosin Va, carries one positive net charge less than the three other myosins 
assayed (Figure 59). In addition, the sequence length of the Xenopus l. Myosin Va 
loop 2 with 46 amino acids is one residue longer than the loop 2 of chicken, 
mouse and human Myosin Va. In previous studies, it has been shown that the 
number of positive net charges on loop 2 positively correlates with the exhibited 
actin-binding affinity during the initial filament encounter 24,111,183,184. In addition, 
loop 2 is known to interlink the initial actin binding to subequent phosphate 
release. This in turn initiates the strong-binding state upon which the rate-limiting 
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ADP-release step occurs 24,33,111,183,184. In this respect, the lower positive net-
charge on loop 2 of Xenopus l. Myosin V, might affect its behavior on F-actin. 
Previous studies on Myosin V mutants showed that a less positively charged loop 
2 results in decreased ATPase activity 35,44. Decreased ATPase activity typically 
also leads to decreased speed in motility, as it takes the myosin longer to 
complete the mechano-kinetical cycle. So far only addressed by a number of 
preliminary motility studies, the here described full-length Myosin Va protein 
indeed showed slightly lower velocities on F-actin compared to the three 
homologous Myosin V species 35,38,43,45,48,167,179,262.  
The neck domain (or lever arm) is an extended helix that fulfills regulatory as well 
as structurally important functions. It contains six of the so-called IQ motifs that 
preferentially bind calmodulin or calmodulin-like light chains 34,166,263. Even though 
the IQ motif as such is conserved, compared to the head domain it (in particular 
IQ motifs #3, #4 and #5) displays more divergence (77.4 % identity) (Figure 60). At 
this point still speculative but nevertheless also likely is the notion that Myosin Va 
from different species might employ different regulatory conditions such as for 
instance Ca2+ concentrations 264,265,266. Therefore, by keeping the consensus motif 
(IQxxxRGxxxRxxY) similar, the neck domain primarily ensures the Ca2+-
dependent binding of those light chains. However, the binding affinity depends on 
the cellular environment of the respective Myosin V and therefore might be 
subject to fine-tuning for cell-specific functions by the described sequence 
diversity. 
The divergence that was observed for the proximal tail domain (#915-1320 of 
complete alignment in Section 7) encompasses both, the first and second coiled-
coil region. Both coiled-coil domains, as part of the stalk-like structure, are 
required for the efficient dimerization of the molecule 34,263,264. Interestingly, this 
portion shares only 60% identity, while most of it is accounted by the stretch that 
follows the last IQ repeat (up to position #1064). A similar observation was made 
in a study dealing with the analysis of the Squid Myosin Va 173, implying that this 
portion of the primary protein sequence allows for more sequence variability. This 
variability most likely is due to the fact that coiled-coil motifs represent α-helical 
segments that via heptad-repeats mediate exclusively dimerization 265,267,268. 
Therefore, unlike the ATP- or actin-binding site, a coiled-coil motif does not 
constitute a site that is to be recognized by a specific tertiary structure of another 
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protein or chemical and thus allows for higher variability in between the crucial 
heptad-repeats. 
By contrast, the so-called PEST site (Figure 61), which in class V myosins 
separates the first two coiled-coil regions from each other 34,267, shows high 
conservation among the four species. Mainly this is because it serves as 
recognition sequence for the endoprotease Calpain, which is known to cleave 
Myosin Va at this site in vitro 34,267. Furthermore, the PEST-site has been 
suggested to function as a means of specific regulation by proteolytic-based 
depleting of the Myosin V on neuronal vesicles 269,270. Thus the PEST-site would 
be expected of being subject to strong sequence conservation. 
In contrast to the rather divergent proximal tail domain (for the complete 
alignment, refer to Section 7), the first 60 amino acid residues of the distal tail 
portion show high sequence identity (90%) for all four Myosin V sequences. Along 
with chicken, the Xenopus l. Myosin Va lacks a stretch of 25 amino acids just 
before the beginning of coiled-coil #3, while both the mammalian sequences 
contain this exact portion (Figure 62). Interestingly, towards the end of the 
otherwise very conserved coiled-coil #3, at position # 1385, the Xenopus l. 
sequence is characterized by a unique insertion of 25 amino acids (Figure 62). 
With 99 amino acids in length, the coiled-coil #3 portion from Xenopus l. is 
significantly longer than the third coiled-coil of mouse, human and chicken Myosin 
Va. In addition, due to this insertion, the Xenopus l. construct is predicted to form 
a coiled-coil only upto residue #1361 while continuing as rather unstructured 
helical region to the end of the described sequence (for the complete alignment, 
refer to Section 7). In line with this, more recently it has been proposed that the 
elongation of a given coiled-coil sequence can as well lead to destabilization, 
rather than hydrophobic density-mediated stabilization of the structure 265. 
The distal tail portion, at large is constituted of the globular tail domain (GTD or 
cargo binding domain) and is a distinct feature of the class V myosins. Being used 
primarily for the binding to cargo molecules such as vesicles, mRNA, ER to name 
a few, the functions of the GTD overlap across all the Myosin Va from different 
species and/or different cell types. This and the fact that GTD-mediated cargo-
binding of any sort preferentially occurs via the tripartite adaptor complex Myosin 
Va-Melanophilin-Rab27a (reviewed in 34,263), accounts most likely for the 
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observed strong conservation of the distal tail portion across the four Myosin Va 
sequences. 
6.4.2 Expression and purification of full-length Xenopus l. Myosin Va 
In addition to determining the complete full-length sequence of the Xenopus l. 
Myosin Va, as is shown in Section 5.4.2.3 of this work, the full-length protein (size 
of dimer: 434 kDa) was successfully expressed and FLAG-affinity purified. At this 
point, typically concentrations of approx. 0.3 mg/ml in considerably large final 
volumes (i.e., greater 500 µl) of dialyzed (i.e., zero ATP) full-length protein are 
obtained (Figure 65). To set the basis for increased protein yields, baculovirus-
titers as well as the amount of cells to be infected have been scaled up. The initial 
problem of having had lost large amounts of protein after the FLAG-affinity 
column, was solved by performing an additional incubation round with fresh anti-
FLAG agarose. Thereby at least twice as high protein concentrations were 
obtained. Also, by using higher concentrations of FLAG-peptides during the 
elution, along with three to five successive elution cycles, protein yield was 
significantly increased. Most importantly, by simply prolonging the time period 
after the infection with baculovirus and prior cell harvesting to at least 75 hours, a 
significant increase in protein yield was achieved. This way over-expression of the 
full-length protein could be improved, while keeping protein degradation at similar 
levels as before. 
Besides yield, purity of the overexpressed protein is usually an issue. Here, 
relative to the increased yield in full-length protein, protein degradation was 
slightly reduced by omitting any detergent during the process of breaking up the 
cells. In turn, to still obtain high cell-lysis yields, sonication instead of glass 
dounce-homogenization was used to break up the cells.  
As shown in Figure 64, the prominent bands running at lower sizes than the full-
length protein band, via mass-spectrometry were confirmed to be truncation 
products of the purified full-length protein (Table 31) and thus most likely represent 
degradation products. Except for the band at approx. 125 kDa (C’FLAG-tagged 
version only), all the appearing bands were observed for both, the N’ and 
C’FLAG-tagged version of the full-length Myosin Va. This implies that the large 
majority of the “by-products” resolved via SDS-PAGE, are missing most likely 
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parts somewhere between the N- and C-terminal domain, rather than missing the 
N- or C-terminus itself. 
In general, for Myosin Va being a large (217 kDa per heavy chain), complex 
(dimer-forming molecule with light chains bound to the neck domain) protein that 
in addition contains proteolysis-sensitive recognition motifs (e.g., PEST site), the 
half life is expected to be rather short mainly due to intracellular degradation 
267,271,272. Even though not of immediate interest, to investigate the nature of the 
observed degradation, several approaches could be undertaken. For instance, 
one could perform western-blot analyses against certain regions of the protein to 
thereby localize the approximate regions of preferred degradation. Subsequently, 
further analyses involving mass-spectrometry or N-terminal Edman-sequencing 
273 in combination with 2D-SDS-gel electrophoresis could be carried out. 
In addition to further up-scaling the protein yield, the next and most important step 
will involve the further purification by either size-exclusion or ion-exchange 
chromatography FPLC (Fast Performance Liquid Chromatography). By the fact 
that with approx. 140 kDa the largest prominent degradation product runs almost 
80 kDa lower than the full-length protein (217 kDa), size-exclusion 
chromatography will most likely serve the purpose. FPLC in combination with 
MALS (multi-angle light scattering) will be required to confirm the efficiency in 
homo-dimerization of the heavy chains of the full-length Myosin Va. 
6.4.3 In vitro motility of full-length Xenopus l. Myosin Va 
In this work initial motility assays were carried out to determine the functional 
behavior of the full-length Xenopus l. Myosin Va on F-actin in vitro. 
In gliding-filament assays, immediate binding-down of actin filaments by both the 
N’ and C’FLAG-tagged full-length Myosin Va, was observed (Figure 66 A and 
Figure 67 A, Videos 9 and 12). In agreement with previous work, the initial weak 
binding to F-actin is an ATP-independent process 112,181,182. For both the versions 
no noteworthy difference in their capability to bind to F-actin was observed, 
indicating that neither the N- nor the C-terminal FLAG-tag seem to impact on the 
actin-binding capacity of the respective construct. Studies using recombinant 
HMM-like Myosin Va protein constructs (i.e., lacking most of the tail portion; for 
details, see also Section 5.1.1.1) have revealed that both C’ and N’FLAG-tagged 
HMM-like Myosin V constructs are likewise proficient in binding to F-actin 110,189. 
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In contrast, upon addition of 2 mM ATP, a major difference in the gliding behavior 
of the two FLAG-versions was displayed. While for the N’FLAG-tagged version 
nearly all before rigor-bound filaments showed long-range gliding motility (Figure 
67 B and C, Videos 10 and 11), for the C’FLAG-tagged construct only very few of 
the bound filaments showed directed and smooth gliding movements (Figure 66 B, 
Video 9). This observation was made repeatedly with independent batches of 
protein purifications, and including probes from simultaneously purified N’ and 
C’FLAG-tagged constructs using the same protocol and buffer components. Thus, 
the high fraction of non-motile C’FLAG-tagged Myosin Va molecules is highly 
unlikely due to erroneous protein purification. The FLAG-tag at the C’FLAG-
tagged Myosin Va seems to affect the regions responsible for the actual ATPase 
or/and power-stroke activity but not actin binding (Figure 66). 
Further support for this notion comes from the finding that the N’FLAG-tagged 
Myosin Va at high concentrations is capable of fully disintegrating the long actin 
filaments (compare Figure 67 A and B, Videos 10 and 12) upon the addition of 
ATP, while for the C’FLAG-tagged construct such observation could not be made 
(Figure 66 A, Video 9). The here described filament-rupturing showed clear ATP-
dependence, which disproves the possibility of accidently co-purified gelsolin or 
severin being responsible for this observation, as both proteins sever F-actin in an 
ATP-independent manner 274,275. 
With 70 individual gliding events obtained from the N’FLAG-tagged Myosin Va the 
first biophysical characterization of this motor species was performed (Figure 68 
and Table 32). Smooth and continuous filament gliding was determined to take 
place for on average 31.4 seconds, while covering an average distance of nearly 
4 µm. The average single gliding-filament velocity as determined from the 
obtained Gaussian-fit function was 131.2 nm s-1 (Figure 68 and Table 32). This 
value is highly similar to what Wu et al. reported for the in vivo Myosin Va-driven 
melanosome transport (140 nm s-1) 106,174. 
As shown in Figure 69 (and Video 13), by reducing the amount of surface-adhered 
motor protein, single-point attachments of actin filaments via the involvement of 
single Myosin Va molecules were achieved. Now on single-molecular level, this 
finding underlines even more the notion that an individual Xenopus l. Myosin Va 
motor is capable of transporting actin filaments in a processive manner.  
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In the initial single-molecule motility assays, with N’FLAG-tagged Xenopus l. 
Myosin Va attached to the glass surface, only infrequent but unambiguous 
walking events lasting three seconds or longer could be acquired. This behavior is 
most likely attributed to the fact that under the here assayed conditions (i.e., no 
Ca2+) the full-length Xenopus l. Myosin Va resides in an inactive though actin-
bound state. 
This assumption is based on results from studies, where at low Ca2+ 
concentrations for the full-length Myosin Va from mouse virtually no activity has 
been observed 54,178,276. Further studies involving analytical ultracentrifugation 
provided first evidence that at low Ca2+ concentrations the full-length Myosin Va 
adopts a rather compact structure 21, whereas at high Ca2+ concentrations this 
structure becomes less compact 53,266. Via advanced techniques in the 3D-
reconstruction of EM negative-stain and tomographical images, Liu et al. 
confirmed that the inhibited (i.e., without calcium) full-length Myosin Va from 
mouse adopts a compact triangular-like shape 55. In this state, the two lever arms 
along with the motor domains fold onto lobes of the cargo-binding domain (CBD). 
Thereby the molecule’s ATPase activity becomes basically abrogated, while 
actin-binding remains unaffected 55. 
In line with this, for the here assayed full-length Xenopus l. Myosin Va, actin 
binding was by no means affected and therefore over time increasing numbers of 
single Myosin Va molecules could be observed binding to the immobilized F-actin 
(Figure 70 A and B, Videos 14 and 15). Furthermore, when bound to an actin 
filament the lever arm of the inhibited full-length Myosin Va was reported to adopt 
the post-power-stroke conformation, inferring that inhibited Myosin Va resides in a 
strongly-bound state on the actin filament 55. This fits the herein obtained 
observation that once bound to actin, the actin-bound full-length Xenopus l. 
Myosin Va molecules remained stationary and hardly ever detached (Videos 14 
and 15). The same observation was made in the very recent study by Armstrong, 
et al. 179. 
In this very same study, the authors showed that in vitro a small fraction of full-
length (mouse) Myosin Va turns infrequently active before it becomes again 
switched off via the previously shown head-tail interaction 277. The authors argue 
that in cases where the full-length Myosin Va is assayed under low ionic strength 
(50 mM or lower) conditions without tail-bound cargo, the equilibrium between the 
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closed (i.e., inactive) and open (i.e., active) conformation is shifted towards the 
closed state 179. It was further proposed that this equilibrium can be shifted 
towards the unfolded, non-inhibited state when elevating the salt concentration in 
the assay to 150-200 mM. 
However, such putative unfolding was not observed with the full-length Xenopus l. 
Myosin Va at 150 mM final salt concentration (Figure 71 A and B, Video 16). Based 
on studies dealing with the regulation of chicken and mouse Myosin V 54,278, it is 
fairly likely that the Xenopus l. Myosin Va for instance exhibits a yet unknown light 
chain-binding behavior and thus for its re-activation would require more than just 
an increase in ionic strength.  
Interestingly, it has been shown that cargo-binding domain (CBD)-lacking HMM-
like Myosin V exhibits high ATPase activity independent of the Ca2+ concentration 
that is present 51,279. It was therefore speculated that the CBD might play an 
essential role for the regulation of Myosin V. While previous ATPase activity 
studies demonstrated that high Ca2+ concentrations or high ionic strength leads to 
the re-activation of inhibited full-length Myosin V 52, for full-length Myosin Va it has 
not yet been shown that cargo-binding to the CBD indeed unfolds and thereby 
activates the auto-inhibited Myosin Va. However, due to the fact that kinesin 
motors show a highly similar inactivation pattern and are known to be re-activated 
upon cargo-binding 280, it is conceivable that receptor-specific cargo binding 
would compete with and disrupt the intramolecular interaction between the CBD 
and motor domain 55. 
To assay whether unfolding of the full-length Myosin Va would be achieved via 
attaching an artificial cargo (e.g., QDot), in this work the C’FLAG-tagged full-
length Myosin Va version was targeted for tail-specific QDot-labeling (Figure 72). 
This idea based on previous studies, where for the purpose of optical trap assays 
full-length (chicken) Myosin Va was attached to polystyrene beads and was 
thereby was forced to unfold 38. While the applied conditions resulted in the 
efficient labeling of full-length Xenopus l. Myosin Va with QDots, unfortunately no 
movement but instead only stationary actin-bound Qdots could be observed. This 
observation could be explained by at least two reasons: One, the potential 
improper protein integrity of the C’FLAG-tagged construct (as earlier no filament-
gliding motility was observed, discussed above); or two, the here performed 
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QDot-Myosin conjugation was simply not proficient in unfolding the auto-inhibited 
motor protein. 
Therefore, further experiments will be required to pinpoint the walking behavior of 
individual full-length Xenopus l. Myosin Va molecules on F-actin. 
6.4.4 Summary and Outlook 
In this work, the complete coding sequence of the full-length Myosin Va from 
Xenopus l. was determined. On protein level, the primary sequence shows high 
similarity to Myosin Va from other species. Besides a less positively charged loop 
2 sequence, the Xenopus l. Myosin Va sequence has an extended third coiled-
coil region, that is unique among the four species herein compared. Similar to 
what has been reported for Myosin Va sequences from other species, the highest 
divergence was observed within the proximal tail region, while the head and distal 
tail domain (contains the cargo-binding domain) constitute the most conserved 
domains as expected.  
In addition to the described successful sequence retrieval, in this work the 
expression and subsequent purification of this large and complex protein was 
achieved. However, due to the large size (217 kDa), its complexity and potential 
degradation sites (e.g., PEST site) of the full-length Myosin Va, instant 
degradation of the over-expressed protein still poses a problem. The optimized 
protein expression, will now allow further purification of the full-length protein by 
native size-exclusion chromatography. Along with the enriched full-length protein 
the dimerization-state can now be determined via MALS. 
Herein performed in vitro gliding-filament motility assays revealed the unperturbed 
movement of the N’FLAG-tagged full-length Myosin Va version, while exhibiting 
velocities similar to those reported for Myosin Va-driven melanosome transport 
inside cells 106. Initial experiments provided evidence that single full-length Myosin 
Va molecules can be visualized either by Cy3-conjugated anti-FLAG antibody or 
by Quantum dot labeling. However, up to this point only very few single-molecule 
walking events could be recorded, most likely due to auto-inhibition of the full-
length protein, as has been previously reported for the full-length Myosin Va from 
mouse and chicken 21,50,51,52,53,266,276. Further experiments will be required to find 
experimental conditions under which the auto-inhibited full-length Myosin Va can 
be re-activated into a constitutively active motor protein. For this, not only the 
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efficiency in fluorescent single-molecule labeling but also adaptation of the 
optimal ionic strength and Ca2+ concentrations will be necessary. The putative 
head-tail interaction that is proposed to mediate auto-inhibition can be disrupted 
by generating C-terminally truncated Myosin Va constructs, lacking the C-terminal 
globular tail domain 51,279. Another way to prevent auto-inhibition, would be to 
introduce a stretch of amino acids (e.g., glutamic acids) that make the molecule 
inapt of folding back and thus would turn it intrinsically active 179,281, while 
retaining the globular tail domain. In vivo, cargo-binding to the CBD of Myosin Va 
occurs via recruiting the tripartite adaptor protein complex 
melanophilin:Rab27a:Myosin Va 57,58,59,92. However, presently melanophilin is the 
only confirmed cargo-receptor for Myosin Va and has been shown to be capable 
of markedly increasing ATPase activity of the auto-inhibited full-length mouse 
Myosin Va 279. For this reason, currently I have been over-expressing 
recombinant FLAG-tagged melanophilin, to then assess whether auto-inhibited 
full-length Xenopus l. Myosin Va can be re-activated in vitro. 
Once re-activation is successful, the in vitro behavior of the here introduced and 
described motor protein will be compared and correlated to the well studied 
intracellular Myosin Va-driven transport behavior on F-actin inside Xenopus l. 
melanophores. 
While for the auto-inhibited form of the full-length chicken Myosin Va electron-
microscopy deduced high-resolution structures have been useful in providing 
useful insights, for the open unfolded full-length version, via x-ray crystallography 
only parts (head, neck and globular tail domain) of the full-length Myosin Va were 
successfully resolved 192,282,283,284,285. With this gap of structural knowledge, any 
descent structure-prediction via the currently available software remains 
impossible, leaving the field with an incomplete view of this (not only in pigment 
cells) important molecular transporter. Now that the full-length Myosin Va from 
Xenopus l. can be expressed and purified as recombinant protein, in the future it 
should be focused on also obtaining the extended non-inhibited structure of the 
full-length Myosin Va by either (cryo) electron microscopy. 
How exactly does the previously reported tail-phosphorylation of the full-length 
Myosin Va regulate Myosin V-driven transport in Xenopus l. melanophores? As 
this question has still remained poorly answered, rather than using a short tail 
construct from mouse 88,103,106,286, with the now available Xenopus-specific tail 
Discussion 
________________________________________________________ 
 202 
domain the specific phosphorylation sites of e.g., PKA and CaMKII-α can now be 
investigated biochemically in vitro 121,287. Furthermore, with the purified full-length 
protein it will be possible to study the interaction of those but also other kinases or 
phosphatases as well as other proposed Myosin V-interacting and adaptor 
proteins (e.g., melanophilin) in vitro. 
At last with the here provided full-length sequence of the Xenopus l. Myosin Va, a 
tail construct similar to the short-tail construct from mouse, can be generated and 
used for dominant-negative over-expression in Xenopus l. melanophores. This 
way for the first time it would be possible to study Myosin Va’s role during 
intracellular cargo transport in a species-specific background. Based on the here 
determined sequence of the full-length Xenopus l. Myosin Va, it now has become 
possible to generate specific Myosin Va mutants, by which sequence-specific 
and/or structural clues regarding the Myosin Va-driven cargo transport inside 
melanophores can then be elucidated in vivo. 
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7 Supporting Information 
7.1 Maps of baculovirus transfer vectors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vector map and features of p2bac/pfastbac baculovirus transfer vector. 
The two promoters (poly H and p10, dark blue) of this vector allow for simultaneous 
overexpression of two different proteins encoded on the same plasmid. The expression 
cassette is flanked by the left (L) and right (R) arms of Tn7, which are mini Tn7 elements that 
permit site-specific transposition of the gene of interest into the baculovirus genome (green). 
The antibiotic resistance genes encoding for ampicillin and gentamicin are also depicted (light 
red). This vector was used for the overexpression of HMM-like Myosin V loop 2 constructs in 
insect cells. While the gene encoding for myosin was cloned under the control of p10, the 
calmodulin gene was cloned under the control of poly H. Courtesy of J. Spudich (Stanford 
University, Stanford, U.S.A.). 
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Vector map and features of pFastBac™ 
Dual baculovirus transfer vector. 
As for the p2bac/pfastbac vector, with the 
polyhedrin (here PH) and p10 promoters the 
pFastBac Dual vector (Invitrogen) contains 
the same two promoters, allowing for 
simultaneous overexpresssion of two 
different proteins encoded by the same 
vector. Except for the multiple cloning sites 
of each of the two promoters, antibiotic 
resistance genes as well as left and right 
Tn7 transposons are the same as for the 
p2bac/pfastbac vector. This vector was used 
for the overexpression of the N’ and 
C’FLAG-tagged full-length Xenopus l. 
Myosin Va (loned under the control of p10). 
Vector map adapted from Invitrogen™ life 
technologies (Grand Island, U.S.A.). 
Vector map and features of pFastBac™ 1 
baculovirus transfer vector. 
This vector was used to overexpress N’ and 
C’FLAG-tagged CaMKII-α as well as 
calmodulin. While pFastBac 1 encodes for 
the same antibiotic resistances (ampicillin 
and gentamicin) as the p2bac/pfastbac or 
pFastBac Dual vectors, it contains only one 
promoter (PH) and expression cassette. 
Vector map adapted from Invitrogen™ life 
technologies (Grand Island, U.S.A.). 
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7.2 Mass-spectrometry on crudely isolated melanosomes and 
melanosomes purified by density gradient ultra-
centrifugation 
Tables 1 and 2: Samples of crudely isolated melanosomes (Table 1) as well as of 
melanosomes that had been further purified by density gradient ultra-
centrifugation (DC, Table 2) were resolved on a 12% SDS polyacryl amide gel 
(Section 5.3.1.1). Following the standard trypsin in-gel digestion, the protein 
samples were subjected to Nanospray-LC tandem mass-spectrometry (for more 
details, refer to Section 4.3.1.2). All identified proteins that gave significant 
spectra-deduced protein hits (i.e., above unspecific spectra background) are 
listed according to their respective protein search scores (from high to low, sixth 
column from left). Protein scores derived from ions scores as a non-probabilistic 
basis for ranking protein hits. Ions scores refer to -10*Log(p), where p is the 
probability that the observed match is a random event. The Mascot protein search 
was conducted using protein sequence libraries from Xenopus l. In those cases, 
where peptide matches were obtained but the given protein has not yet been 
annotated, a subsequent species-independent BLAST search was performed 
(forth column from left). In addition, all proteins here identified are annotated to 
the respective protein group to which they belong (fifth column from left). The 
bioinformatical analysis was carried out by the Zentrum für Proteinanalytik (ZfP, 
LMU, Munich, Germany). The herein identified proteins were compared to two 
studies that applied proteomics on melanosomes from human melanoma cells. 
Green and yellow shading: indicates consistency with proteins identified by 
Basrur et al. 125  (green) and/or Chi et al. 126 (yellow). 
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7.2.1 Table 1: Crudely isolated melanosomes 
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7.2.2 Table 2: DC-purified melanosomes 
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Designated protein categories 
14-3-3 Pr Members of the 14-3-3 protein family 
Actin Actin isoforms 
Actin-BP Actin-binding proteins 
AKAP A-kinase anchoring proteins 
Chaperone Chaperone-related proteins 
Chromatin Chromatin-binding proteins 
Cytoplasmic Pr Abundant proteins that predominantly localize to the 
cytoplasm 
DNA-BP DNA-binding proteins 
Endo Pr Endosomal proteins 
ER Pr Proteins that primarily localize to the endoplasmatic reticulum 
GA Pr Golgi-apparatus related proteins 
GF Members of the growth-factor family 
Histone Histone (or histone-associated) proteins 
Housekeeping Members of the housekeeping protein family  
IF Pr Intermediate filament proteins 
Lyso+LRP Lysosomes and lysosome-related proteins 
Mel Melanosome (-associated) proteins 
Mito Pr Mitochondrial (or mitochondria-associated) proteins 
Myosin Proteins of the myosin superfamily 
Nucelar Pr Proteins that primarily localize to the nucleus 
PLipid-BP Phospholipid-binding proteins 
Rab family Proteins of the Rab family 
Rho-BP Rho-binding proteins 
Ribo Pr Ribosomal (or ribosome-associated) proteins 
RNA-BP RNA-binding proteins 
TM-Pr Transmembrane Receptor proteins 
Tr IF Translation initiation factor proteins 
Tubulin Tubulin isoforms 
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7.3 Comparative sequence alignment of full-length Myosin Va 
from Xenopus l. with other vertebrate class V myosins 
The here determined full-length Myosin Va from Xenopus laevis was aligned with 
the class V myosins from chicken (Gallus gallus, accession number: NP_990631), 
mouse (Mus musculus, accession number: CAX15576.1) and human (Homo 
sapiens, accession number: NP_000250.3). The conserved motifs and/or regions 
of interest in the head, neck and tail domain are labeled and color coded. The 
sequence aligment was performed using Megalign 2.1.0.97 (DNAStar) and the 
blosum62 amino acid table. The classification of the structural relevant motifs was 
adapted from Espreafico et al. (1992) and Larson et al. (1996) 288,289 as follows. 
Head domain (aa1-775, maroon color): ATP binding site (aa167-177), Loop 1 
(aa193-203), Actin-binding region (aa505-532), Loop 2 (aa594-639) and Loop 3 
(aa719-744). Neck domain (aa776-908, blue color): Six IQ motifs (aa776, 799, 
824, 847, 872, 895). Proximal tail domain, also referred to as rod region (aa915-
approx. 1320, light grey color): Coiled-coil 1 (aa915-1116), PEST site (aa1119-
1135) and Coiled-coil 2 (aa1142-1223). Distal tail domain (aa1321-1852, dark 
grey color): Coiled-coil 3 (aa1325-1427) and Dilute (DIL) domain, composing the 
globular domain that mediates cargo binding (aa1683-1789). The here named 
amino acid (aa) positions refer to those of the full-length Myosin Va sequence 
from Xenopus l. Conservation for a given aa among the species here tested, is 
indicated by red (identical), green (one divergence), light blue (two divergences) 
and dark blue (all four species diverge at the given aa) bars. 
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7.4 Protein sequences 
7.4.1 HMM-like Myosin Va Wildtype (Gallus gallus) 
M D Y K D D D D K G A A S E L Y T K Y A R V W I P D P E E V W K S A E L L K D Y K P G D K V L 
Q L R L E E G K D L E Y C L D P K T K E L P P L R N P D I L V G E N D L T A L S Y L H E P A V L H N 
L K V R F I D S K L I Y T Y C G I V L V A I N P Y E Q L P I Y G E D I I N A Y S G Q N M G D M D P 
H I F A V A E E A Y K Q M A R D E R N Q S I I V S G E S G A G K T V S A K Y A M R Y F A T V S G 
S A S E A N V E E K V L A S N P I M E S I G N A K T T R N D N S S R F G K Y I E I G F D K R Y R I I 
G A N M R T Y L L E K S R V V F Q A E E E R N Y H I F Y Q L C A S A A L P E F K T L R L G N A N Y 
F H Y T K Q G G S P V I D G I D D A K E M V N T R Q A C T L L G I S D S Y Q M G I F R I L A G I L 
H L G N V E F A S R D S D S C A I P P K H D P L T I F C D L M G V D Y E E M A H W L C H R K L 
A T A T E T Y I K P I S K L H A I N A R D A L A K H I Y A N L F N W I V D H V N K A L H S T V K Q H 
S F I G V L D I Y G F E T F E I N S F E Q F C I N Y A N E K L Q Q Q F N M H V F K L E Q E E Y M K 
E Q I P W T L I D F Y D N Q P C I N L I E A K M G V L D L L D E E C K M P K G S D D T W A Q K L 
Y N T H L N K C A L F E K P R L S N K A F I I K H F A D K V E Y Q C E G F L E K N K D T V Y E E Q I 
K V L K S S K K F K L L P E L F Q D E E K A I S P T S A T P S G R V P L S R T P V K P A K A R P G Q 
T S K E H K K T V G H Q F R N S L H L L M E T L N A T T P H Y V R C I K P N D F K F P F T F D E K R 
A V Q Q L R A C G V L E T I R I S A A G F P S R W T Y Q E F F S R Y R V L M K Q K D V L S D R K 
Q T C K N V L E K L I L D K D K Y Q F G K T K I F F R A G Q V A Y L E K I R A D K L R A A C I R I 
Q K T I R G W L M R K K Y M R M R R A A I T I Q R Y V R G H Q A R C Y A T F L R R T R A A I I I 
Q K F Q R M Y V V R K R Y Q C M R D A T I A L Q A L L R G Y L V R N K Y Q M M L R E H K S I I I 
Q K H V R G W L A R V H Y H R T L K A I V Y L Q C C Y R R M M A K R E L K K L K I E A R S V E R 
Y K K L H I G L E N K I M Q L Q R K V D E Q N K D Y K C L M E K L T N L E G V Y N S E T E K L R N 
D V E R L Q L S E E E A K V A T G R V L S L Q E E I A K L R K D L E Q T R S E K K S I E E R A D K Y 
K Q E T D Q L V S N L K E E N T L L K Q E K E T L N H R I V E Q A K E M T E T M E R K L V E E T K 
Q L E L D L N D E R L R Y Q N L L N E F S R L E E R Y D D L K E E M T L M L N V M K Q L E D K V E 
E L L S K N Y H L E N E V A R L K K L V G E 
Color code: FLAG   Loop 2   IQ-motifs   Rod   GCN4 
 
7.4.2 Calmodulin light chain (Drosophila melanogaster) 
M A D Q L T E E Q I A E F K E A F S L F D K D G D G T I T T K E L G T V M R S L G Q N P T E A E L 
Q D M I N E V D A D G N G T I D F P E F L T M M A R K M K D T D S E E E I R E A F R V F D K D G 
N G Y I S A A E L R H V M T N L G E K L T D E E V D E M I R E A D I D G D G Q V N Y E E F V Q 
M M T A K 
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7.4.3 Essential Light Chain (Dictyostelium discoideum) 
M S A S A D Q I Q E C F S I F D K D N D G K V S V E D I G A C L R S L G K S P T M A D I E A L K 
T E I G A K E F D I N T L K S I Y K K P N I K T P Q E Q Q K E M L D A F K A L D K E G H G T I Q G 
A E L R Q L L T T L G D Y L S T A E V D E L F K E I S V D S T T G A V S Y A S L V N T I V S G Y P E F 
R H K F Q S G F R V K R E H Y H Q F 
 
7.4.4 Calcium-/calmodulin-dependent kinase II-α (N’-FLAG-tagged) 
M D Y K D D D D K G A P A T I T C T R F T E E Y Q L F E E L G K G A F S V V R R C V K V L A G 
Q E Y A A K I I N T K K L S A R D H Q K L E R E A R I C R L L K H P N I V R L H D S I S E E G H H Y 
L I F D L V T G G E L F E D I V A R E Y Y S E A D A S H C I Q Q I L E A V L H C H Q M G V V H R 
D L K P E N L L L A S K L K G A A V K L A D F G L A I E V E G E Q Q A W F G F A G T P G Y L S P 
E V L R K D P Y G K P V D L W A C G V I L Y I L L V G Y P P F W D E D Q H R L Y Q Q I K A G A 
Y D F P S P E W D T V T P E A K D L I N K M L T I N P S K R I T A A E A L K H P W I S H R S T V A S 
C M H R Q E T V D C L K K F N A R R K L K G A I L T T M L A T R N F S G G K S G G N K K N D G 
V K E S S E S T N T T I E D E D T K V R K Q E I I K V T E Q L I E A I S N G D F E S Y T K M C D P G M 
T A F E P E A L G N L V E G L D F H R F Y F E N L W S R N S K P V H T T I L N P H I H L M G D E S 
A C I A Y I R I T Q Y L D A G G I P R T A Q S E E T R V W H R R D G K W Q I V H F H R S G A P S 
V L P H 
Color code: FLAG 
 
7.4.5 Calcium-/calmodulin-dependent kinase II-α (C’-FLAG-tagged) 
M A T I T C T R F T E E Y Q L F E E L G K G A F S V V R R C V K V L A G Q E Y A A K I I N T K K L S 
A R D H Q K L E R E A R I C R L L K H P N I V R L H D S I S E E G H H Y L I F D L V T G G E L F E D I 
V A R E Y Y S E A D A S H C I Q Q I L E A V L H C H Q M G V V H R D L K P E N L L L A S K L K G 
A A V K L A D F G L A I E V E G E Q Q A W F G F A G T P G Y L S P E V L R K D P Y G K P V D L 
W A C G V I L Y I L L V G Y P P F W D E D Q H R L Y Q Q I K A G A Y D F P S P E W D T V T P E 
A K D L I N K M L T I N P S K R I T A A E A L K H P W I S H R S T V A S C M H R Q E T V D C L K K F 
N A R R K L K G A I L T T M L A T R N F S G G K S G G N K K N D G V K E S S E S T N T T I E D E D 
T K V R K Q E I I K V T E Q L I E A I S N G D F E S Y T K M C D P G M T A F E P E A L G N L V E G 
L D F H R F Y F E N L W S R N S K P V H T T I L N P H I H L M G D E S A C I A Y I R I T Q Y L D A G 
G I P R T A Q S E E T R V W H R R D G K W Q I V H F H R S G A P S V L P H G A P D Y K D D D D 
K 
Color code: FLAG 
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7.5 Videos/DVD 
The provided DVD contains video material from single-molecule motility as well 
as filament gliding experiments of HMM-like Myosin V loop 2 mutants and the full-
length Myosin Va from Xenopus l. For details, please refer to the respective video 
legend (below and as a pdf-file on DVD). 
In addition, a copy of the publication that deals with the first part of this thesis 
(Zimmermann et al., PLoSOne, 2011)191  is attached on the provided DVD. 
7.5.1 Video Legends 
Video 1 
One-dimensional diffusion of Wildtype Myosin V on microtubules under high ionic 
strength. 
Cy3-labeled HMM-like Myosin V Wildtype (bright particles) was infused into a flow cell containing 
surface-attached Atto 488-labeled microtubules (dim filaments). Assay was performed in 100 mM 
KCl. Excitation wavelength was 532 nm and representative image sequences were false-colored. 
This movie (89 frames) was recorded at 5 frames s-1 and is displayed at three-fold speed. Scale 
bar represents 2 µm. 
 
Video 2  
One-dimensional diffusion of Wildtype Myosin V on microtubules.  
Cy3-labeled HMM-like Myosin V Wildtype (bright particles) was infused into a flow cell containing 
surface-attached Atto 488-labeled microtubules (dim filaments). Assay was performed in 25 mM 
KCl. Excitation wavelength was 532 nm and representative image sequences were false-colored. 
This movie (236 frames) was recorded at 5 frames s-1 and is displayed at three-fold speed. Scale 
bar represents 2 µm. 
 
Video 3 
One-dimensional diffusion of Minus13 Myosin V on microtubules.  
Cy3-labeled HMM-like Myosin V Minus13 (bright particles) was infused into a flow cell containing 
surface-attached Atto 488-labeled microtubules (dim filaments). Assay was performed in 25 mM 
KCl. Excitation wavelength was 532 nm and representative image sequences were false-colored. 
This movie (272 frames) was recorded at 5 frames s-1 and is displayed at three-fold speed. Scale 
bar represents 2 µm. 
 
Video 4 
One-dimensional diffusion of Wildtype Myosin V on microtubules lacking E-hooks.  
Cy3-labeled HMM-like Myosin V Wildtype (bright particles) was infused into a flow cell containing 
surface-attached Atto 488-labeled subtilisin-treated microtubules (dim filaments). Assay was 
performed in 25 mM KCl. Excitation wavelength was 532 nm and representative image sequences 
were false-colored. This movie (328 frames) was recorded at 5 frames s-1 and is displayed at 
three-fold speed. Scale bar represents 2 µm. 
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Video 5 
Negatively charged Minus4 Myosin V shows strongly impaired binding to F-actin. 
Cy3-labeled HMM-like Myosin Va Minus4 (bright particles) was infused into a flow cell containing 
surface-attached Atto-488-labeled F-actin (fuzzy filaments). Assay was performed in 25 mM KCl 
and 1 mM ATP. Exitation wavelength was 532 nm and representative image sequences were 
false-colored. This movie (200 frames) was recorded at 5 frames s-1 and is displayed at six-fold 
speed. Scale bar represents 10 µm. 
 
Video 6 
Processive movement of the K-loop containing Myosin Va loop 2 mutant on F-actin. 
Cy3-labeled HMM-like Myosin Va K-loop (bright particles) was infused into a flow cell containing 
surface-attached Atto-488-labeled F-actin (fuzzy filaments). Assay was performed in 25 mM KCl 
and 1 mM ATP. Exitation wavelength was 532 nm and representative image sequences were 
false-colored. This movie (270 frames) was recorded at 5 frames s-1 and is displayed at six-fold 
speed. Scale bar represents 10 µm. 
 
Video 7 
Processive walking behavior of K-loop Myosin Va on F-actin − A closeup. 
Here, a closeup (20 × 20 µm) of the image sequence from Video 6 is presented. This movie (250 
frames) was recorded at 5 frames s-1 and is displayed at six-fold speed. Scale bar represents 5 
µm. 
 
Video 8 
Processive movement of Wildtype Myosin Va on F-actin. 
Cy3-labeled HMM-like Myosin Va Wildtype (bright particles) was infused into a flow cell containing 
surface-attached Atto-488-labeled F-actin (fuzzy filaments). Assay was performed in 25 mM KCl 
and 1 mM ATP. Exitation wavelength was 532 nm and representative image sequences were 
false-colored. This movie (197 frames) was recorded at 5 frames s-1 and is displayed at six-fold 
speed. Scale bar represents 10 µm. 
 
Video 9 
Actin filament gliding behavior of C’FLAG-tagged full-length Myosin Va from Xenopus l. 
Atto488-labeled F-actin (green filaments) was infused into a flow cell containing surface-adhered 
C’FLAG-tagged full-length Xenopus l. Myosin Va. Assay was performed in 25 mM KCl and 2 mM 
ATP. Excitation wavelength was 488 nm and representative image sequences were false-colored. 
This movie (330 frames) was recorded at 5 frames s-1 and is displayed at six-fold speed. Scale bar 
represents 10 µm. 
 
Video 10 
Actin filament gliding behavior of N’FLAG-tagged full-length Myosin Va from Xenopus l. 
Atto488-labeled F-actin (green filaments) was infused into a flow cell containing surface-adhered 
N’FLAG-tagged full-length Xenopus l. Myosin Va. Assay was performed in 25 mM KCl and 2 mM 
ATP. Excitation wavelength was 488 nm and representative image sequences were false-colored. 
This movie (95 frames) was recorded at 1.4 frames s-1 and is displayed at 3.6-fold speed. Scale 
bar represents 10 µm. 
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Video 11 
Smooth actin filament gliding of N’FLAG-tagged full-length Xenopus l. Myosin Va − A 
closeup. 
Here, a closeup (20 × 20 µm) of the image sequence from Video 10 is presented. This movie (95 
frames) was recorded at 1.4 frames s-1 and is displayed at 3.6-fold speed. Scale bar represents 5 
µm. 
 
Video 12 
ATP-dependent movement of the full-length Myosin Va from Xenopus l. 
Atto488-labeled F-actin (green filaments) was infused into a flow cell containing surface-adhered 
N’FLAG-tagged full-length Xenopus l. Myosin Va. Assay was performed in 25 mM KCl under zero-
ATP conditions. Excitation wavelength was 488 nm and representative image sequences were 
false-colored. This movie (34 frames) was recorded at 1.3 frames s-1 and is displayed at 3.8-fold 
speed. Scale bar represents 10 µm. 
 
Video 13 
Signs of Processivity: Single-point attachments for full-length Xenopus l. Myosin Va on F-
actin. 
Atto488-labeled F-actin (green filaments) was infused into a flow cell containing scarcely 
distributed surface-adhered N’FLAG-tagged full-length Xenopus l. Myosin Va molecules. Assay 
was performed in 25 mM KCl and 2 mM ATP. Excitation wavelength was 488 nm and 
representative image sequences were false-colored. This movie (100 frames) was recorded at 1.4 
frames s-1 and is displayed at 3.6-fold speed. Scale bar represents 10 µm. 
 
Video 14 
Single-molecule behavior of full-length Xenopus l. Myosin Va on F-actin. 
Cy3-labeled N’FLAG-tagged full-length Xenopus l. Myosin Va (bright particles) was infused into a 
flow cell containing surface-attached Atto-488-labeled F-actin (fuzzy green filaments in 
background). Assay was performed in 25 mM KCl and 2 mM ATP. Exitation wavelength was 532 
nm and representative image sequences were false-colored after channels were merged. This 
movie (42 frames) was recorded at 1 frame s-1 and is displayed at five-fold speed. Scale bar 
represents 10 µm. 
 
Video 15 
Single-molecule behavior of full-length Xenopus l. Myosin Va on F-actin. 
Here, a closeup (20 × 20 µm) of the image sequence from Video 14 is presented. This movie (42 
frames) was recorded at 1 frames s-1 and is displayed at five-fold speed. Scale bar represents 5 
µm. 
 
Video 16 
Single-molecule behavior of full-length Xenopus l. Myosin Va on F-actin at high ionic 
strength. 
Cy3-labeled N’FLAG-tagged full-length Xenopus l. Myosin Va (bright particles) was infused into a 
flow cell containing surface-attached Atto-488-labeled F-actin (fuzzy green filaments in 
background). Assay was performed in 150 mM KCl and 2 mM ATP. Exitation wavelength was 532 
nm and representative image sequences were false-colored after channels were merged. This 
movie (22 frames) was recorded at 1 frame s-1 and is displayed at five-fold speed. Scale bar 
represents 10 µm. 
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9  Abbreviations 
ABSA Assay buffer with BSA 
ADP Adenosine 5’-diphosphate 
Amp Ampicillin 
APS Ammonium peroxodisulfate 
ATP Adenosine 5’-triphosphate 
BBSA Biotinylated bovine serum albumin  
Bluo-Gal Halogenated indolyl-β-galactosidase 
bp Base pair 
BSA Bovine serum albumin 
c Concentration 
C-terminus (C’) Carboxy-terminus 
CaM Calmodulin 
CaMK Calcium-/Calmodulin-dependent Kinase 
CCD charge-coupled device 
cDNA Copy DNA 
Da Dalton 
DC Density gradient ultra-centrifugation 
DMSO Dimethylsolfoxide 
DNA Desoxyribonucleic acid 
dNTP Desoxynucleotide-5’-triphosphate 
DTT Dithiothreitol 
EB Elution buffer 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene-bis(oxyethylenenitrilo) tetraacetic acid 
ELC Essential light chain 
F-actin Filamentous actin 
FACS Fluorescent activated cell sorting 
FBS Fetal bovine serum 
FL Full-length 
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FPLC Fast performance liquid chromatography 
G-actin Globular actin 
GCN4 General Control Nondepressible transcriptional activator gene 
4 
GTD Globular tail domain 
GTP Guanosin 5’-triphosphate 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HMM Heavy-meromyosin 
HMW High molecular weight 
IPTG Isopropyl-β-D-thiogalactopyranoside 
kbp kilo base pair 
LB Luria Broth 
LC-MS/MS Liquid chromatography tandem mass spectrometry 
LDH Lactic Dehydrogenase 
LMU Ludwig-Maximilians-University Munich 
MACS Magnetic activation cell sorting 
MALDI-TOF Matrix-asssisted laser desorption/ionization-Time of flight 
MAPs Microtubule associated proteins 
min minutes 
mRNA Messenger ribonucleic acid 
MT Microtubules 
MWCO Molecular weight cut-off 
Myo V Myosin V 
N-terminus (N’) Ammino-terminus 
NADH Nicotinamide-adenine-dinucleotide 
OD Optical density 
PAGE Polyacryl amide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEP Phospho(enol)pyruvic acid 
Pi Inorganic phosphate 
PIPES Piperazine-1,4-bis(2-ethanesulfonic) acid 
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PK Pyruvic Kinase 
RACE Rapid amplification of cDNA ends 
rpm Rounds per minute 
RT Room temperature 
s Seconds 
S.D. Standard deviation 
S.E.M. Standard error of the mean 
S.O.C. Super Optimal Catabolite 
SDS Sodium dodecyl sulfate 
TAE Tris-buffered acidic EDTA solution 
Taq Thermus aquaticus 
TBS Tris-buffered sodium 
TE Tris EDTA 
TEMED N, N, N’, N’-Tetramethylethylenediamine 
TIRF Total internal reflection fluorescence 
Tris Base Tris (hydroxylmethyl) aminomethan 
TRITC Tetramethylrhodamine isothiocyanate 
TRP1 Tyrosinase-related protein 1 
UV-Light Ultra violet Light 
WB Wash buffer 
x g Gravitational force 
ZfP Zentrallabor für Proteinanalytik 
ε Molar absorptivity 
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